Third I-GENE
, O
consistent I-GENE
with O
these O
data O
, O
N O
- I-GENE
acetylcysteine I-GENE
reduced I-GENE
the O
stimulatory I-GENE
effect O
of O
HGF I-GENE
on O
stress O
kinase I-GENE
activities O
, O
while O
p42 I-GENE
/ O
44 I-GENE
mitogen I-GENE
activated I-GENE
kinase I-GENE
( O
MAPK I-GENE
) O
was O
unmodified I-GENE
, O
suggesting O
an O
involvement I-GENE
of O
c O
- I-GENE
Jun I-GENE
- I-GENE
N O
- I-GENE
terminal I-GENE
kinase I-GENE
( O
JNK I-GENE
) O
and O
p38 I-GENE
MAPK I-GENE
in O
HIF I-GENE
- I-GENE
1 I-GENE
activation I-GENE
. O

The O
Sox I-GENE
gene O
family I-GENE
( O
Sry I-GENE
like O
HMG I-GENE
box I-GENE
gene O
) O
is O
characterised I-GENE
by O
a O
conserved I-GENE
DNA I-GENE
sequence O
encoding I-GENE
a O
domain I-GENE
of O
approximately I-GENE
80 I-GENE
amino I-GENE
acids I-GENE
which O
is O
responsible O
for I-GENE
sequence O
specific O
DNA I-GENE
binding O
. O

Respiratory I-GENE
parameters O
suggested O
that O
M6G I-GENE
produced O
less O
respiratory O
depression O
than O
morphine I-GENE
. O

This I-GENE
slow I-GENE
progression I-GENE
through O
the O
early O
G1 I-GENE
- I-GENE
phase I-GENE
resulted O
in O
decreased O
phosphorylation I-GENE
of O
the O
RB I-GENE
protein O
and O
subsequent O
delay I-GENE
into O
the O
S O
phase I-GENE
transition I-GENE
. O

Responses I-GENE
of O
TLD I-GENE
Mg2SiO4 I-GENE
: O
Tb I-GENE
and O
radiophotoluminescent I-GENE
glass I-GENE
to O
heavy O
charged I-GENE
particles I-GENE
and O
space I-GENE
radiation O
. O

In I-GENE
the O
meantime I-GENE
, O
one O
has O
succeeded I-GENE
to O
establish I-GENE
the O
deammonification I-GENE
processes O
in O
a O
continuous O
flow O
moving I-GENE
- I-GENE
bed I-GENE
pilot I-GENE
plant I-GENE
. O

An I-GENE
18 O
- I-GENE
kb O
genomic I-GENE
clone I-GENE
including O
sequences O
encoding I-GENE
for I-GENE
the O
two O
GHS I-GENE
- I-GENE
R O
variants I-GENE
was O
isolated O
. O

In I-GENE
the O
further O
development O
of O
bladder O
neck O
suspension I-GENE
according I-GENE
to O
Stamey I-GENE
- I-GENE
Pereyra I-GENE
, O
the O
use O
of O
miniature I-GENE
bone O
anchors I-GENE
received O
considerable I-GENE
support O
. O

CHAP I-GENE
and O
the O
Department I-GENE
of O
Veterans I-GENE
Affairs I-GENE
. O

Finally I-GENE
, O
a O
chromogenic I-GENE
method O
was O
used O
, O
based O
on O
thrombin I-GENE
inhibition O
and O
the O
substrate I-GENE
S O
- I-GENE
2238 I-GENE
. O

As I-GENE
an O
oral O
, O
nontoxic I-GENE
compound O
with O
a O
mechanism O
of O
action O
distinct O
from O
that O
of O
ABL I-GENE
tyrosine I-GENE
kinase I-GENE
inhibition O
, O
FTI I-GENE
SCH66336 I-GENE
shows O
promise I-GENE
for I-GENE
the O
treatment O
of O
BCR I-GENE
/ O
ABL I-GENE
- I-GENE
induced I-GENE
leukemia O
. O

Recruitment I-GENE
of O
an O
RNA O
polymerase I-GENE
II I-GENE
complex O
is O
mediated I-GENE
by O
the O
constitutive I-GENE
activation I-GENE
domain I-GENE
in O
CREB I-GENE
, O
independently I-GENE
of O
CREB I-GENE
phosphorylation I-GENE
. O

Our I-GENE
results O
are O
reassuring I-GENE
and O
we O
therefore I-GENE
advise I-GENE
that O
in O
patients O
undergoing O
free O
jejunum I-GENE
flap I-GENE
reconstruction O
of O
the O
hypopharyngo I-GENE
- I-GENE
esophageal I-GENE
tract I-GENE
voice I-GENE
restoration I-GENE
should O
be O
attempted I-GENE
by O
placing I-GENE
a O
voice I-GENE
prosthesis I-GENE
through O
a O
secondary O
tracheo I-GENE
- I-GENE
esophageal I-GENE
puncture I-GENE
and O
providing I-GENE
intensive I-GENE
speech I-GENE
training I-GENE
. O

Regarding I-GENE
gestational O
risk O
, O
3 O
, O
243 I-GENE
drugs O
used O
( O
34 I-GENE
%) O
belonged I-GENE
to O
category I-GENE
A I-GENE
risk O
, O
1 I-GENE
, O
923 I-GENE
( O
22 I-GENE
. O
6 I-GENE
%) O
to O
category I-GENE
B I-GENE
, O
3 O
, O
798 I-GENE
( O
39 I-GENE
. O
7 O
%) O
to O
category I-GENE
C O
, O
289 I-GENE
( O
3 O
. O
0 I-GENE
%) O
to O
category I-GENE
D O
, O
and O
55 I-GENE
( O
0 I-GENE
. O
6 I-GENE
%) O
to O
category I-GENE
X I-GENE
. O

The O
human I-GENE
ABCG1 I-GENE
gene O
encodes I-GENE
a O
member I-GENE
of O
the O
ATP O
- I-GENE
binding O
cassette I-GENE
( O
ABC I-GENE
) O
superfamily I-GENE
of O
transporter I-GENE
proteins O
and O
is O
highly O
induced I-GENE
when O
macrophages I-GENE
are O
incubated O
with O
oxysterols I-GENE
. O

At I-GENE
the O
end O
of O
each O
day O
of O
migration I-GENE
the O
pulmonary O
hemolymph I-GENE
PO2 I-GENE
decreased O
by O
1 I-GENE
- I-GENE
2 I-GENE
. O
5 I-GENE
kPa I-GENE
, O
but O
the O
hemocyanin I-GENE
remained O
saturated I-GENE
with O
O2 I-GENE
and O
the O
venous O
reserve I-GENE
was O
largely I-GENE
unchanged I-GENE
( O
O2 I-GENE
> I-GENE
0 I-GENE
. O
4 O
mmol I-GENE
x I-GENE
l I-GENE
(- I-GENE
1 I-GENE
)). I-GENE

We I-GENE
have O
investigated O
the O
role O
of O
NGF I-GENE
in O
regulating I-GENE
gene O
transcription O
in O
PC12 I-GENE
and O
INS I-GENE
- I-GENE
1 I-GENE
cells O
, O
in O
order O
to O
define I-GENE
if O
there O
are O
NGF I-GENE
- I-GENE
regulated I-GENE
genes I-GENE
per O
se I-GENE
. O

Thus I-GENE
, O
through O
a O
change O
in O
conformation I-GENE
upon O
repair I-GENE
of O
the O
6RG I-GENE
lesion O
, O
MGMT I-GENE
switches I-GENE
from O
a O
DNA I-GENE
repair I-GENE
factor I-GENE
to O
a O
transcription O
regulator I-GENE
( O
R O
- I-GENE
MGMT I-GENE
), I-GENE
enabling I-GENE
the O
cell O
to O
sense O
as I-GENE
well I-GENE
as I-GENE
respond O
to O
mutagens I-GENE
. O

TaqMan I-GENE
analysis O
of O
gene O
expression I-GENE
following O
chronic O
FA I-GENE
treatment O
showed O
neither I-GENE
a O
decrease O
in O
the O
amount O
of O
leptin I-GENE
receptor I-GENE
( O
Ob I-GENE
- I-GENE
R O
) O
mRNA I-GENE
, O
nor I-GENE
an O
increase O
in O
the O
negative O
regulators I-GENE
of O
STAT I-GENE
signalling I-GENE
, O
SOCS3 I-GENE
( O
suppressors I-GENE
of O
cytokine I-GENE
signalling I-GENE
) O
or O
cytokine I-GENE
inducible I-GENE
sequence O
( O
CIS I-GENE
). O

Nine I-GENE
animals O
served I-GENE
as I-GENE
control O
animals O
, O
whereas O
20 O
animals O
received O
a O
focal I-GENE
arachnoid I-GENE
scar I-GENE
at I-GENE
C1 O
- I-GENE
C2 I-GENE
, O
which O
was O
produced O
by O
placement I-GENE
of O
a O
kaolin I-GENE
- I-GENE
soaked I-GENE
fibrin I-GENE
sponge I-GENE
on O
the O
posterior I-GENE
surface I-GENE
of O
the O
spinal I-GENE
cord O
. O

A I-GENE
comparison O
of O
the O
duplicated I-GENE
Vkappa I-GENE
genes I-GENE
suggests O
positive O
selection O
on O
the O
complementarity I-GENE
- I-GENE
determining I-GENE
regions O
of O
the O
duplicated I-GENE
genes I-GENE
by O
point I-GENE
mutations I-GENE
. O

They I-GENE
have O
not O
been O
previously O
reported O
as I-GENE
a O
reaction O
to O
i O
. O
v O
. O
contrast O
material O
. O

The O
presence O
of O
AS I-GENE
- I-GENE
oligo I-GENE
had O
no I-GENE
further O
effect O
on O
the O
FSH I-GENE
- I-GENE
mediated I-GENE
activation I-GENE
of O
the O
EB I-GENE
*- I-GENE
mTf I-GENE
- I-GENE
CAT I-GENE
construct I-GENE
but O
reduced I-GENE
cAMP I-GENE
- I-GENE
mediated I-GENE
activation I-GENE
. O

The O
homologous O
active I-GENE
- I-GENE
site I-GENE
framework I-GENE
of O
these O
enzymes I-GENE
with O
distinct O
structures I-GENE
suggests O
convergent I-GENE
evolution I-GENE
of O
a O
common O
catalytic I-GENE
mechanism O
. O

Additional I-GENE
education I-GENE
and O
research O
is O
needed I-GENE
to O
provide O
further O
direction O
for I-GENE
intervention I-GENE
and O
incorporation I-GENE
into O
practice O
. O

Many I-GENE
of O
the O
important O
genes I-GENE
associated O
with O
G1 I-GENE
regulation I-GENE
have O
been O
shown O
to O
play I-GENE
a O
key I-GENE
role O
in O
proliferation I-GENE
, O
differentiation I-GENE
and O
oncogenic I-GENE
transformation I-GENE
and O
programmed I-GENE
cell O
death I-GENE
( O
apoptosis I-GENE
). O

Drug I-GENE
interactions O
have O
been O
found O
with O
drugs O
that O
compete I-GENE
for I-GENE
the O
same O
CYP450 I-GENE
isoenzymes I-GENE
as I-GENE
statins I-GENE
. O

Regulation I-GENE
of O
laminin I-GENE
beta2 I-GENE
chain I-GENE
gene O
expression I-GENE
in O
human I-GENE
cancer I-GENE
cell O
lines I-GENE
. O

Mutation I-GENE
of O
the O
NF I-GENE
- I-GENE
kappaB I-GENE
site I-GENE
in O
the O
Mdr1b I-GENE
promoter I-GENE
prevents O
its O
induction O
by O
TNF I-GENE
- I-GENE
alpha I-GENE
. O

Effect I-GENE
of O
heat O
treatments I-GENE
on O
the O
meltability I-GENE
of O
cheeses I-GENE
. O

In I-GENE
vitro O
binding O
studies O
demonstrate O
that O
eIF I-GENE
- I-GENE
5A I-GENE
is O
required O
for I-GENE
efficient O
interaction O
of O
Rev I-GENE
- I-GENE
NES I-GENE
with O
CRM1 I-GENE
/ O
exportin1 I-GENE
and O
that O
eIF I-GENE
- I-GENE
5A I-GENE
interacts I-GENE
with O
the O
nucleoporins I-GENE
CAN I-GENE
/ O
nup214 I-GENE
, O
nup153 I-GENE
, O
nup98 I-GENE
, O
and O
nup62 I-GENE
. O

Forced I-GENE
expression I-GENE
of O
BZAP45 I-GENE
strongly O
stimulates I-GENE
H4 I-GENE
promoter I-GENE
( O
nt I-GENE
- I-GENE
215 I-GENE
to O
- I-GENE
1 I-GENE
)/ I-GENE
CAT I-GENE
reporter I-GENE
gene O
activity O
. O

Copyright I-GENE
2001 I-GENE
Academic I-GENE
Press I-GENE
. O

The O
diagnosis O
of O
HCV I-GENE
arthritis O
in O
patients O
with O
positive O
rheumatoid O
factor I-GENE
and O
chronic O
inflammatory O
polyarthritis I-GENE
may O
be O
difficult O
. O

The O
UBA I-GENE
domains I-GENE
of O
RAD23 I-GENE
and O
DDI1 I-GENE
are O
required O
for I-GENE
these O
interactions O
. O

E47 I-GENE
protein O
levels O
remain I-GENE
high O
until O
the O
double O
positive O
developmental I-GENE
stage I-GENE
, O
at I-GENE
which O
point I-GENE
they O
drop O
to O
relatively O
moderate O
levels O
, O
and O
are O
further O
downregulated I-GENE
upon O
transition I-GENE
to O
the O
single O
positive O
stage I-GENE
. O

By I-GENE
Caveman I-GENE
. O

These I-GENE
findings O
suggest O
that O
the O
adapter I-GENE
Gab1 I-GENE
may O
redirect I-GENE
c O
- I-GENE
Met I-GENE
signaling I-GENE
through O
PI3K I-GENE
away I-GENE
from O
a O
c O
- I-GENE
Akt I-GENE
/ O
Pak1 I-GENE
cell O
survival I-GENE
pathway I-GENE
. O

Another I-GENE
mutant I-GENE
, O
T255A I-GENE
, O
lost O
the O
ability O
to O
bind I-GENE
E4orf6 I-GENE
, O
but O
unexpectedly I-GENE
, O
viral I-GENE
late I-GENE
- I-GENE
gene O
expression I-GENE
was O
not O
affected O
. O

However I-GENE
, O
the O
N63S I-GENE
mutation I-GENE
in O
the O
wild I-GENE
- I-GENE
type I-GENE
VP5 I-GENE
background O
increased O
the O
interaction O
, O
as I-GENE
judged O
by O
the O
beta I-GENE
- I-GENE
galactosidase I-GENE
activity O
, O
by O
a O
factor I-GENE
of O
9 O
relative O
to O
when O
the O
PR7 I-GENE
mutation I-GENE
was O
present O
. O

Here I-GENE
we O
report O
the O
isolation I-GENE
and O
characterization I-GENE
of O
the O
forkhead I-GENE
homologue I-GENE
in O
rhabdomyosarcoma I-GENE
( O
FKHR I-GENE
), I-GENE
a O
recently I-GENE
described O
member I-GENE
of O
the O
hepatocyte I-GENE
nuclear O
factor I-GENE
3 O
/ O
forkhead I-GENE
homeotic I-GENE
gene O
family I-GENE
, O
as I-GENE
a O
nuclear O
hormone I-GENE
receptor I-GENE
( O
NR I-GENE
) O
intermediary I-GENE
protein O
. O

Unlike I-GENE
other O
progenitor I-GENE
cells O
of O
the O
brain O
, O
SVZa I-GENE
progenitor I-GENE
cells O
have O
the O
capacity O
to O
divide I-GENE
even O
though I-GENE
they O
express I-GENE
a O
neuronal I-GENE
phenotype I-GENE
. O

We I-GENE
previously O
reported O
that O
Tax I-GENE
induced I-GENE
cell O
cycle I-GENE
progression I-GENE
from O
G0 I-GENE
/ O
G1 I-GENE
phase I-GENE
to O
S O
and O
G2 I-GENE
/ O
M O
phases O
in O
human I-GENE
T I-GENE
- I-GENE
cell O
line I-GENE
Kit I-GENE
225 I-GENE
cells O
. O

Phosphotyrosyl I-GENE
peptides I-GENE
block I-GENE
Stat3 I-GENE
- I-GENE
mediated I-GENE
DNA I-GENE
binding O
activity O
, O
gene O
regulation I-GENE
, O
and O
cell O
transformation I-GENE
. O

In I-GENE
Exp I-GENE
. O

Human I-GENE
brain O
cDNA I-GENE
library I-GENE
screening I-GENE
and O
5 I-GENE
' O
rapid O
amplification I-GENE
of O
cDNA I-GENE
ends O
yielded O
full I-GENE
- I-GENE
length O
DENTT I-GENE
cDNA I-GENE
containing O
an O
1899 I-GENE
- I-GENE
bp I-GENE
open I-GENE
reading I-GENE
frame I-GENE
encoding I-GENE
a O
predicted I-GENE
633 I-GENE
- I-GENE
amino I-GENE
- I-GENE
acid I-GENE
protein O
with O
four O
potential I-GENE
nuclear O
localization I-GENE
signals I-GENE
( O
NLSs I-GENE
) O
and O
two O
coiled I-GENE
- I-GENE
coil I-GENE
regions O
. O

NaeI I-GENE
, O
a O
novel I-GENE
DNA I-GENE
endonuclease I-GENE
, O
shows O
topoisomerase I-GENE
and O
recombinase I-GENE
activities O
when O
a O
Lys I-GENE
residue I-GENE
is O
substituted I-GENE
for I-GENE
Leu I-GENE
43 I-GENE
. O

We I-GENE
used O
a O
rev I-GENE
- I-GENE
and O
RRE I-GENE
- I-GENE
defective I-GENE
HIV I-GENE
type I-GENE
1 I-GENE
( O
HIV I-GENE
- I-GENE
1 I-GENE
) O
molecular I-GENE
clone I-GENE
in O
complementation I-GENE
experiments I-GENE
to O
establish I-GENE
a O
method O
for I-GENE
the O
rapid O
isolation I-GENE
of O
posttranscriptional I-GENE
regulatory I-GENE
elements I-GENE
from O
the O
mammalian I-GENE
genome I-GENE
by O
selecting I-GENE
for I-GENE
rescue I-GENE
of O
virus O
replication I-GENE
. O

OBJECTIVES I-GENE
: O
The O
objective I-GENE
of O
this O
review O
was O
to O
compare I-GENE
the O
effectiveness I-GENE
, O
safety I-GENE
and O
acceptability I-GENE
of O
the O
diaphragm O
with O
and O
without O
spermicide I-GENE
. O

DESIGN I-GENE
: O
Retrospective I-GENE
study O
. O

Considering I-GENE
that O
the O
reactor I-GENE
is O
thoroughly I-GENE
mixed I-GENE
during I-GENE
each O
discharge O
and O
that O
LD50 I-GENE
= O
0 I-GENE
. O
9 O
values O
are O
nearly I-GENE
independent O
of O
E I-GENE
. O
coli I-GENE
concentrations O
in O
the O
range O
of O
2 I-GENE
x I-GENE
10 O
( O
3 O
) O
< I-GENE
or O
= O
E I-GENE
coli I-GENE
/ O
cfu I-GENE
mL I-GENE
(- I-GENE
1 I-GENE
) O
< I-GENE
or O
= O
3 O
x I-GENE
10 O
( O
6 I-GENE
), I-GENE
we O
ascribe I-GENE
the O
nonexponential I-GENE
Pn I-GENE
decay I-GENE
of O
single O
- I-GENE
strain I-GENE
E I-GENE
. O
coli I-GENE
colonies I-GENE
to O
a O
shielding I-GENE
phenomenon O
where I-GENE
inactive I-GENE
cells O
protect I-GENE
the O
successively I-GENE
smaller O
numbers O
of O
viable I-GENE
cells O
in O
the O
EHD I-GENE
. O

These I-GENE
genes I-GENE
encode I-GENE
a O
tryptophanyl I-GENE
tRNA I-GENE
, O
the O
protein O
translocase I-GENE
component I-GENE
SecE I-GENE
, O
the O
antiterminator I-GENE
protein O
NusG I-GENE
, O
and O
the O
ribosomal I-GENE
proteins O
L11 I-GENE
and O
L1 O
in O
addition O
to O
PkwR I-GENE
, O
a O
putative I-GENE
regulatory I-GENE
protein O
of O
the O
LacI I-GENE
- I-GENE
GalR I-GENE
family I-GENE
. O

Body I-GENE
fat O
distribution O
was O
determined O
by O
abdominal O
computed I-GENE
tomography O
. O

The O
telomerase I-GENE
RNA O
- I-GENE
protein O
complex O
responsible O
for I-GENE
maintenance I-GENE
of O
telomeric I-GENE
DNA I-GENE
at I-GENE
chromosome I-GENE
ends O
, O
is O
usually O
inactive I-GENE
in O
most O
primary I-GENE
somatic O
human I-GENE
cells O
, O
but O
is O
specifically I-GENE
activated I-GENE
with O
in O
vitro O
immortalization I-GENE
and O
during I-GENE
tumorigenesis I-GENE
. O

This I-GENE
is O
a O
challenging I-GENE
task O
insofar I-GENE
as I-GENE
direct O
measures I-GENE
of O
ISF I-GENE
glucose O
are O
not O
readily I-GENE
available O
. O

SELECTION I-GENE
CRITERIA I-GENE
: O
All I-GENE
randomised I-GENE
controlled I-GENE
trials I-GENE
comparing O
IUSs I-GENE
with O
other O
forms I-GENE
of O
reversible I-GENE
contraceptives I-GENE
and O
reporting I-GENE
on O
pre I-GENE
- I-GENE
determined O
outcomes I-GENE
in O
women O
of O
reproductive O
years O
. O

There I-GENE
was O
a O
statistically O
significant O
correlation O
between O
simultaneous I-GENE
weekly O
average O
pollen I-GENE
levels O
in O
Philadelphia I-GENE
and O
in O
Cherry I-GENE
Hill I-GENE
( O
Acer I-GENE
, O
r I-GENE
( O
p O
) O
= O
0 I-GENE
. O
987 I-GENE
, O
Quercus I-GENE
, O
r I-GENE
( O
p O
) O
= O
0 I-GENE
. O
645 I-GENE
, O
Betula I-GENE
, O
r I-GENE
( O
p O
) O
= O
0 I-GENE
. O
896 I-GENE
, O
Pinus I-GENE
, O
r I-GENE
( O
p O
) O
= O
0 I-GENE
. O
732 I-GENE
, O
Cupressaceae I-GENE
, O
r I-GENE
( O
p O
) O
= O
0 I-GENE
. O
695 I-GENE
, O
Poaceae I-GENE
, O
r I-GENE
( O
p O
) O
= O
0 I-GENE
. O
950 I-GENE
, O
Ambrosia I-GENE
, O
r I-GENE
( O
p O
) O
= O
0 I-GENE
. O
903 I-GENE
, O
and O
Rumex I-GENE
, O
r I-GENE
( O
p O
) O
= O
0 I-GENE
. O
572 I-GENE
, O
P I-GENE
< I-GENE
0 I-GENE
. O
001 O
). O

Through I-GENE
two O
novel I-GENE
mechanisms O
, O
Arf I-GENE
inhibits O
the O
oncoprotein I-GENE
Hdm2 I-GENE
, O
a O
negative O
regulator I-GENE
of O
p53 I-GENE
. O

2 I-GENE
: O
The O
dynamic O
moduli I-GENE
of O
microcrystalline I-GENE
cellulose I-GENE
. O

Such I-GENE
knowledge I-GENE
could O
advance I-GENE
diagnosis O
and O
treatment O
of O
the O
patient O
and O
counseling I-GENE
of O
the O
affected O
family I-GENE
. O

Here I-GENE
we O
show O
that O
independent O
of O
uncertainties I-GENE
in O
the O
models I-GENE
, O
terrestrial I-GENE
planets I-GENE
with O
dense I-GENE
atmosphere I-GENE
like O
Venus I-GENE
can O
evolve I-GENE
into O
one O
of O
only O
four O
possible O
rotation I-GENE
states O
. O

Our I-GENE
results O
suggest O
that O
WASP I-GENE
activates I-GENE
transcription O
following O
TCR I-GENE
stimulation I-GENE
in O
a O
manner I-GENE
that O
is O
independent O
of O
its O
role O
in O
Arp2 I-GENE
/ O
3 O
- I-GENE
directed I-GENE
actin I-GENE
polymerization I-GENE
. O

In I-GENE
contrast O
, O
the O
ubiquitous I-GENE
expression I-GENE
of O
p19 I-GENE
( O
INK4d I-GENE
) O
has O
not O
been O
previously O
described O
in O
human I-GENE
or O
murine I-GENE
B I-GENE
- I-GENE
lineage I-GENE
cells O
. O

This I-GENE
animal I-GENE
model O
of O
dystonia I-GENE
appears O
to O
be O
a O
model O
of O
NAD I-GENE
in O
man O
from O
the O
viewpoint I-GENE
of O
treatment O
- I-GENE
response O
. O

These I-GENE
results O
indicate O
that O
evaluation O
of O
exposure O
to O
S O
. O
neurona I-GENE
by O
WB I-GENE
analysis O
of O
serum I-GENE
may O
be O
misleading I-GENE
in O
young I-GENE
horses I-GENE
. O

The O
Delta6CCI I-GENE
virus O
was O
extremely O
attenuated I-GENE
in O
replication I-GENE
capacity O
yet I-GENE
retained I-GENE
infectiousness I-GENE
for I-GENE
CEMx174 I-GENE
and O
MT4 I-GENE
cells O
. O

OBJECTIVE I-GENE
: O
To I-GENE
determine O
the O
association O
of O
depressive I-GENE
symptoms O
with O
HIV I-GENE
- I-GENE
related O
mortality O
and O
decline O
in O
CD4 I-GENE
lymphocyte O
counts O
among O
women O
with O
HIV I-GENE
. O

Phase O
II I-GENE
study O
of O
paclitaxel I-GENE
and O
oral O
etoposide I-GENE
in O
patients O
with O
locally I-GENE
advanced O
or O
metastatic I-GENE
non O
- I-GENE
small O
cell O
lung I-GENE
cancer I-GENE
. O

Analyses I-GENE
revealed I-GENE
that O
scale O
matters I-GENE
above O
and O
beyond I-GENE
the O
effect O
of O
quadrat I-GENE
area O
. O

Rind I-GENE
et O
al O
.' I-GENE
s O
study O
' O
s O
main O
conclusions I-GENE
were O
not O
supported I-GENE
by O
the O
original O
data O
. O

Not I-GENE
Available I-GENE

Lactate I-GENE
accumulation I-GENE
peak O
was O
unaffected O
by O
supplementation O
( O
HMB I-GENE
, O
8 I-GENE
. O
1 I-GENE
+/- O
1 I-GENE
. O
1 I-GENE
mM I-GENE
; O
LEU I-GENE
, O
6 I-GENE
. O
2 I-GENE
+/- O
0 I-GENE
. O
8 I-GENE
mM I-GENE
; O
CON I-GENE
, O
7 O
. O
5 I-GENE
+/- O
1 I-GENE
. O
3 O
mM I-GENE
). O

However I-GENE
, O
the O
abi1 I-GENE
- I-GENE
1 I-GENE
gene O
product I-GENE
has O
no I-GENE
effect O
on O
the O
ABA I-GENE
suppression O
of O
a O
GA I-GENE
- I-GENE
responsive O
alpha I-GENE
- I-GENE
amylase I-GENE
gene O
. O

Polyclonal I-GENE
antibodies I-GENE
against O
the O
N O
- I-GENE
terminal I-GENE
part O
( O
amino I-GENE
acids I-GENE
12 O
- I-GENE
363 I-GENE
) O
and O
the O
C O
- I-GENE
terminal I-GENE
part O
( O
amino I-GENE
acids I-GENE
330 I-GENE
- I-GENE
730 I-GENE
) O
of O
rainbow I-GENE
trout I-GENE
HIF I-GENE
- I-GENE
1alpha I-GENE
protein O
recognized I-GENE
rainbow I-GENE
trout I-GENE
and O
chinook I-GENE
salmon I-GENE
HIF I-GENE
- I-GENE
1alpha I-GENE
protein O
in O
Western I-GENE
blot I-GENE
analysis O
. O

Southern O
blot I-GENE
analysis O
of O
genomic I-GENE
DNA I-GENE
from O
somatic O
cell O
hybrids I-GENE
showed O
that O
endothelial O
- I-GENE
TACC I-GENE
- I-GENE
related O
cDNA I-GENE
maps I-GENE
to O
chromosome I-GENE
10 O
. O

PABP I-GENE
is O
a O
modular I-GENE
protein O
, O
with O
four O
N O
- I-GENE
terminal I-GENE
RNA O
- I-GENE
binding O
domains I-GENE
and O
an O
extensive O
C O
terminus I-GENE
. O

9 O
. O
7 O
( O
95 I-GENE
% O
CI I-GENE
: O
9 O
. O
6 I-GENE
- I-GENE
9 O
. O
7 O
) O
micromol I-GENE
/ O
L O
among O
women O
( O
P I-GENE
= O
0 I-GENE
. O
003 I-GENE
). O

The O
mean O
waiting I-GENE
time O
to O
receive I-GENE
the O
pancreas O
transplant I-GENE
was O
244 I-GENE
days O
for I-GENE
SPK I-GENE
and O
167 I-GENE
days O
for I-GENE
PAK I-GENE
recipients O
( O
P I-GENE
= O
0 I-GENE
. O
001 O
). O

Zarix I-GENE
expected O
patient O
enrollment I-GENE
in O
Canadian I-GENE
clinical O
sites O
to O
begin I-GENE
in O
Spring I-GENE
2001 I-GENE
[ I-GENE
397955 I-GENE
], I-GENE
[ I-GENE
405928 I-GENE
]. I-GENE

The O
isoform I-GENE
, O
designated I-GENE
HDAC9a I-GENE
, O
is O
132 I-GENE
aa I-GENE
shorter I-GENE
at I-GENE
the O
C O
terminus I-GENE
than O
HDAC9 I-GENE
. O

Long I-GENE
- I-GENE
range O
comparison O
of O
human I-GENE
and O
mouse O
SCL I-GENE
loci O
: O
localized O
regions O
of O
sensitivity O
to O
restriction I-GENE
endonucleases I-GENE
correspond I-GENE
precisely I-GENE
with O
peaks O
of O
conserved I-GENE
noncoding I-GENE
sequences O
. O

In I-GENE
Saccharomyces I-GENE
cerevisiae I-GENE
, O
eIF6 I-GENE
is O
encoded I-GENE
by O
a O
single O
- I-GENE
copy I-GENE
essential O
gene O
. O

Three I-GENE
patients O
received O
additional I-GENE
cycles O
of O
5 I-GENE
- I-GENE
fluorouracil I-GENE
+/- O
leucovorin I-GENE
as I-GENE
maintenance I-GENE
chemotherapy I-GENE
. O
RESULTS I-GENE
: O
Thirty I-GENE
males O
and O
21 O
females O
with O
a O
median O
age O
of O
55 I-GENE
years O
( O
range O
31 I-GENE
-- I-GENE
73 I-GENE
years O
) O
were O
treated O
. O

RESULTS I-GENE
: O
Within I-GENE
7 O
days O
, O
all O
groups O
re O
- I-GENE
acquired I-GENE
responding O
for I-GENE
heroin I-GENE
under O
CRF I-GENE
at I-GENE
rates O
similar O
to O
their O
pre I-GENE
- I-GENE
lesion O
performance O
. O

The O
application O
of O
the O
biotechnology I-GENE
at I-GENE
the O
plants I-GENE
for I-GENE
treatment O
of O
the O
surface I-GENE
storm I-GENE
waters I-GENE
from O
the O
industrial I-GENE
zone I-GENE
Telychka I-GENE
of O
the O
city I-GENE
of O
Kyiv I-GENE
has O
allowed O
the O
content O
of O
petroleum I-GENE
in O
water O
dropped I-GENE
to O
the O
Dnieper I-GENE
to O
be O
constantly I-GENE
reduced I-GENE
50 O
- I-GENE
100 I-GENE
times O
. O

Using I-GENE
immunochemical I-GENE
co I-GENE
- I-GENE
precipitation I-GENE
methods O
, O
we O
also O
found O
that O
the O
two O
proteins O
are O
bound I-GENE
in O
vivo O
. O

Utility I-GENE
of O
OAE I-GENE
screener I-GENE
( O
GSI I-GENE
70 O
) O
for I-GENE
the O
evaluation O
of O
distortion I-GENE
product I-GENE
otoacoustic I-GENE
emissions I-GENE
] O
The O
purpose I-GENE
of O
this O
study O
was O
to O
investigate O
the O
ability O
of O
the O
OAE I-GENE
screener I-GENE
GSI I-GENE
70 O
to O
evaluate I-GENE
of O
cochlea I-GENE
function O
in O
neonates I-GENE
, O
infants O
and O
adults O
. O

Our I-GENE
results O
demonstrated O
that O
50 O
% O
of O
the O
hepatic I-GENE
artery O
- I-GENE
alone O
ALT I-GENE
graft I-GENE
showed O
almost O
normal O
structure I-GENE
histologically I-GENE
at I-GENE
1 I-GENE
month O
after O
grafting I-GENE
, O
with O
bile O
secretion I-GENE
preserved I-GENE
. O

Mean I-GENE
Hg I-GENE
concentrations O
in O
the O
livers I-GENE
of O
mice O
at I-GENE
some O
sites O
in O
Isle I-GENE
Royale I-GENE
are O
not O
significantly O
lower O
( O
P I-GENE
= O
0 I-GENE
. O
62 I-GENE
) O
than O
Hg I-GENE
concentrations O
considered O
by O
some O
government I-GENE
agencies I-GENE
to O
be O
unhealthy I-GENE
for I-GENE
human I-GENE
consumption I-GENE
. O

We I-GENE
show O
here I-GENE
that O
the O
in O
vitro O
transcription O
extract I-GENE
contains I-GENE
a O
binding O
activity O
that O
is O
specific O
for I-GENE
the O
initiator I-GENE
element I-GENE
and O
thus O
may O
participate I-GENE
in O
recruiting I-GENE
RNA O
polymerase I-GENE
II I-GENE
to O
the O
SL I-GENE
RNA O
gene O
promoter I-GENE
. O

The O
desirability I-GENE
function O
is O
based O
on O
the O
search I-GENE
for I-GENE
a O
global O
optimum I-GENE
[ I-GENE
D O
= O
f I-GENE
( O
Y1 I-GENE
, O
Y2 I-GENE
, O
..., I-GENE
Yn I-GENE
)] O
by O
the O
transformation I-GENE
of O
the O
measured O
property I-GENE
to O
a O
dimensionless I-GENE
scale O
for I-GENE
each O
criterion I-GENE
. O

Naltrexone I-GENE
hydrochloride I-GENE
is O
a O
synthetic I-GENE
opioid I-GENE
receptor I-GENE
antagonist I-GENE
recently I-GENE
used O
in O
efforts I-GENE
to O
provide O
rapid O
opioid I-GENE
detoxification I-GENE
. O

We I-GENE
mapped I-GENE
the O
DGCR6 I-GENE
gene O
to O
chromosome I-GENE
22q11 I-GENE
within O
a O
low O
copy I-GENE
repeat I-GENE
, O
termed I-GENE
sc11 I-GENE
. O
1a I-GENE
, O
and O
identified O
a O
second O
copy I-GENE
of O
the O
gene O
, O
DGCR6L I-GENE
, O
within O
the O
duplicate I-GENE
locus I-GENE
, O
termed I-GENE
sc11 I-GENE
. O
1b I-GENE
. O

Proliferative I-GENE
vasculopathy I-GENE
and O
cutaneous O
hemorrhages I-GENE
in O
porcine I-GENE
neonates I-GENE
infected I-GENE
with O
the O
porcine I-GENE
reproductive O
and O
respiratory O
syndrome I-GENE
virus O
. O

The O
child O
left I-GENE
behind I-GENE
. O

Using I-GENE
the O
two O
- I-GENE
hybrid I-GENE
system I-GENE
, O
we O
show O
that O
nonprenylated I-GENE
Rac1 I-GENE
interacts I-GENE
very O
weakly O
with O
Rho I-GENE
- I-GENE
GDI I-GENE
, O
pointing I-GENE
to O
the O
predominant O
role O
of O
protein O
- I-GENE
isoprene I-GENE
interaction O
in O
complex O
formation O
. O

In I-GENE
contrast O
, O
neither I-GENE
I O
. O
argentina I-GENE
nor I-GENE
I O
. O
theezans I-GENE
exerted I-GENE
any O
effect O
on O
BF I-GENE
or O
intestinal I-GENE
propulsion I-GENE
. O

The O
region O
containing O
both O
serines I-GENE
is O
homologous O
to O
the O
N O
- I-GENE
terminal I-GENE
destruction I-GENE
box I-GENE
of O
IkappaBalpha I-GENE
, O
- I-GENE
beta I-GENE
, O
and O
- I-GENE
epsilon I-GENE
. O

No O
dominant I-GENE
clinical O
factor I-GENE
of O
risk O
was O
found O
, O
but O
multiple O
regression I-GENE
analysis O
identified O
age O
, O
body O
surface I-GENE
area O
, O
valve O
size O
, O
shop I-GENE
order O
fracture I-GENE
rate O
, O
and O
manufacturing I-GENE
period O
as I-GENE
risk O
factors I-GENE
for I-GENE
OSF I-GENE
. O

A I-GENE
novel I-GENE
growth O
- I-GENE
related O
nuclear O
protein O
binds I-GENE
and O
inhibits O
rat O
aldolase I-GENE
B I-GENE
gene O
promoter I-GENE
. O

Northern O
blot I-GENE
analysis O
revealed I-GENE
that O
mlt I-GENE
1 I-GENE
is O
normally O
expressed I-GENE
in O
brain O
, O
spleen I-GENE
, O
stom I-GENE
ach I-GENE
, O
and O
liver O
. O

NO I-GENE
metabolites O
were O
determined O
by O
the O
measurement O
of O
nitrate I-GENE
/ O
nitrite I-GENE
( O
NOx I-GENE
, O
micromol I-GENE
/ O
mmol I-GENE
creatinine I-GENE
) O
and O
cyclic O
guanosine I-GENE
monophosphate I-GENE
( O
cGMP I-GENE
, O
nmol I-GENE
/ O
mmol I-GENE
creatinine I-GENE
) O
in O
plasma I-GENE
and O
urine I-GENE
. O

As I-GENE
a O
complement I-GENE
to O
genome I-GENE
- I-GENE
wide I-GENE
mapping I-GENE
and O
sequencing I-GENE
efforts I-GENE
, O
it O
is O
often I-GENE
important O
to O
generate I-GENE
detailed O
maps I-GENE
and O
sequence O
data O
for I-GENE
specific O
regions O
of O
interest O
. O

The O
observed O
phenotypes I-GENE
may O
be O
explained O
by O
( O
i O
) O
a O
selective O
disruption I-GENE
of O
very O
- I-GENE
low O
- I-GENE
density O
lipoprotein I-GENE
secretion I-GENE
due O
to O
decreased O
expression I-GENE
of O
genes I-GENE
encoding I-GENE
apolipoprotein I-GENE
B I-GENE
and O
microsomal I-GENE
triglyceride I-GENE
transfer I-GENE
protein O
, O
( O
ii I-GENE
) O
an O
increase O
in O
hepatic I-GENE
cholesterol O
uptake O
due O
to O
increased O
expression I-GENE
of O
the O
major O
high O
- I-GENE
density O
lipoprotein I-GENE
receptor I-GENE
, O
scavenger I-GENE
receptor I-GENE
BI I-GENE
, O
and O
( O
iii I-GENE
) O
a O
decrease O
in O
bile O
acid I-GENE
uptake O
to O
the O
liver O
due O
to O
down I-GENE
- I-GENE
regulation I-GENE
of O
the O
major O
basolateral I-GENE
bile O
acid I-GENE
transporters I-GENE
sodium I-GENE
taurocholate I-GENE
cotransporter I-GENE
protein O
and O
organic I-GENE
anion I-GENE
transporter I-GENE
protein O
1 I-GENE
. O

Effects O
of O
aerosol I-GENE
- I-GENE
vapor I-GENE
JP I-GENE
- I-GENE
8 I-GENE
jet I-GENE
fuel I-GENE
on O
the O
functional I-GENE
observational I-GENE
battery I-GENE
, O
and O
learning I-GENE
and O
memory I-GENE
in O
the O
rat O
. O

In I-GENE
mouse O
, O
Mmip1 I-GENE
( O
Mad I-GENE
member I-GENE
interacting I-GENE
protein O
1 I-GENE
) O
and O
Smc3 I-GENE
share I-GENE
99 I-GENE
% O
sequence O
identity O
and O
are O
products I-GENE
of O
the O
same O
gene O
. O

To I-GENE
identify I-GENE
the O
important O
cis I-GENE
- I-GENE
DNA I-GENE
regulatory I-GENE
element I-GENE
( O
s O
) O
involved I-GENE
in O
the O
tissue O
-, I-GENE
region O
-, I-GENE
and O
cell O
- I-GENE
specific O
expression I-GENE
of O
the O
mE I-GENE
- I-GENE
RABP I-GENE
gene O
, O
the O
5 I-GENE
- I-GENE
kb O
DNA I-GENE
fragment O
was O
sequenced I-GENE
. O

Regional I-GENE
blood I-GENE
blow I-GENE
was O
measured O
by O
means I-GENE
of O
microspheres I-GENE
in O
predefined I-GENE
regions O
of O
the O
C6 I-GENE
, O
T11 I-GENE
, O
and O
L6 I-GENE
vertebrae I-GENE
. O

Breast I-GENE
cancer I-GENE
risk O
assessment O
: O
Who I-GENE
holds I-GENE
the O
magic I-GENE
crystal I-GENE
ball I-GENE
? O

The O
frameshift I-GENE
initiated I-GENE
by O
ADEx2 I-GENE
is O
believed I-GENE
to O
alter O
the O
regular I-GENE
coding I-GENE
sequence O
, O
acting I-GENE
as I-GENE
a O
loss I-GENE
- I-GENE
of O
- I-GENE
function O
ASIP I-GENE
mutation I-GENE
. O

CONCLUSIONS I-GENE
: O
Adding I-GENE
MMF I-GENE
, O
a O
potent O
topical I-GENE
corticosteroid I-GENE
, O
to O
an O
emollient I-GENE
cream I-GENE
is O
statistically O
significantly O
more O
effective O
than O
emollient I-GENE
cream I-GENE
alone O
in O
reducing I-GENE
acute O
radiation O
dermatitis I-GENE
. O

Copyright I-GENE
2001 I-GENE
Academic I-GENE
Press I-GENE
. O

CONCLUSIONS I-GENE
: O
Although I-GENE
the O
levels O
of O
oxLDL I-GENE
antibodies I-GENE
might O
be O
modified O
in O
early O
hypertension O
, O
once O
advanced O
coronary O
artery O
disease I-GENE
has O
developed O
the O
presence O
of O
hypertension O
does O
not O
affect O
anti I-GENE
- I-GENE
oxLDL I-GENE
levels O
. O

As I-GENE
an O
application O
of O
reverse I-GENE
genetics I-GENE
, O
we O
introduced O
one O
nucleotide I-GENE
change O
( O
UCU I-GENE
to O
ACU I-GENE
) O
to O
immediate I-GENE
downstream I-GENE
of O
the O
RNA O
- I-GENE
editing I-GENE
site I-GENE
of O
the O
V I-GENE
gene O
in O
the O
full I-GENE
- I-GENE
length O
hPIV2 I-GENE
cDNA I-GENE
and O
were O
able O
to O
obtain O
infectious O
viruses O
[ I-GENE
rPIV2V I-GENE
(-)] I-GENE
from O
the O
cDNA I-GENE
. O

At I-GENE
both O
companies I-GENE
sites O
Salmonella I-GENE
enteritidis I-GENE
and O
Salmonella I-GENE
typhimurium I-GENE
Tr104 I-GENE
were O
also O
isolated O
occasionally I-GENE
from O
various O
locations I-GENE
. O

Most I-GENE
yeast I-GENE
peroxisomal I-GENE
matrix I-GENE
proteins O
contain O
a O
type I-GENE
1C I-GENE
- I-GENE
terminal I-GENE
peroxisomal I-GENE
targeting I-GENE
signal I-GENE
( O
PTS1 I-GENE
) O
consisting I-GENE
of O
the O
tripeptide I-GENE
SKL I-GENE
or O
a O
conservative I-GENE
variant O
thereof I-GENE
. O

Tumor I-GENE
- I-GENE
like O
accumulation I-GENE
on O
Tl I-GENE
- I-GENE
201 I-GENE
SPECT I-GENE
in O
subacute O
hemorrhagic I-GENE
cerebral O
infarction O
. O

WRN I-GENE
helicase I-GENE
resolves I-GENE
alternate O
DNA I-GENE
structures I-GENE
including O
tetraplex I-GENE
and O
triplex I-GENE
DNA I-GENE
, O
and O
Holliday I-GENE
junctions I-GENE
. O

The O
increase O
in O
number O
of O
terminal I-GENE
hairs I-GENE
, O
which O
are O
defined O
as I-GENE
hairs I-GENE
more O
than O
60 I-GENE
microm I-GENE
in O
diameter O
, O
in O
the O
designated I-GENE
area O
( O
0 I-GENE
. O
5 I-GENE
cm O
square I-GENE
= O
0 I-GENE
. O
25 I-GENE
cm2 I-GENE
area O
) O
of O
the O
procyanidin I-GENE
B I-GENE
- I-GENE
2 I-GENE
group O
subjects O
after O
the O
6 I-GENE
- I-GENE
month O
trial O
was O
significantly O
greater O
than O
that O
of O
the O
placebo O
control O
group O
subjects O
( O
procyanidin I-GENE
B I-GENE
- I-GENE
2 I-GENE
, O
1 I-GENE
. O
99 I-GENE
+/- O
2 I-GENE
. O
58 I-GENE
( O
mean O
+/- O
SD O
)/ I-GENE
0 I-GENE
. O
25 I-GENE
cm2 I-GENE
; O
placebo O
, O
- I-GENE
0 I-GENE
. O
82 I-GENE
+/- O
3 O
. O
40 O
( O
mean O
+/- O
SD O
)/ I-GENE
0 I-GENE
. O
25 I-GENE
cm2 I-GENE
; O
P I-GENE
< I-GENE
0 I-GENE
. O
02 I-GENE
, O
two O
- I-GENE
sample O
t I-GENE
test O
). O

SKP1 I-GENE
- I-GENE
SnRK I-GENE
protein O
kinase I-GENE
interactions O
mediate O
proteasomal I-GENE
binding O
of O
a O
plant I-GENE
SCF I-GENE
ubiquitin I-GENE
ligase I-GENE
. O

Based I-GENE
on O
the O
hypothesis I-GENE
that O
evolutionarily I-GENE
conserved I-GENE
regions O
are O
functionally O
important O
and O
likely I-GENE
to O
interact I-GENE
with O
coactivators I-GENE
, O
we O
compared O
the O
amino I-GENE
acid I-GENE
sequence O
of O
C O
/ O
EBPalpha I-GENE
from O
different O
species O
( O
frog I-GENE
to O
human I-GENE
) O
and O
identified O
four O
highly O
conserved I-GENE
regions O
( O
CR1 I-GENE
- I-GENE
CR4 I-GENE
) O
within O
the O
transactivation I-GENE
domain I-GENE
. O

Colorectal I-GENE
cancer I-GENE
was O
shown O
to O
disproportionately I-GENE
overburden I-GENE
Ashkenazi I-GENE
Jews I-GENE
, O
who O
may O
also O
be O
at I-GENE
increased O
risk O
for I-GENE
ovarian O
, O
pancreatic O
and O
stomach I-GENE
cancer I-GENE
, O
and O
non O
- I-GENE
Hodgkin O
' O
s O
lymphoma I-GENE
. O

Percentages I-GENE
of O
recovery O
for I-GENE
overload I-GENE
and O
dilution O
tests O
were O
between O
87 I-GENE
and O
120 I-GENE
%. O

This I-GENE
shows O
that O
in O
situations I-GENE
of O
separated O
breaks I-GENE
, O
NHEJ I-GENE
deficiency O
leads I-GENE
to O
genomic I-GENE
rearrangements I-GENE
, O
in O
agreement I-GENE
with O
chromosomal I-GENE
studies O
. O

Copyright I-GENE
2001 I-GENE
S O
. O

After I-GENE
nerve I-GENE
injury I-GENE
, O
the O
nociceptive I-GENE
responses O
through O
type I-GENE
I O
neurons O
, O
which O
are O
polymodal I-GENE
C O
- I-GENE
fibers O
and O
drive I-GENE
NK1 I-GENE
- I-GENE
receptor I-GENE
mechanisms O
in O
spinal I-GENE
pain O
transmission I-GENE
, O
were O
completely I-GENE
lost O
, O
but O
without O
changes O
in O
type I-GENE
II I-GENE
ones I-GENE
, O
which O
are O
polymodal I-GENE
C O
- I-GENE
fibers O
and O
drive I-GENE
NMDA I-GENE
receptor I-GENE
- I-GENE
mechanisms O
, O
while O
type I-GENE
III I-GENE
ones I-GENE
, O
which O
are O
capsaicin I-GENE
- I-GENE
insensitive I-GENE
( O
possibly I-GENE
A I-GENE
- I-GENE
fibers O
) O
and O
drive I-GENE
NMDA I-GENE
- I-GENE
receptor I-GENE
mechanisms O
, O
were O
markedly O
enhanced I-GENE
. O

SV1 I-GENE
has O
a O
33 I-GENE
- I-GENE
amino I-GENE
acid I-GENE
insert I-GENE
in O
the O
S1 I-GENE
transmembrane I-GENE
domain I-GENE
that O
does O
not O
alter O
S1 I-GENE
overall O
hydrophobicity I-GENE
, O
but O
makes O
the O
S0 I-GENE
- I-GENE
S1 I-GENE
linker I-GENE
longer O
. O

A I-GENE
variety I-GENE
of O
receptor I-GENE
- I-GENE
mediated I-GENE
signaling I-GENE
pathways I-GENE
are O
controlled I-GENE
by O
both O
positive O
and O
negative O
extracellular O
regulators I-GENE
. O

A I-GENE
20 O
- I-GENE
base I-GENE
pair I-GENE
oligonucleotide I-GENE
containing O
this O
nonamer I-GENE
confers I-GENE
up I-GENE
- I-GENE
regulation I-GENE
by O
hypoxia I-GENE
and O
inhibition O
by O
unsaturated I-GENE
fatty I-GENE
acids I-GENE
when O
placed I-GENE
upstream O
of O
a O
heterologous I-GENE
promoter I-GENE
in O
a O
lacZ I-GENE
reporter I-GENE
construct I-GENE
. O

Our I-GENE
results O
indicate O
that O
D O
( O
4 O
) O
and O
D O
( O
2L I-GENE
) O
receptors I-GENE
activate I-GENE
the O
ERK I-GENE
kinase I-GENE
cascade I-GENE
by O
first I-GENE
mobilizing I-GENE
signaling I-GENE
by O
the O
PDGF I-GENE
receptor I-GENE
, O
followed O
by O
the O
subsequent O
activation I-GENE
of O
ERK1 I-GENE
/ O
2 I-GENE
by O
pathways I-GENE
associated O
with O
this O
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
. O

Raes I-GENE
, O
P I-GENE
. O

Finally I-GENE
, O
we O
compared O
the O
differential O
screening I-GENE
techniques O
in O
terms O
of O
sensitivity O
, O
efficiency I-GENE
and O
occurrence O
of O
false I-GENE
positives I-GENE
. O

C O
/ O
EBPbeta I-GENE
LIP I-GENE
overexpressing I-GENE
HC11 I-GENE
cells O
did O
not O
express I-GENE
beta I-GENE
- I-GENE
casein I-GENE
mRNA I-GENE
( O
mammary I-GENE
epithelial I-GENE
cell O
differentiation I-GENE
marker I-GENE
) O
in O
response O
to O
lactogenic I-GENE
hormones I-GENE
. O

NF I-GENE
- I-GENE
kappaB I-GENE
is O
involved I-GENE
in O
the O
regulation I-GENE
of O
CD154 I-GENE
( O
CD40 I-GENE
ligand I-GENE
) O
expression I-GENE
in O
primary I-GENE
human I-GENE
T I-GENE
cells O
. O

Subacute I-GENE
diencephalic I-GENE
angioencephalopathy I-GENE
( O
SDAE I-GENE
) O
is O
a O
rare I-GENE
and O
fatal O
disease I-GENE
of O
unknown I-GENE
etiology I-GENE
that O
involves I-GENE
the O
thalami I-GENE
bilaterally I-GENE
. O

NGF I-GENE
elicits I-GENE
a O
more O
delayed I-GENE
and O
sustained I-GENE
ERK I-GENE
phosphorylation I-GENE
than O
EGF I-GENE
, O
consistent I-GENE
with O
previous O
reports I-GENE
. O

TBARS I-GENE
levels O
, O
oxygen O
- I-GENE
radical I-GENE
absorbing I-GENE
capacity O
assay O
and O
AFR I-GENE
release O
assessed O
by O
electron O
paramagnetic I-GENE
resonance I-GENE
( O
EPR I-GENE
) O
were O
used O
to O
explore I-GENE
the O
existence O
of O
oxidative I-GENE
stress O
in O
diabetes O
. O

Pulmonary I-GENE
vein I-GENE
varix I-GENE
in O
association O
with O
bilateral O
pulmonary O
vein I-GENE
stenosis O
. O

Derivation I-GENE
and O
initial O
characterization I-GENE
of O
a O
mouse O
mammary I-GENE
tumor O
cell O
line I-GENE
carrying I-GENE
the O
polyomavirus I-GENE
middle I-GENE
T I-GENE
antigen I-GENE
: O
utility I-GENE
in O
the O
development O
of O
novel I-GENE
cancer I-GENE
therapeutics I-GENE
. O

The O
images O
showed O
rapid O
, O
predominantly I-GENE
urinary I-GENE
excretion O
of O
99mTc O
ciprofloxacin I-GENE
, O
with O
low O
to O
absent O
brain O
, O
lung I-GENE
and O
bone O
marrow O
uptake O
and O
low O
liver O
uptake O
and O
excretion O
. O

Thus I-GENE
, O
the O
anti I-GENE
- I-GENE
interferon I-GENE
functions O
of O
vIRF I-GENE
- I-GENE
2 I-GENE
may O
contribute I-GENE
to O
the O
establishment O
of O
a O
chronic O
or O
latent I-GENE
infection O
. O

Topological I-GENE
and O
mutational I-GENE
analysis O
of O
Saccharomyces I-GENE
cerevisiae I-GENE
Ste14p I-GENE
, O
founding I-GENE
member I-GENE
of O
the O
isoprenylcysteine I-GENE
carboxyl I-GENE
methyltransferase I-GENE
family I-GENE
. O

Two I-GENE
remotely I-GENE
situated I-GENE
exons I-GENE
within O
the O
complement I-GENE
C3 I-GENE
gene O
locus I-GENE
encode I-GENE
an O
alternate O
5 I-GENE
' O
end O
and O
proximal I-GENE
ORF I-GENE
under O
the O
control O
of O
a O
bidirectional I-GENE
promoter I-GENE
. O

Although I-GENE
there O
was O
a O
high O
correlation O
between O
sap I-GENE
flux I-GENE
densities I-GENE
registered I-GENE
by O
the O
old O
and O
new O
sensors I-GENE
, O
significant O
differences O
in O
sap I-GENE
flux I-GENE
densities I-GENE
between O
the O
duplicated I-GENE
sensors I-GENE
were O
detected O
. O

Their I-GENE
numbers O
have O
regularly I-GENE
increased O
since I-GENE
the O
mid O
- I-GENE
1970s I-GENE
. O

The O
hcKrox I-GENE
gene O
family I-GENE
regulates I-GENE
multiple O
extracellular O
matrix I-GENE
genes I-GENE
. O

NB I-GENE
- I-GENE
506 I-GENE
completely I-GENE
inhibits O
the O
capacity O
of O
topoisomerase I-GENE
I O
to O
phosphorylate I-GENE
, O
in O
vitro O
, O
the O
human I-GENE
splicing I-GENE
factor I-GENE
2 I-GENE
/ O
alternative I-GENE
splicing I-GENE
factor I-GENE
( O
SF2 I-GENE
/ O
ASF I-GENE
). O

Recent I-GENE
studies O
using O
isolated O
rat O
adipocytes I-GENE
and O
chemically I-GENE
synthesized O
PIG I-GENE
compounds O
point I-GENE
to O
IRS1 I-GENE
/ O
3 O
tyrosine I-GENE
phosphorylation I-GENE
by O
p59Lyn I-GENE
kinase I-GENE
as I-GENE
the O
site I-GENE
of O
cross O
- I-GENE
talk I-GENE
, O
the O
negative O
regulation I-GENE
of O
which O
by O
interaction O
with O
caveolin I-GENE
is O
apparently I-GENE
abrogated I-GENE
by O
PIG I-GENE
. O

To I-GENE
investigate O
the O
effects O
of O
exogenous I-GENE
hyaluronic I-GENE
acid I-GENE
, O
the O
development O
of O
port I-GENE
- I-GENE
site I-GENE
metastasis I-GENE
was O
examined O
using O
mouse O
adenocarcinoma I-GENE
cell O
- I-GENE
line I-GENE
colon I-GENE
26 I-GENE
cells O
. O

METHODS I-GENE
: O
Thyroid I-GENE
status O
was O
measured O
at I-GENE
baseline O
( O
1990 I-GENE
- I-GENE
93 I-GENE
), I-GENE
through O
assessment O
of O
serum I-GENE
antibodies I-GENE
to O
thyroid O
peroxidase I-GENE
( O
TPO I-GENE
- I-GENE
Abs I-GENE
, O
positive O
: O
> I-GENE
10 O
IU O
/ O
ml O
), I-GENE
serum I-GENE
TSH I-GENE
levels O
, O
and O
when O
TSH I-GENE
was O
abnormal O
(< I-GENE
0 I-GENE
. O
4 O
or O
> I-GENE
4 O
. O
0 I-GENE
mU I-GENE
/ O
l I-GENE
), I-GENE
serum I-GENE
thyroxin I-GENE
levels O
( O
T4 I-GENE
). O

Mechanical I-GENE
ventilation O
in O
control O
lungs I-GENE
produced O
a O
47 I-GENE
% O
decrease O
in O
chord I-GENE
compliance O
, O
an O
increase O
in O
lung I-GENE
lavage I-GENE
levels O
of O
tumor O
necrosis I-GENE
factor I-GENE
( O
TNF I-GENE
)- O
alpha I-GENE
( O
722 I-GENE
+/- O
306 I-GENE
pg O
/ O
ml O
), I-GENE
interleukin I-GENE
( O
IL I-GENE
)- O
1beta I-GENE
( O
902 I-GENE
+/- O
322 I-GENE
pg O
/ O
ml O
), I-GENE
and O
macrophage O
inflammatory O
protein O
- I-GENE
2 I-GENE
( O
MIP I-GENE
- I-GENE
2 I-GENE
) O
( O
363 I-GENE
+/- O
104 I-GENE
pg O
/ O
ml O
) O
as I-GENE
compared O
with O
low O
levels O
of O
cytokines I-GENE
detected O
in O
preventilation I-GENE
data O
, O
and O
no I-GENE
change O
in O
percentage O
of O
surfactant I-GENE
large O
aggregates I-GENE
( O
LA O
). O

Autoregulation I-GENE
enables I-GENE
different O
pathways I-GENE
to O
control O
CCAAT I-GENE
/ O
enhancer I-GENE
binding O
protein O
beta I-GENE
( O
C O
/ O
EBP I-GENE
beta I-GENE
) O
transcription O
. O

In I-GENE
the O
past I-GENE
decade I-GENE
, O
there O
have O
been O
enormous I-GENE
advances I-GENE
in O
the O
use O
of O
Bayesian I-GENE
methodology I-GENE
for I-GENE
analysis O
of O
epidemiologic I-GENE
data O
, O
and O
there O
are O
now O
many O
practical I-GENE
advantages O
to O
the O
Bayesian I-GENE
approach O
. O

In I-GENE
strains O
lacking I-GENE
tup11 I-GENE
and O
tup12 I-GENE
, O
the O
atf1 I-GENE
- I-GENE
pcr1 I-GENE
transcriptional I-GENE
activator I-GENE
continues I-GENE
to O
play I-GENE
a O
central O
role O
in O
fbp1 I-GENE
- I-GENE
lacZ I-GENE
expression I-GENE
; O
however O
, O
spc1 I-GENE
MAPK I-GENE
phosphorylation I-GENE
of O
atf1 I-GENE
is O
no I-GENE
longer O
essential O
for I-GENE
its O
activation I-GENE
. O

Single I-GENE
amino I-GENE
acid I-GENE
substitutions I-GENE
at I-GENE
the O
acyl I-GENE
- I-GENE
CoA I-GENE
- I-GENE
binding O
domain I-GENE
interrupt I-GENE
14 O
[ I-GENE
C O
] O
palmitoyl I-GENE
- I-GENE
CoA I-GENE
binding O
of O
ACBP2 I-GENE
, O
an O
Arabidopsis I-GENE
acyl I-GENE
- I-GENE
CoA I-GENE
- I-GENE
binding O
protein O
with O
ankyrin I-GENE
repeats I-GENE
. O

RESULTS I-GENE
: O
Sixty I-GENE
per O
cent O
of O
African O
Americans I-GENE
exposed O
in O
26 I-GENE
community O
outbreaks I-GENE
were O
TST I-GENE
positive O
compared O
to O
only O
40 O
% O
of O
whites I-GENE
following O
comparable O
exposures I-GENE
. O

For I-GENE
immunological I-GENE
methods O
, O
identification I-GENE
of O
such O
antigens O
with O
intermolecular I-GENE
variability O
, O
e I-GENE
. O
g O
., O
the O
structural I-GENE
aescin I-GENE
analogs I-GENE
, O
is O
of O
unknown I-GENE
validity I-GENE
. O

It O
was O
found O
that O
intrathecal I-GENE
administration O
( O
i O
. O
t I-GENE
.) O
of O
D2 I-GENE
receptor I-GENE
agonist I-GENE
LY171555 I-GENE
or O
D1 I-GENE
/ O
D2 I-GENE
receptor I-GENE
agonist I-GENE
apomorphine I-GENE
increased O
pain O
threshold O
and O
had O
a O
potentiating I-GENE
effect O
on O
AA I-GENE
. O

Interactions I-GENE
between O
the O
checkpoint I-GENE
abrogator I-GENE
UCN I-GENE
- I-GENE
01 O
and O
several I-GENE
pharmacological O
inhibitors I-GENE
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein O
kinase I-GENE
( O
MAPK I-GENE
) O
kinase I-GENE
( O
MEK I-GENE
)/ I-GENE
MAPK I-GENE
pathway I-GENE
have O
been O
examined O
in O
a O
variety I-GENE
of O
human I-GENE
leukemia O
cell O
lines I-GENE
. O

Analysis I-GENE
of O
regulatory I-GENE
regions O
in O
the O
promoter I-GENE
of O
the O
ctr4 I-GENE
(+) I-GENE
copper I-GENE
transporter I-GENE
gene O
in O
fission I-GENE
yeast I-GENE
Schizosaccharomyces I-GENE
pombe I-GENE
reveals I-GENE
the O
identity O
of O
a O
conserved I-GENE
copper I-GENE
- I-GENE
signaling I-GENE
element I-GENE
( O
CuSE I-GENE
), I-GENE
which O
is O
recognized I-GENE
by O
the O
transcription O
factor I-GENE
Cuf1 I-GENE
. O

However I-GENE
, O
during I-GENE
our O
work O
with O
a O
replication I-GENE
- I-GENE
deficient I-GENE
virus O
expressing I-GENE
the O
ASF I-GENE
/ O
SF2 I-GENE
splicing I-GENE
factor I-GENE
from O
a O
progesterone O
antagonist I-GENE
- I-GENE
inducible I-GENE
gene O
cassette I-GENE
, O
we O
discovered I-GENE
that O
ASF I-GENE
/ O
SF2 I-GENE
was O
expressed I-GENE
at I-GENE
a O
significant O
level O
in O
the O
293 I-GENE
producer I-GENE
cell O
line I-GENE
, O
even O
in O
the O
absence O
of O
inducer I-GENE
. O

This I-GENE
study O
suggests O
that O
PSP I-GENE
is O
more O
common O
than O
previously O
considered O
, O
is O
commonly O
misdiagnosed I-GENE
and O
that O
the O
majority O
of O
cases O
are O
not O
initially O
referred I-GENE
to O
neurologists I-GENE
. O

Between I-GENE
1967 I-GENE
and O
1994 O
, O
495 I-GENE
patients O
underwent O
surgery O
for I-GENE
primary I-GENE
PTC I-GENE
at I-GENE
the O
Department I-GENE
of O
Surgery I-GENE
, O
Helsinki I-GENE
University O
Central I-GENE
Hospital I-GENE
. O

The O
described O
results O
show O
that O
DTD I-GENE
is O
fast O
, O
simple O
, O
and O
easy I-GENE
to O
automate I-GENE
; O
requires O
only O
a O
small O
amount O
of O
sample O
( O
approximately I-GENE
50 O
mg O
); O
and O
affords I-GENE
quantitative O
information I-GENE
about O
the O
main O
groups O
of O
compounds O
present O
in O
cheeses I-GENE
. O

Srb10 I-GENE
is O
a O
physiological O
regulator I-GENE
of O
Gcn4 I-GENE
stability O
because I-GENE
both O
phosphorylation I-GENE
and O
turnover O
of O
Gcn4 I-GENE
are O
diminished I-GENE
in O
srb10 I-GENE
mutants I-GENE
. O

The O
promoter I-GENE
activity O
of O
the O
proximal I-GENE
region O
was O
found O
to O
be O
restricted I-GENE
to O
a O
subset I-GENE
of O
prestalk I-GENE
cells O
. O

Two I-GENE
nuclear O
medicine O
physicians I-GENE
blinded I-GENE
to O
the O
surgical O
findings O
interpreted O
all O
available O
images O
and O
various O
Tc O
- I-GENE
99m O
MIBI I-GENE
image I-GENE
combinations I-GENE
at I-GENE
15 I-GENE
minutes O
alone O
; O
15 I-GENE
minutes O
and O
2 I-GENE
hours O
, O
15 I-GENE
minutes O
and O
4 O
hours O
; O
and O
15 I-GENE
minutes O
and O
2 I-GENE
and O
4 O
hours O
each O
with O
and O
without O
correlative I-GENE
pertechnetate I-GENE
thyroid O
imaging O
. O

We I-GENE
demonstrated O
that O
, O
under O
serum I-GENE
- I-GENE
starved I-GENE
conditions O
, O
KMS I-GENE
- I-GENE
11 O
and O
OPM I-GENE
- I-GENE
2 I-GENE
cells O
express I-GENE
appreciable I-GENE
levels O
of O
phosphorylated I-GENE
FGFR3 I-GENE
mutants I-GENE
indicating I-GENE
a O
constitutive I-GENE
activation I-GENE
of O
the O
Y373C I-GENE
and O
K650E I-GENE
receptors I-GENE
; O
the O
addition O
of O
the O
aFGF I-GENE
ligand I-GENE
further O
increased O
the O
level O
of O
receptor I-GENE
phosphorylation I-GENE
. O

Identical I-GENE
effects O
were O
obtained O
when O
inhibitors I-GENE
and O
dominant I-GENE
negative O
mutants I-GENE
were O
tested O
on O
the O
- I-GENE
29 O
to O
+ O
139 I-GENE
bp I-GENE
region O
of O
the O
cyclin I-GENE
D1 I-GENE
promoter I-GENE
. O

In I-GENE
this O
paper O
the O
tyrosine I-GENE
dephosphorylating I-GENE
enzymes I-GENE
, O
the O
protein O
- I-GENE
tyrosine I-GENE
phosphatases I-GENE
( O
PTPs I-GENE
), I-GENE
are O
studied O
which O
can O
be O
grouped I-GENE
into O
two O
subfamilies I-GENE
, O
the O
soluble I-GENE
PTPs I-GENE
and O
the O
receptor I-GENE
PTPs I-GENE
( O
RPTPs I-GENE
). O

Coexposure I-GENE
to O
FP I-GENE
also O
resulted O
in O
a O
more O
pronounced O
and O
sustained I-GENE
activation I-GENE
of O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein O
kinase I-GENE
kinase I-GENE
/ O
extracellular O
signal I-GENE
- I-GENE
regulated I-GENE
protein O
kinase I-GENE
cascade I-GENE
after O
PMA I-GENE
treatment O
, O
although O
disruption I-GENE
of O
this O
pathway I-GENE
by O
the O
mitogen I-GENE
- I-GENE
activated I-GENE
protein O
kinase I-GENE
kinase I-GENE
1 I-GENE
inhibitor I-GENE
U0126 I-GENE
did O
not O
prevent I-GENE
potentiation I-GENE
of O
apoptosis I-GENE
. O

The O
LA O
50s I-GENE
derived I-GENE
from O
this O
combined O
data O
when O
compared O
with O
our O
earlier O
series O
from O
1965 I-GENE
to O
1970 I-GENE
also O
did O
not O
show O
a O
significant O
change O
in O
mortality O
. O

Most I-GENE
patients O
harboring I-GENE
metronidazole I-GENE
- I-GENE
and O
clarithromycin I-GENE
- I-GENE
resistant O
strains O
were O
eradicated I-GENE
at I-GENE
an O
equal O
rate O
by O
each O
of O
the O
three O
regimens O
. O

Responses I-GENE
of O
single O
- I-GENE
unit O
carotid O
body O
chemoreceptors I-GENE
in O
adult O
rats O
. O

Thus I-GENE
, O
MKK7 I-GENE
is O
an O
essential O
and O
specific O
regulator I-GENE
of O
stress O
- I-GENE
induced I-GENE
SAPK I-GENE
/ O
JNK I-GENE
activation I-GENE
in O
mast I-GENE
cells O
and O
MKK7 I-GENE
negatively I-GENE
regulates I-GENE
growth O
factor I-GENE
and O
antigen I-GENE
receptor I-GENE
- I-GENE
driven I-GENE
proliferation I-GENE
in O
hematopoietic I-GENE
cells O
. O

The O
N O
- I-GENE
terminal I-GENE
portion O
of O
Notch I-GENE
( O
IC I-GENE
) O
inhibited O
p50 I-GENE
DNA I-GENE
binding O
and O
interacted I-GENE
specifically I-GENE
with O
p50 I-GENE
subunit I-GENE
, O
not O
p65 I-GENE
of O
NF I-GENE
- I-GENE
kappaB I-GENE
. O

To I-GENE
account O
for I-GENE
this O
observation I-GENE
, O
other O
possible O
causes O
include I-GENE
increased O
CSF O
pulsation I-GENE
in O
children O
creating I-GENE
motion I-GENE
artifact I-GENE
, O
changes O
in O
arterial O
oxygen O
concentration O
intrinsic I-GENE
to O
propofol I-GENE
or O
related O
to O
the O
supplemental I-GENE
oxygen O
normally O
administered O
, O
or O
changes O
in O
CSF O
protein O
levels O
related O
to O
propofol I-GENE
binding O
to O
proteins O
for I-GENE
uptake O
into O
CSF O
. O

Molecular I-GENE
cloning I-GENE
and O
characterization I-GENE
of O
OsPSK I-GENE
, O
a O
gene O
encoding I-GENE
a O
precursor I-GENE
for I-GENE
phytosulfokine I-GENE
- I-GENE
alpha I-GENE
, O
required O
for I-GENE
rice I-GENE
cell O
proliferation I-GENE
. O

The O
present O
study O
was O
initiated I-GENE
to O
explore I-GENE
the O
potential I-GENE
of O
a O
hybrid I-GENE
biological O
reactor I-GENE
, O
combining I-GENE
trickling I-GENE
filter I-GENE
( O
TF I-GENE
) O
and O
activated I-GENE
sludge I-GENE
process O
( O
ASP I-GENE
), I-GENE
to O
treat I-GENE
wastewater I-GENE
containing O
trichloroethylene I-GENE
( O
TCE I-GENE
) O
at I-GENE
ambient I-GENE
temperature I-GENE
at I-GENE
different O
hydraulic I-GENE
retention O
time O
( O
HRT I-GENE
). O

If I-GENE
you I-GENE
think I-GENE
education I-GENE
is O
expensive I-GENE
-- I-GENE
try I-GENE
ignorance I-GENE
-- I-GENE
Bok I-GENE
' O
s O
Law I-GENE
. O

The O
COD I-GENE
and O
color O
removals I-GENE
were O
both O
more O
than O
90 I-GENE
% O
when O
FeCl3 I-GENE
was O
used O
as I-GENE
the O
coagulation O
( O
dosages I-GENE
of O
two O
- I-GENE
step I-GENE
coagulation O
were O
0 I-GENE
. O
031 I-GENE
and O
0 I-GENE
. O
012 I-GENE
mol I-GENE
/ O
L O
respectively O
) O
after O
a O
ferrous I-GENE
hydrogen I-GENE
peroxide I-GENE
oxidation I-GENE
pretreatment I-GENE
at I-GENE
a O
H2O2 I-GENE
dosage O
of O
0 I-GENE
. O
06 I-GENE
mol I-GENE
/ O
L O
. O

An I-GENE
element I-GENE
within O
the O
5 I-GENE
' O
untranslated I-GENE
region O
of O
human I-GENE
Hsp70 I-GENE
mRNA I-GENE
which O
acts I-GENE
as I-GENE
a O
general I-GENE
enhancer I-GENE
of O
mRNA I-GENE
translation I-GENE
. O

The O
selective O
alteration I-GENE
of O
the O
genome I-GENE
using O
Cre I-GENE
recombinase I-GENE
to O
target I-GENE
the O
rearrangement I-GENE
of O
genes I-GENE
flanked I-GENE
by O
LOX I-GENE
recognition O
sequences O
has O
required O
the O
use O
of O
two O
separate O
genetic I-GENE
constructs I-GENE
in O
trans I-GENE
, O
one O
containing O
cre I-GENE
and O
the O
other O
containing O
the O
gene O
of O
interest O
flanked I-GENE
by O
LOX I-GENE
sites O
. O

It O
has O
been O
suggested O
that O
members I-GENE
of O
this O
protein O
family I-GENE
exhibit O
both O
prolyl I-GENE
isomerase I-GENE
and O
chaperone I-GENE
activity O
. O

Newcastle I-GENE
disease I-GENE
antibody I-GENE
titre I-GENE
is O
dependent O
on O
serum I-GENE
calcium I-GENE
concentration O
. O

In I-GENE
three O
cases O
( O
21 O
. O
4 O
%), I-GENE
the O
MR O
imaging O
was O
interpreted O
as I-GENE
negative O
, O
but O
microscopic O
tumor O
was O
shown O
around O
seroma I-GENE
on O
reexcision I-GENE
. O

2 I-GENE
were O
nonviable I-GENE
, O
and O
the O
mutant I-GENE
Vp1s I-GENE
unexpectedly I-GENE
failed O
to O
localize I-GENE
to O
the O
nucleus O
though I-GENE
Vp2 I-GENE
and O
Vp3 I-GENE
did O
, O
suggesting O
that O
the O
mutated I-GENE
NLS1 I-GENE
acted I-GENE
as I-GENE
a O
dominant I-GENE
signal I-GENE
for I-GENE
the O
cytoplasmic I-GENE
localization I-GENE
of O
Vp1 I-GENE
. O

Compared I-GENE
with O
normal O
control O
subjects O
, O
all O
74 I-GENE
TOF I-GENE
patients O
had O
decreased O
systolic O
and O
diastolic O
myocardial I-GENE
velocities I-GENE
and O
a O
longer O
isovolumic I-GENE
relaxation I-GENE
time O
. O

The O
corresponding O
orifice I-GENE
voltages I-GENE
for I-GENE
the O
three O
instruments I-GENE
were O
20 O
/ O
50 O
/ O
80 I-GENE
V I-GENE
( O
API I-GENE
365 I-GENE
), I-GENE
30 I-GENE
/ O
90 I-GENE
/ O
130 I-GENE
V I-GENE
( O
API I-GENE
2000 I-GENE
) O
and O
40 O
/ O
80 I-GENE
/ O
120 I-GENE
V I-GENE
( O
API I-GENE
3000 I-GENE
). O

We I-GENE
compared O
previously O
the O
methylation I-GENE
status O
between O
normal O
liver O
and O
liver O
tumors O
in O
SV40 O
T I-GENE
/ O
t I-GENE
antigen I-GENE
transgenic I-GENE
mice O
( O
MT I-GENE
- I-GENE
D2 I-GENE
mice O
) O
using O
Restriction I-GENE
Landmark I-GENE
Genomic I-GENE
Scanning I-GENE
for I-GENE
Methylation I-GENE
( O
RLGS I-GENE
- I-GENE
M O
) O
and O
identified O
several I-GENE
loci O
/ O
spots I-GENE
that O
appeared O
to O
be O
methylated I-GENE
frequently O
in O
liver O
tumors O
. O

We I-GENE
have O
cloned I-GENE
a O
novel I-GENE
mouse O
protein O
, O
TAF I-GENE
( O
II I-GENE
) O
140 I-GENE
, O
containing O
an O
HFD I-GENE
and O
a O
plant I-GENE
homeodomain I-GENE
( O
PHD I-GENE
) O
finger I-GENE
, O
which O
we O
demonstrated O
by O
immunoprecipitation I-GENE
to O
be O
a O
mammalian I-GENE
TFIID I-GENE
component I-GENE
. O

3D I-GENE
image I-GENE
- I-GENE
processing I-GENE
permits I-GENE
to O
analyse I-GENE
ultrasound I-GENE
data O
interactively I-GENE
in O
three O
orthogonal I-GENE
planes I-GENE
( O
section O
mode O
) O
or O
in O
realistic I-GENE
3D I-GENE
views I-GENE
( O
rendering I-GENE
mode O
). O

A I-GENE
proposal I-GENE
of O
50 O
performance O
indicators I-GENE
divided O
into O
five O
different O
groups O
is O
presented O
here I-GENE
, O
namely O
structural I-GENE
indicators I-GENE
, O
operational I-GENE
indicators I-GENE
, O
water O
and O
service I-GENE
quality O
indicators I-GENE
, O
personnel I-GENE
indicators I-GENE
and O
economic I-GENE
indicators I-GENE
. O

These I-GENE
analyses O
re O
- I-GENE
open I-GENE
the O
question I-GENE
whether O
all O
the O
CesA I-GENE
genes I-GENE
encode I-GENE
cellulose I-GENE
synthases I-GENE
or O
whether O
some O
of O
the O
sub O
- I-GENE
class O
members I-GENE
may O
encode I-GENE
other O
non O
- I-GENE
cellulosic I-GENE
( O
1 I-GENE
--> I-GENE
4 O
) O
beta I-GENE
- I-GENE
glycan I-GENE
synthases I-GENE
in O
plants I-GENE
. O

The O
relationship O
of O
the O
factor I-GENE
V I-GENE
Leiden I-GENE
mutation I-GENE
or O
the O
deletion I-GENE
- I-GENE
deletion I-GENE
polymorphism I-GENE
of O
the O
angiotensin I-GENE
converting I-GENE
enzyme O
to O
postoperative I-GENE
thromboembolic I-GENE
events I-GENE
following O
total I-GENE
joint O
arthroplasty I-GENE
. O

In I-GENE
contrast O
, O
exogenous I-GENE
PTHrP1 I-GENE
- I-GENE
34 I-GENE
and O
1 I-GENE
- I-GENE
86 I-GENE
peptides I-GENE
did O
not O
significantly O
affect O
IL I-GENE
- I-GENE
8 I-GENE
production O
; O
moreover I-GENE
, O
PTHrP I-GENE
- I-GENE
neutralizing I-GENE
antibodies I-GENE
did O
not O
inhibit I-GENE
the O
production O
of O
IL I-GENE
- I-GENE
8 I-GENE
by O
transfected I-GENE
PTHrP I-GENE
. O

Furthermore I-GENE
, O
this O
kinase I-GENE
- I-GENE
deficient I-GENE
mutant I-GENE
inhibited O
2 I-GENE
- I-GENE
MeSADP I-GENE
- I-GENE
induced I-GENE
caspase I-GENE
- I-GENE
3 O
stimulation I-GENE
and O
the O
associated O
decrease O
in O
cell O
number O
. O

Against I-GENE
gram O
- I-GENE
positive O
organisms O
, O
E I-GENE
- I-GENE
4767 I-GENE
and O
E I-GENE
- I-GENE
5065 I-GENE
were O
, O
in O
general I-GENE
, O
eight I-GENE
- I-GENE
and O
fourfold I-GENE
more O
active I-GENE
than O
tosufloxacin I-GENE
, O
which O
is O
the O
most O
potent O
of O
the O
reference I-GENE
compounds O
. O

The O
results O
presented O
here I-GENE
show O
that O
AR1 I-GENE
of O
the O
promoter I-GENE
- I-GENE
proximal I-GENE
CAP I-GENE
subunit I-GENE
was O
required O
for I-GENE
papBA I-GENE
transcription O
even O
in O
the O
absence O
of O
the O
histone I-GENE
- I-GENE
like O
protein O
H O
- I-GENE
NS I-GENE
. O

CONCLUSIONS I-GENE
: O
Under I-GENE
current I-GENE
immunization I-GENE
practices I-GENE
, O
the O
authors O
estimate I-GENE
that O
nearly I-GENE
13 I-GENE
, O
000 I-GENE
Asian I-GENE
and O
Pacific I-GENE
Islander I-GENE
children O
living I-GENE
in O
the O
United I-GENE
States I-GENE
today I-GENE
will I-GENE
become O
infected I-GENE
with O
HBV I-GENE
in O
the O
future I-GENE
, O
resulting O
in O
more O
than O
600 O
liver O
carcinoma O
deaths I-GENE
. O

METHODS I-GENE
: O
A I-GENE
structured I-GENE
interview I-GENE
was O
undertaken O
at I-GENE
the O
time O
of O
initial O
consultation I-GENE
and O
at I-GENE
subsequent O
1 I-GENE
- I-GENE
year O
intervals O
regarding I-GENE
type I-GENE
of O
BHS I-GENE
, O
frequency O
of O
spells I-GENE
, O
associated O
phenomenon O
, O
sequelae I-GENE
, O
family I-GENE
history O
, O
and O
age O
at I-GENE
termination I-GENE
of O
spells I-GENE
. O

Cell I-GENE
. O

Rapid I-GENE
evolution I-GENE
of O
the O
DNA I-GENE
- I-GENE
binding O
site I-GENE
in O
LAGLIDADG I-GENE
homing I-GENE
endonucleases I-GENE
. O

These I-GENE
mutations I-GENE
, O
when O
placed I-GENE
in O
a O
wild I-GENE
- I-GENE
type I-GENE
fliF I-GENE
background O
, O
had O
no I-GENE
mutant I-GENE
phenotype I-GENE
. O

Inhibition I-GENE
of O
JNK1 I-GENE
and O
ERK I-GENE
kinase I-GENE
activities O
either O
by O
expression I-GENE
of O
the O
dominant I-GENE
negative O
mutant I-GENE
JNK1 I-GENE
or O
by O
treatment O
with O
a O
selective O
chemical O
inhibitor I-GENE
of O
ERK I-GENE
( O
PD098059 I-GENE
) O
substantially I-GENE
abrogates I-GENE
the O
UV I-GENE
induction O
of O
the O
GADD45 I-GENE
promoter I-GENE
. O

At I-GENE
termination I-GENE
( O
gd I-GENE
20 O
), I-GENE
confirmed I-GENE
- I-GENE
pregnant I-GENE
females O
( O
21 O
to O
25 I-GENE
per O
group O
) O
were O
evaluated O
for I-GENE
clinical O
status O
and O
gestational O
outcome I-GENE
; O
live O
fetuses I-GENE
were O
examined O
for I-GENE
external O
, O
visceral I-GENE
, O
and O
skeletal O
malformations I-GENE
. O

In I-GENE
mammals I-GENE
, O
the O
transcriptional I-GENE
repressors I-GENE
in O
the O
Wnt I-GENE
pathway I-GENE
are O
not O
well I-GENE
defined O
. O

Intravenous I-GENE
L O
- I-GENE
carnitine I-GENE
treatment O
increased O
plasma I-GENE
carnitine I-GENE
concentrations O
, O
improved O
patient O
- I-GENE
assessed O
fatigue I-GENE
, O
and O
may O
prevent I-GENE
the O
decline O
in O
peak O
exercise O
capacity O
in O
hemodialysis I-GENE
patients O
. O

The O
Van I-GENE
der I-GENE
Hoeve I-GENE
' O
s O
syndrome I-GENE
lesions O
as I-GENE
poorly I-GENE
mineralized I-GENE
, O
with O
low O
calcium I-GENE
salt I-GENE
and O
apparent O
increase O
of O
phosphates I-GENE
. O

A I-GENE
computerized O
method O
of O
determining I-GENE
the O
focal I-GENE
point I-GENE
of O
electrical I-GENE
activity O
in O
the O
pallidum I-GENE
of O
parkinsonian I-GENE
patients O
was O
developed O
using O
on O
- I-GENE
line I-GENE
quantitative O
physiological O
data O
analysis O
. O

The O
first I-GENE
hypothesis I-GENE
was O
supported I-GENE
in O
the O
sense O
that O
stimulus O
differences O
might O
affect O
behaviour O
even O
without O
their O
successful I-GENE
attentive I-GENE
processing I-GENE
in O
normal O
participants I-GENE
. O

We I-GENE
interpret I-GENE
these O
data O
as I-GENE
further O
evidence O
that O
interaction O
with O
a O
small O
GTPase I-GENE
is O
the O
main O
regulatory I-GENE
function O
of O
the O
C1 O
domain I-GENE
in O
yeast I-GENE
. O

This I-GENE
effect O
was O
observed O
in O
the O
absence O
of O
de I-GENE
novo I-GENE
protein O
synthesis I-GENE
and O
was O
independent O
of O
histone I-GENE
deacetylase I-GENE
activity O
. O

Mutation I-GENE
analyses O
identified O
the O
cobalt I-GENE
- I-GENE
responsive O
sequences O
as I-GENE
the O
stress O
- I-GENE
response O
elements I-GENE
( O
StREs I-GENE
). O

In I-GENE
order O
to O
quantify I-GENE
these O
effects O
, O
tests O
were O
conducted O
in O
the O
NASA I-GENE
MSFC I-GENE
Neutral I-GENE
Buoyancy I-GENE
Simulator I-GENE
, O
in O
the O
NASA I-GENE
KC I-GENE
- I-GENE
135 O
in O
parabolic I-GENE
flight I-GENE
, O
and O
in O
space I-GENE
with O
the O
EASE I-GENE
program O
during I-GENE
the O
Shuttle I-GENE
Atlantis I-GENE
mission I-GENE
61 I-GENE
- I-GENE
B I-GENE
. O

OBJECTIVE I-GENE
: O
To I-GENE
investigate O
the O
association O
between O
complete I-GENE
congenital I-GENE
heart I-GENE
block I-GENE
( O
CCHB I-GENE
) O
in O
the O
fetus I-GENE
and O
adult O
disease I-GENE
. O

The O
present O
chemotherapy I-GENE
of O
AE I-GENE
is O
based O
on O
the O
administration O
of O
benzimidazole I-GENE
carbamate I-GENE
derivatives I-GENE
, O
such O
as I-GENE
mebendazole I-GENE
and O
albendazole I-GENE
. O

The O
uptake O
of O
fluorine I-GENE
- I-GENE
18 O
fluorodeoxyglucose I-GENE
( O
F O
- I-GENE
18 O
FDG I-GENE
) O
by O
a O
malignant I-GENE
tumor O
depends I-GENE
on O
the O
blood I-GENE
glucose O
level O
. O

Deterministic I-GENE
effects O
. O

DESIGN I-GENE
: O
A I-GENE
retrospective I-GENE
chart I-GENE
review O
of O
9 O
, O
322 I-GENE
patients O
undergoing O
surgical O
procedures O
in O
the O
period O
January I-GENE
1993 I-GENE
to O
December I-GENE
1998 I-GENE
. O

Peripheral I-GENE
and O
preemptive I-GENE
opioid I-GENE
antinociception I-GENE
in O
a O
mouse O
visceral I-GENE
pain O
model O
. O

METHODS I-GENE
: O
We I-GENE
studied O
the O
clinical O
benefit I-GENE
of O
depth O
- I-GENE
dependent O
RR I-GENE
, O
nonuniform I-GENE
AC I-GENE
using O
a O
scanning I-GENE
line I-GENE
source O
, O
and O
scatter I-GENE
correction I-GENE
( O
photon I-GENE
energy I-GENE
recovery O
[ I-GENE
PER I-GENE
]) I-GENE
compared O
with O
filtered I-GENE
backprojection I-GENE
alone O
. O

Cloning I-GENE
and O
characterization I-GENE
of O
the O
murine I-GENE
beta I-GENE
( O
3 O
) O
integrin I-GENE
gene O
promoter I-GENE
: O
identification I-GENE
of O
an O
interleukin I-GENE
- I-GENE
4 O
responsive O
element I-GENE
and O
regulation I-GENE
by O
STAT I-GENE
- I-GENE
6 I-GENE
. O

DNA I-GENE
binding O
assays O
confirmed I-GENE
the O
interference O
of O
p30 I-GENE
( O
II I-GENE
) O
with O
the O
assembly I-GENE
of O
CREB I-GENE
- I-GENE
Tax I-GENE
- I-GENE
p300 I-GENE
/ O
CBP I-GENE
multiprotein I-GENE
complexes I-GENE
on O
21 O
- I-GENE
bp I-GENE
repeat I-GENE
oligonucleotides I-GENE
in O
vitro O
. O

Transient I-GENE
transfections I-GENE
showed O
that O
a O
single O
mutation I-GENE
( O
556M I-GENE
) O
decreased O
TBLV I-GENE
enhancer I-GENE
activity O
at I-GENE
least O
20 O
- I-GENE
fold I-GENE
in O
two O
different O
T I-GENE
- I-GENE
cell O
lines I-GENE
. O

In I-GENE
conclusion I-GENE
, O
tube I-GENE
size O
estimated O
by O
Cole I-GENE
' O
s O
formula I-GENE
tends I-GENE
to O
be O
smaller O
than O
practically I-GENE
appropriate I-GENE
tube I-GENE
size O
for I-GENE
pediatric O
cardiac O
anesthesia O
, O
and O
therefore I-GENE
we O
suggest O
new O
formula I-GENE
to O
estimate I-GENE
the O
tube I-GENE
size O
. O

Thus I-GENE
, O
in O
T47D I-GENE
breast O
carcinoma O
cells O
, O
IL I-GENE
- I-GENE
6 I-GENE
acts I-GENE
in O
synergy I-GENE
with O
EGF I-GENE
receptor I-GENE
autocrine I-GENE
activity O
to O
signal I-GENE
through O
the O
MAPK I-GENE
/ O
PI3K I-GENE
pathways I-GENE
. O

Nerve I-GENE
growth O
factor I-GENE
( O
NGF I-GENE
) O
and O
retinoic I-GENE
acid I-GENE
( O
RA I-GENE
) O
exert I-GENE
important O
actions O
on O
PC12 I-GENE
cells O
. O

HexA71 I-GENE
negatively I-GENE
affects I-GENE
RpoS I-GENE
, O
as I-GENE
the O
levels O
of O
this O
alternative I-GENE
sigma I-GENE
factor I-GENE
are O
higher I-GENE
in O
the O
HexA I-GENE
- I-GENE
mutant I-GENE
than O
in O
the O
HexA I-GENE
+ O
strain I-GENE
. O

Moreover I-GENE
, O
elderly I-GENE
men O
with O
bioavailable I-GENE
estradiol I-GENE
levels O
below O
the O
median O
[ I-GENE
40 O
pmol I-GENE
/ O
liter O
( O
11 O
pg O
/ O
ml O
)] O
had O
significantly O
higher I-GENE
rates O
of O
bone O
loss I-GENE
and O
levels O
of O
bone O
resorption I-GENE
markers I-GENE
than O
men O
with O
bioavailable I-GENE
estradiol I-GENE
levels O
above O
40 O
pmol I-GENE
/ O
liter O
. O

The O
histamine I-GENE
H1 I-GENE
receptor I-GENE
antagonists I-GENE
( O
antihistamines I-GENE
) O
are O
an O
important O
class O
of O
medications I-GENE
used O
for I-GENE
the O
relief I-GENE
of O
common O
symptoms O
associated O
with O
hyperhistaminic I-GENE
conditions O
occurring O
in O
children O
and O
adults O
. O

The O
production O
of O
ceramide I-GENE
is O
emerging I-GENE
as I-GENE
a O
fixture I-GENE
of O
programmed I-GENE
cell O
death I-GENE
. O

The O
flux I-GENE
rates O
of O
p O
- I-GENE
toluidine I-GENE
decreased O
as I-GENE
the O
pH O
value O
in O
the O
donor I-GENE
solution O
increased O
. O

Managing I-GENE
HIV I-GENE
. O

BACKGROUND I-GENE
: O
There I-GENE
is O
increasing O
interest O
on O
the O
part O
of O
investigators I-GENE
and O
the O
public I-GENE
at I-GENE
large O
in O
finding O
ways I-GENE
to O
study O
and O
improve I-GENE
treatments I-GENE
for I-GENE
the O
seriously I-GENE
mentally I-GENE
ill I-GENE
without O
exposing I-GENE
such O
individuals I-GENE
to O
unnecessary I-GENE
risks I-GENE
. O

Multidrug I-GENE
resistance O
in O
Saccharomyces I-GENE
cerevisiae I-GENE
mainly O
results O
from O
the O
overexpression I-GENE
of O
genes I-GENE
coding I-GENE
for I-GENE
the O
membrane O
efflux I-GENE
pumps I-GENE
, O
the O
major O
facilitators I-GENE
and O
the O
ABC I-GENE
binding O
cassette I-GENE
transporters I-GENE
, O
under O
the O
control O
of O
key I-GENE
transcription O
regulators I-GENE
encoded I-GENE
by O
the O
PDR1 I-GENE
and O
PDR3 I-GENE
genes I-GENE
. O

Serum I-GENE
PTH I-GENE
tended O
to O
increase O
in O
the O
WL I-GENE
group O
but O
not O
in O
the O
WM I-GENE
group O
( O
P I-GENE
< I-GENE
0 I-GENE
. O
06 I-GENE
). O

Bandshift I-GENE
experiments I-GENE
demonstrate O
that O
BmHR3A I-GENE
binds I-GENE
specifically I-GENE
to O
RORE I-GENE
( O
Retinoic I-GENE
acid I-GENE
- I-GENE
related O
Orphan I-GENE
receptor I-GENE
Response I-GENE
Element I-GENE
)- O
like O
sequences O
in O
the O
promoters I-GENE
of O
both O
genes I-GENE
, O
thus O
suggesting O
a O
direct O
role O
for I-GENE
BmHR3A I-GENE
in O
regulating I-GENE
the O
expression I-GENE
of O
BmGATAbeta I-GENE
and O
ESP I-GENE
genes I-GENE
during I-GENE
vitellogenesis I-GENE
. O

Efficacy I-GENE
of O
first I-GENE
- I-GENE
generation O
Cavermap I-GENE
to O
verify I-GENE
location I-GENE
and O
function O
of O
cavernous I-GENE
nerves O
during I-GENE
radical I-GENE
prostatectomy I-GENE
: O
a O
multi I-GENE
- I-GENE
institutional I-GENE
evaluation O
by O
experienced I-GENE
surgeons I-GENE
. O

During I-GENE
most O
of O
the O
cell O
cycle I-GENE
, O
separase I-GENE
is O
kept O
inactive I-GENE
by O
binding O
to O
an O
inhibitory I-GENE
protein O
called I-GENE
securin I-GENE
. O

In I-GENE
conclusion I-GENE
, O
obesity I-GENE
, O
alcohol I-GENE
intake O
, O
and O
multimetabolic I-GENE
disorders O
were O
determined O
to O
be O
independent O
predictors I-GENE
for I-GENE
the O
development O
of O
hyperuricemia I-GENE
. O

This I-GENE
study O
examined O
the O
role O
of O
cholesteryl I-GENE
ester I-GENE
transfer I-GENE
( O
CET I-GENE
), I-GENE
cholesteryl I-GENE
ester I-GENE
transfer I-GENE
protein O
( O
CETP I-GENE
) O
activity O
, O
and O
phospholipid I-GENE
transfer I-GENE
protein O
( O
PLTP I-GENE
) O
activity O
in O
the O
increased O
prevalence O
of O
coronary O
artery O
calcification I-GENE
( O
CAC I-GENE
) O
in O
diabetic O
subjects O
compared O
with O
nondiabetic I-GENE
subjects O
and O
in O
the O
loss I-GENE
of O
the O
sex I-GENE
difference O
in O
CAC I-GENE
in O
diabetes O
. O

In I-GENE
the O
mouse O
, O
both O
genes I-GENE
reside I-GENE
in O
the O
syntenic I-GENE
region O
8E1 I-GENE
on O
chromosome I-GENE
8 I-GENE
. O

We I-GENE
observed O
NP I-GENE
/ O
NMP4 I-GENE
/ O
CIZ I-GENE
expression I-GENE
in O
osteocytes I-GENE
, O
osteoblasts I-GENE
, O
and O
chondrocytes I-GENE
in O
rat O
bone O
. O

Following I-GENE
baseline O
clinical O
examination I-GENE
and O
initial O
periodontal I-GENE
therapy O
, O
32 I-GENE
patients O
received O
mucogingival I-GENE
surgery O
with O
free O
gingival I-GENE
grafts I-GENE
for I-GENE
treatment O
of O
insufficient O
attached I-GENE
gingiva I-GENE
. O

In I-GENE
contrast O
, O
the O
failure O
of O
the O
QKTT I-GENE
motif I-GENE
and O
TGN46 I-GENE
cytoplasmic I-GENE
tail I-GENE
to O
induce I-GENE
steady I-GENE
- I-GENE
state O
ER I-GENE
localization I-GENE
of O
vesicular I-GENE
stomatitis I-GENE
virus O
glycoprotein I-GENE
( O
VSVG I-GENE
) O
chimeras I-GENE
in O
HeLa I-GENE
and O
NRK I-GENE
cells O
indicates O
that O
significant O
differences O
in O
early O
secretory I-GENE
trafficking I-GENE
also O
exist O
. O

We I-GENE
previously O
showed O
that O
this O
proteolysis I-GENE
1 I-GENE
) O
can O
be O
acutely I-GENE
promoted I-GENE
by O
the O
phorbol I-GENE
ester I-GENE
phorbol I-GENE
12 O
- I-GENE
myristate I-GENE
13 I-GENE
- I-GENE
acetate I-GENE
( O
PMA I-GENE
), I-GENE
2 I-GENE
) O
requires O
a O
metalloprotease I-GENE
activity O
, O
3 O
) O
generates I-GENE
both O
shed I-GENE
GHBP I-GENE
and O
a O
membrane O
- I-GENE
associated O
GHR I-GENE
transmembrane I-GENE
/ O
cytoplasmic I-GENE
domain I-GENE
remnant I-GENE
, O
and O
4 O
) O
results O
in O
down I-GENE
- I-GENE
regulation I-GENE
of O
GHR I-GENE
abundance I-GENE
and O
GH I-GENE
signaling I-GENE
. O

Our I-GENE
data O
indicate O
that O
SIP1 I-GENE
is O
required O
to O
confine I-GENE
XBra I-GENE
gene O
expression I-GENE
to O
the O
mesoderm I-GENE
. O

Changes I-GENE
of O
the O
DB I-GENE
sequence O
without O
affecting O
the O
postulated O
stem I-GENE
structure I-GENE
led O
to O
drastic I-GENE
losses I-GENE
of O
translation I-GENE
efficiency I-GENE
. O

This I-GENE
subfamily I-GENE
of O
genes I-GENE
all O
have O
a O
single O
ATP O
- I-GENE
binding O
domain I-GENE
at I-GENE
the O
N O
- I-GENE
terminus I-GENE
and O
a O
single O
C O
- I-GENE
terminal I-GENE
set I-GENE
of O
transmembrane I-GENE
segments I-GENE
. O

Subsequently I-GENE
, O
these O
coordinates I-GENE
must O
be O
interpreted O
to O
define I-GENE
particular I-GENE
tissues O
and O
organs O
. O

The O
cyclins I-GENE
bind I-GENE
to O
and O
activate I-GENE
the O
CDK I-GENE
, O
which O
leads I-GENE
to O
phosphorylation I-GENE
( O
and O
then O
inhibition O
) O
of O
the O
tumor O
suppressor I-GENE
protein O
, O
pRb I-GENE
. O
pRb I-GENE
controls O
commitment I-GENE
to O
progress O
from O
the O
G1 I-GENE
to O
S O
phase I-GENE
, O
at I-GENE
least O
in O
part O
by O
repressing I-GENE
the O
activity O
of O
the O
E2F I-GENE
transcription O
factors I-GENE
known O
to O
promote I-GENE
cell O
proliferation I-GENE
. O

The O
mean O
serum I-GENE
creatinine I-GENE
level O
did O
not O
change O
during I-GENE
the O
first I-GENE
6 I-GENE
months O
after O
withdrawal I-GENE
of O
MMF I-GENE
. O

The O
severity I-GENE
of O
pathologic O
changes O
increased O
with O
the O
magnitude O
of O
percussion I-GENE
. O

Patients O
with O
antibody I-GENE
peaks O
, O
defined O
as I-GENE
fivefold I-GENE
or O
higher I-GENE
increase O
in O
antibody I-GENE
titer I-GENE
compared O
to O
the O
lowest O
antibody I-GENE
titer I-GENE
over O
the O
course O
of O
GBS I-GENE
, O
had O
higher I-GENE
disability I-GENE
scores O
during I-GENE
the O
first I-GENE
two O
weeks O
of O
GBS I-GENE
and O
a O
worse I-GENE
clinical O
outcome I-GENE
( O
anti I-GENE
- I-GENE
GM1 I-GENE
IgG I-GENE
and O
anti I-GENE
- I-GENE
GD1a I-GENE
IgM I-GENE
antibody I-GENE
peaks O
) O
and O
axonal I-GENE
damage O
( O
anti I-GENE
- I-GENE
GD1a I-GENE
IgM I-GENE
antibody I-GENE
peaks O
), I-GENE
compared O
to O
patients O
without O
peak O
antibody I-GENE
titers I-GENE
. O

At I-GENE
20 O
days O
( O
D O
) O
and O
at I-GENE
3 O
months O
post O
- I-GENE
TBI I-GENE
, O
irradiated I-GENE
rats O
had O
a O
significantly O
lower O
percentage O
of O
avoidance I-GENE
than O
controls O
but O
no I-GENE
statistical I-GENE
difference O
was O
found O
at I-GENE
5 I-GENE
months O
post O
- I-GENE
TBI I-GENE
. O
b O
/ O
Two I-GENE
- I-GENE
way O
avoidance I-GENE
test O
: O
this O
test O
was O
performed O
only O
after O
TBI I-GENE
. O

TE I-GENE
- I-GENE
671 I-GENE
cells O
that O
were O
transfected I-GENE
with O
cAMP I-GENE
response O
element I-GENE
mutant I-GENE
constructs I-GENE
demonstrated O
a O
diminished I-GENE
basal O
activity O
of O
the O
GnRH I-GENE
- I-GENE
II I-GENE
promoter I-GENE
. O

The O
severity I-GENE
of O
clinical O
course O
was O
expressed I-GENE
by O
means I-GENE
of O
SOFA I-GENE
score O
( O
group O
A I-GENE
0 I-GENE
. O
3 O
- I-GENE
1 I-GENE
- I-GENE
1 I-GENE
. O
3 O
point I-GENE
, O
group O
B I-GENE
2 I-GENE
. O
2 I-GENE
- I-GENE
2 I-GENE
. O
9 O
- I-GENE
2 I-GENE
. O
6 I-GENE
point I-GENE
, O
group O
C O
7 O
. O
4 O
- I-GENE
8 I-GENE
. O
3 O
- I-GENE
7 O
. O
7 O
point I-GENE
) O
and O
APACHE I-GENE
II I-GENE
score O
( O
group O
A I-GENE
3 O
. O
7 O
- I-GENE
7 O
. O
6 I-GENE
- I-GENE
8 I-GENE
. O
1 I-GENE
point I-GENE
, O
group O
B I-GENE
8 I-GENE
. O
6 I-GENE
- I-GENE
11 O
. O
1 I-GENE
- I-GENE
10 O
. O
5 I-GENE
point I-GENE
, O
group O
C O
16 O
. O
3 O
- I-GENE
15 I-GENE
. O
2 I-GENE
- I-GENE
14 O
. O
3 O
point I-GENE
). O

A I-GENE
novel I-GENE
potential I-GENE
effector I-GENE
of O
M O
- I-GENE
Ras I-GENE
and O
p21 I-GENE
Ras I-GENE
negatively I-GENE
regulates I-GENE
p21 I-GENE
Ras I-GENE
- I-GENE
mediated I-GENE
gene O
induction O
and O
cell O
growth O
. O

Promoter I-GENE
transcriptional I-GENE
activity O
was O
determined O
for I-GENE
a O
wide I-GENE
5 I-GENE
' O
portion O
of O
the O
human I-GENE
annexin I-GENE
A5 I-GENE
gene O
, O
from O
bp I-GENE
- I-GENE
1275 I-GENE
to O
+ O
79 I-GENE
relative O
to O
the O
most O
5 I-GENE
' O
of O
several I-GENE
discrete I-GENE
transcription O
start I-GENE
points I-GENE
. O

Structure I-GENE
of O
the O
EMAPII I-GENE
domain I-GENE
of O
human I-GENE
aminoacyl I-GENE
- I-GENE
tRNA I-GENE
synthetase I-GENE
complex O
reveals I-GENE
evolutionary I-GENE
dimer I-GENE
mimicry I-GENE
. O

Adding I-GENE
10 O
mmol I-GENE
SDS I-GENE
/ O
l I-GENE
led O
to O
transient O
inhibition O
of O
acidification I-GENE
, O
metal I-GENE
solubilization I-GENE
and O
sulfur I-GENE
oxidation I-GENE
. O

Competition I-GENE
electrophoretic I-GENE
mobility I-GENE
shift O
and O
immunoshift I-GENE
assays O
confirmed I-GENE
that O
NF1 I-GENE
factors I-GENE
present O
in O
nuclear O
extracts I-GENE
of O
HeLa I-GENE
and O
CV I-GENE
- I-GENE
1 I-GENE
cells O
bind I-GENE
to O
the O
BKV I-GENE
- I-GENE
MLP I-GENE
. O

Northern O
and O
Western I-GENE
blot I-GENE
analyses O
demonstrated O
that O
Graf2 I-GENE
is O
expressed I-GENE
in O
several I-GENE
tissues O
, O
with O
the O
highest O
expression I-GENE
in O
skeletal O
muscle I-GENE
. O

A I-GENE
minimal I-GENE
ER3 I-GENE
sequence O
of O
DNA I-GENE
was O
further O
demonstrated O
to O
function O
as I-GENE
a O
FXR I-GENE
HRE I-GENE
and O
was O
bound I-GENE
in O
vitro O
by O
FXR I-GENE
- I-GENE
expressing I-GENE
yeast I-GENE
extracts I-GENE
. O

In I-GENE
Ka13 I-GENE
cells O
, O
CoCl I-GENE
( O
2 I-GENE
) O
stimulated I-GENE
expression I-GENE
of O
a O
luciferase I-GENE
reporter I-GENE
gene O
under O
the O
control O
of O
a O
15 I-GENE
- I-GENE
kilobase I-GENE
pair I-GENE
mouse O
ho I-GENE
- I-GENE
1 I-GENE
promoter I-GENE
( O
pHO15luc I-GENE
). O

Nine I-GENE
strains O
were O
subtyped I-GENE
as I-GENE
Camp I-GENE
. O
jejuni I-GENE
subsp I-GENE
. O
jejuni I-GENE
biotype I-GENE
II I-GENE
and O
the O
remaining O
ones I-GENE
as I-GENE
biotype I-GENE
I O
. O

The O
Ig I-GENE
- I-GENE
related O
, O
typical O
metazoan I-GENE
, O
module I-GENE
is O
classified I-GENE
to O
the O
disulphide I-GENE
lacking I-GENE
Ig I-GENE
members I-GENE
and O
represents I-GENE
the O
phylogenetic I-GENE
earliest I-GENE
member I-GENE
of O
this O
group O
. O

In I-GENE
budding I-GENE
yeast I-GENE
, O
this O
latter O
checkpoint I-GENE
response O
involves I-GENE
the O
proteins O
Mad1 I-GENE
, O
2 I-GENE
, O
3 O
, O
Bub1 I-GENE
and O
Bub3 I-GENE
, O
whose O
vertebrate I-GENE
counterparts I-GENE
localize I-GENE
to O
unattached I-GENE
kinetochores I-GENE
. O

We I-GENE
investigated O
the O
production O
of O
hyaluronan I-GENE
( O
HA I-GENE
) O
and O
its O
effect O
on O
cell O
motility I-GENE
in O
cells O
expressing I-GENE
the O
v O
- I-GENE
src I-GENE
mutants I-GENE
. O

Oral I-GENE
supplementation O
of O
L O
- I-GENE
arginine I-GENE
significantly O
increased O
plasma I-GENE
L O
- I-GENE
citrulline I-GENE
, O
which O
indicated O
enhancement I-GENE
of O
NO I-GENE
production O
. O

We I-GENE
can O
classify I-GENE
antibiotics O
into O
two O
groups O
based O
on O
initial O
bactericidal O
activity O
against O
P I-GENE
. O
aeruginosa I-GENE
; O
one O
class O
is O
antibiotics O
having O
rapid O
initial O
killing I-GENE
such O
as I-GENE
AMK I-GENE
, O
IPM I-GENE
and O
PAPM I-GENE
, O
the O
other O
is O
CAZ I-GENE
, O
MEPM I-GENE
showing O
slow I-GENE
initial O
killing I-GENE
. O

The O
presence O
of O
truncated I-GENE
receptor I-GENE
isoforms I-GENE
in O
diverse I-GENE
species O
suggests O
that O
these O
proteins O
may O
have O
important O
functional I-GENE
roles I-GENE
in O
regulating I-GENE
EGFR I-GENE
activity O
. O

Of I-GENE
its O
gene O
products I-GENE
, O
E6 I-GENE
binds I-GENE
to O
and O
inactivates I-GENE
p53 I-GENE
tumor O
suppressor I-GENE
protein O
by O
ubiquitin I-GENE
/ O
proteasome I-GENE
- I-GENE
dependent O
degradation I-GENE
. O

Low O
affinity O
binding O
of O
Rab6A I-GENE
- I-GENE
GTP I-GENE
was O
also O
observed O
( O
K O
( O
d O
) O
= O
16 O
microm I-GENE
), I-GENE
whereas O
Rab1B I-GENE
, O
- I-GENE
5 I-GENE
, O
- I-GENE
7 O
, O
- I-GENE
8 I-GENE
, O
or O
- I-GENE
11A I-GENE
did O
not O
bind I-GENE
. O

( O
1997 I-GENE
) O
Nature I-GENE
387 I-GENE
, O
370 I-GENE
- I-GENE
376 I-GENE
)], I-GENE
we O
suggest O
that O
the O
metal I-GENE
fluoride I-GENE
ions I-GENE
replaced I-GENE
phosphate I-GENE
at I-GENE
the O
two O
ATP O
- I-GENE
binding O
sites O
of O
the O
iron O
protein O
, O
Kp2 I-GENE
. O

A I-GENE
1 I-GENE
- I-GENE
base I-GENE
pair I-GENE
mismatch I-GENE
within O
the O
corresponding O
region O
of O
the O
CYP3A4 I-GENE
gene O
was O
sufficient I-GENE
for I-GENE
a O
differential O
enhancer I-GENE
activity O
. O

AIMS I-GENE
: O
To I-GENE
establish I-GENE
a O
baseline O
and O
intraindividual I-GENE
fluctuations I-GENE
of O
the O
tumour I-GENE
markers I-GENE
CEA I-GENE
, O
CA O
50 O
and O
CA O
242 I-GENE
in O
patients O
cured I-GENE
from O
colorectal I-GENE
cancer I-GENE
, O
and O
to O
test O
the O
hypothesis I-GENE
that O
serum I-GENE
concentrations O
and O
intraindividual I-GENE
fluctuations I-GENE
do O
not O
differ O
from O
the O
concentrations O
in O
cancer I-GENE
- I-GENE
free O
individuals I-GENE
. O

Substitution I-GENE
of O
serine I-GENE
residues O
at I-GENE
the O
C O
- I-GENE
terminus I-GENE
indicated O
that O
loss I-GENE
of O
phosphorylation I-GENE
sites O
did O
not O
appear O
to O
have O
any O
effect O
on O
transcription O
and O
replication I-GENE
. O

Molecular I-GENE
analysis O
of O
the O
pRA2 I-GENE
partitioning I-GENE
region O
: O
ParB I-GENE
autoregulates I-GENE
parAB I-GENE
transcription O
and O
forms I-GENE
a O
nucleoprotein I-GENE
complex O
with O
the O
plasmid I-GENE
partition I-GENE
site I-GENE
, O
parS I-GENE
. O

Tumor I-GENE
cell O
lines I-GENE
transduced I-GENE
at I-GENE
an O
MOI I-GENE
of O
8 I-GENE
for I-GENE
3 O
days O
led O
to O
> I-GENE
90 I-GENE
% O
gene O
transfer I-GENE
efficiency I-GENE
. O

No O
ISREs I-GENE
could O
be O
identified O
in O
the O
mouse O
promoter I-GENE
. O

GABA I-GENE
( O
B I-GENE
) O
R1g I-GENE
was O
expressed I-GENE
in O
both O
brain O
and O
peripheral O
tissues O
. O

Granulocyte I-GENE
colony I-GENE
- I-GENE
stimulating I-GENE
factor I-GENE
( O
G I-GENE
- I-GENE
CSF O
) O
administration O
in O
vivo O
has O
been O
shown O
to O
improve I-GENE
the O
defence I-GENE
mechanisms O
against O
infection O
by O
different O
microbes I-GENE
. O

Use I-GENE
of O
a O
dual I-GENE
- I-GENE
pulse I-GENE
lithotripter I-GENE
to O
generate I-GENE
a O
localized O
and O
intensified I-GENE
cavitation I-GENE
field O
. O

The O
best O
regression I-GENE
model O
for I-GENE
predicting I-GENE
changes O
in O
the O
WCXR I-GENE
included O
time O
to O
first I-GENE
positive O
culture O
and O
antibody I-GENE
titer I-GENE
for I-GENE
Pa I-GENE
elastase I-GENE
. O

RESULTS I-GENE
: O
The O
parameters O
SF2 I-GENE
and O
plating I-GENE
efficiency I-GENE
were O
stable O
throughout O
the O
4 O
- I-GENE
year O
test O
period O
. O

The O
process O
has O
been O
applied O
to O
the O
river I-GENE
reclamation I-GENE
in O
Yangpu I-GENE
District I-GENE
of O
Shanghai I-GENE
City I-GENE
, O
China I-GENE
. O

Multiple I-GENE
regression I-GENE
analysis O
performed O
between O
these O
long O
- I-GENE
term O
abiotic I-GENE
factors I-GENE
and O
nymphal I-GENE
abundance I-GENE
in O
positive O
sites O
showed O
high O
relationship O
( O
R2 I-GENE
coefficients I-GENE
) O
for I-GENE
every I-GENE
habitat I-GENE
category I-GENE
and O
explained O
> I-GENE
50 O
% O
of O
the O
variation O
in O
tick I-GENE
abundance I-GENE
. O

The O
v O
- I-GENE
Src I-GENE
SH3 I-GENE
domain I-GENE
facilitates I-GENE
a O
cell O
adhesion I-GENE
- I-GENE
independent O
association O
with O
focal I-GENE
adhesion I-GENE
kinase I-GENE
. O

Of I-GENE
the O
six I-GENE
cases O
of O
malignant I-GENE
polyposis I-GENE
, O
none O
were O
identified O
using O
CT I-GENE
, O
and O
only O
two O
were O
diagnosed I-GENE
by O
small O
bowel I-GENE
follow O
- I-GENE
through O
. O

Right I-GENE
LHR I-GENE
( O
R O
- I-GENE
LHR I-GENE
) O
provided O
the O
best O
interobserver I-GENE
and O
intraobserver I-GENE
reproducibility I-GENE
. O

We I-GENE
also O
reported O
the O
identification I-GENE
of O
three O
corresponding O
alternative I-GENE
first I-GENE
exons I-GENE
and O
an O
intronic I-GENE
promoter I-GENE
in O
the O
human I-GENE
PDE5A I-GENE
gene O
. O

Of I-GENE
major O
concern I-GENE
to O
food O
processors I-GENE
is O
the O
inadvertent I-GENE
cross O
- I-GENE
contact I-GENE
of O
food O
products I-GENE
with O
allergenic I-GENE
residues O
, O
which O
could O
result O
in O
potentially O
life O
- I-GENE
threatening I-GENE
reactions O
in O
those O
with O
a O
food O
allergy I-GENE
. O

Diffuse I-GENE
myalgias I-GENE
were O
more O
frequent O
in O
patients O
with O
than O
without O
an O
MMF I-GENE
lesion O
at I-GENE
deltoid I-GENE
muscle I-GENE
biopsy O
( O
P I-GENE
< I-GENE
0 I-GENE
. O
0001 I-GENE
). O

Functional I-GENE
analysis O
of O
various O
PTP I-GENE
- I-GENE
deficient I-GENE
DT40 I-GENE
B I-GENE
cell O
lines I-GENE
stably I-GENE
expressing I-GENE
wild I-GENE
- I-GENE
type I-GENE
chimeric I-GENE
Fc I-GENE
gamma I-GENE
RIIB1 I-GENE
- I-GENE
PECAM I-GENE
- I-GENE
1 I-GENE
receptor I-GENE
indicated O
that O
cytoplasmic I-GENE
Src I-GENE
homology I-GENE
2 I-GENE
- I-GENE
domain I-GENE
- I-GENE
containing O
phosphatases I-GENE
, O
SHP I-GENE
- I-GENE
1 I-GENE
and O
SHP I-GENE
- I-GENE
2 I-GENE
, O
were O
both O
necessary O
and O
sufficient I-GENE
to O
deliver I-GENE
inhibitory I-GENE
negative O
regulation I-GENE
upon O
coligation I-GENE
of O
BCR I-GENE
complex O
with O
inhibitory I-GENE
receptor I-GENE
. O

Subtraction I-GENE
hybridization I-GENE
identified O
melanoma I-GENE
differentiation I-GENE
associated O
gene O
- I-GENE
7 O
( O
mda I-GENE
- I-GENE
7 O
), I-GENE
as I-GENE
a O
gene O
induced I-GENE
during I-GENE
these O
physiological O
changes O
in O
human I-GENE
melanoma I-GENE
cells O
. O

A I-GENE
rare I-GENE
case O
of O
primary I-GENE
group O
A I-GENE
streptococcal I-GENE
peritonitis I-GENE
. O

Among I-GENE
individuals I-GENE
, O
however O
, O
changes O
were O
strongly O
correlated O
with O
ACR I-GENE
levels O
at I-GENE
baseline O
. O

RESULTS I-GENE
: O
The O
subjects O
in O
the O
augmented O
feedback I-GENE
group O
significantly O
reduced I-GENE
their O
peak O
vertical I-GENE
ground I-GENE
reaction O
force I-GENE
in O
both O
post O
- I-GENE
test O
conditions O
( O
2 I-GENE
- I-GENE
minute O
post O
- I-GENE
test O
reduction O
, O
0 I-GENE
. O
85 I-GENE
+/- O
0 I-GENE
. O
62 I-GENE
; O
1 I-GENE
- I-GENE
week O
post O
- I-GENE
test O
reduction O
, O
0 I-GENE
. O
74 I-GENE
+/- O
0 I-GENE
. O
58 I-GENE
) O
as I-GENE
compared O
to O
the O
sensory O
, O
control O
I O
, O
and O
control O
II I-GENE
feedback I-GENE
groups O
. O

The O
blood I-GENE
levels O
of O
lactate I-GENE
, O
pyruvate I-GENE
and O
amino I-GENE
acids I-GENE
were O
not O
elevated O
. O

Histological I-GENE
examination I-GENE
showed O
lichenoid I-GENE
changes O
, O
acantholytic I-GENE
blister I-GENE
formation O
and O
apoptotic I-GENE
keratinocytes I-GENE
. O

Enantiomer I-GENE
separation I-GENE
of O
venlafaxine I-GENE
and O
O I-GENE
- I-GENE
desmethylvenlafaxine I-GENE
in O
human I-GENE
plasma I-GENE
. O

Paul I-GENE
Monagle I-GENE
addresses I-GENE
the O
epidemiology I-GENE
of O
neonatal O
thrombosis I-GENE
outside I-GENE
of O
the O
central O
nervous O
system I-GENE
in O
both O
arterial O
and O
venous O
locations I-GENE
, O
and O
those O
that O
occur O
in O
utero I-GENE
. O

The O
MSL I-GENE
complex O
is O
specifically I-GENE
localized O
on O
the O
male O
X I-GENE
chromosome I-GENE
to O
increase O
its O
expression I-GENE
approximately I-GENE
2 I-GENE
- I-GENE
fold I-GENE
. O

Effects O
of O
a O
booster I-GENE
dose O
of O
tetanus I-GENE
toxoid I-GENE
after O
different O
primary I-GENE
courses O
of O
vaccination O
: O
implications O
on O
the O
use O
of O
immune I-GENE
globulin I-GENE
. O

Our I-GENE
results O
suggest O
that O
the O
C O
- I-GENE
terminal I-GENE
region O
of O
Crk I-GENE
contains I-GENE
negative O
regulatory I-GENE
elements I-GENE
important O
for I-GENE
both O
Abl I-GENE
and O
FAK I-GENE
dependent O
signal I-GENE
pathways I-GENE
, O
and O
offers I-GENE
a O
paradigm I-GENE
for I-GENE
an O
autoinhibitory I-GENE
region O
in O
the O
SH3 I-GENE
linker I-GENE
/ O
C O
- I-GENE
terminal I-GENE
SH3 I-GENE
domain I-GENE
. O

The O
distribution O
of O
red I-GENE
rice I-GENE
cultivation I-GENE
in O
Sri I-GENE
Lanka I-GENE
is O
coincident I-GENE
with O
the O
HIDD I-GENE
villages I-GENE
. O

Prophylactic I-GENE
lymph O
node O
dissection I-GENE
or O
radiation O
therapy O
to O
the O
nodal I-GENE
chain I-GENE
may O
decrease O
local O
recurrence I-GENE
but O
does O
not O
consistently O
affect O
overall O
survival I-GENE
. O

Secretion I-GENE
of O
interleukin I-GENE
- I-GENE
8 I-GENE
, O
RANTES I-GENE
, O
macrophage O
inflammatory O
protein O
1alpha I-GENE
, O
and O
10 O
- I-GENE
kappaDa I-GENE
IFN I-GENE
- I-GENE
gamma I-GENE
- I-GENE
inducible I-GENE
protein O
were O
increased O
in O
differentiating I-GENE
keratinocytes I-GENE
by O
E6 I-GENE
. O

CONCLUSIONS I-GENE
: O
ChromaFlo I-GENE
- I-GENE
enhanced I-GENE
IVUS I-GENE
demonstrates I-GENE
colorized I-GENE
blood I-GENE
flow O
inside I-GENE
the O
vessel I-GENE
lumen I-GENE
, O
which O
is O
helpful O
in O
distinguishing I-GENE
echolucent I-GENE
disease I-GENE
from O
luminal I-GENE
blood I-GENE
flow O
and O
can O
also O
be O
used O
to O
perform O
peripheral O
interventions I-GENE
in O
patients O
with O
renal I-GENE
failure O
or O
allergy I-GENE
, O
avoiding I-GENE
the O
use O
of O
contrast O
media I-GENE
. O

Additional I-GENE
factors I-GENE
such O
as I-GENE
advanced O
age O
, O
concomitant I-GENE
use O
of O
corticosteroids I-GENE
or O
anticoagulants I-GENE
, O
prior I-GENE
ulcer O
complications O
and O
co I-GENE
- I-GENE
morbid I-GENE
diseases O
may O
further O
increase O
the O
risk O
of O
bleeding I-GENE
. O

CONCLUSIONS I-GENE
: O
Using I-GENE
icodextrin I-GENE
- I-GENE
based O
instead I-GENE
of O
glucose O
- I-GENE
based O
PD I-GENE
fluids O
can O
largely I-GENE
reduce I-GENE
the O
formation O
of O
Amadori I-GENE
albumin I-GENE
and O
AGEs I-GENE
. O

A I-GENE
central O
finding O
is O
the O
identification I-GENE
of O
a O
GC I-GENE
- I-GENE
rich I-GENE
sequence O
in O
the O
- I-GENE
99 I-GENE
/- I-GENE
91 O
Cp I-GENE
region O
that O
is O
essential O
for I-GENE
oriPI I-GENE
- I-GENE
EBNA1 I-GENE
- I-GENE
independent O
as I-GENE
well I-GENE
as I-GENE
oriPI I-GENE
- I-GENE
EBNA1 I-GENE
- I-GENE
dependent O
activity O
of O
the O
promoter I-GENE
. O

Furthermore I-GENE
, O
SB203580 I-GENE
inhibited O
LPS I-GENE
- I-GENE
induced I-GENE
activation I-GENE
of O
Sp1 I-GENE
, O
as I-GENE
well I-GENE
as I-GENE
the O
promoter I-GENE
activity O
in O
cells O
transfected I-GENE
with O
a O
plasmid I-GENE
containing O
the O
Sp1 I-GENE
consensus I-GENE
sequence O
. O

A I-GENE
new O
echocardiographic I-GENE
technique O
is O
described O
with O
a O
conventional O
M O
mode O
, O
digitalised I-GENE
2D I-GENE
and O
tissular I-GENE
Doppler I-GENE
which O
has O
a O
comparable O
ability O
to O
identify I-GENE
the O
anomalous I-GENE
pathways I-GENE
of O
electric I-GENE
conduction O
using O
a O
non O
- I-GENE
invasive I-GENE
method O
. O

Is O
clopidogrel I-GENE
superior O
to O
aspirin I-GENE
in O
secondary O
prevention O
of O
vascular O
disease I-GENE
? O
The O
cornerstone I-GENE
in O
clinical O
evidence O
of O
the O
relative O
efficacy O
of O
thienopyridines I-GENE
( O
clopidogrel I-GENE
, O
ticlopidine I-GENE
) O
versus O
aspirin I-GENE
in O
the O
secondary O
prevention O
of O
vascular O
disease I-GENE
is O
the O
Clopidogrel I-GENE
versus O
Aspirin I-GENE
in O
Patients O
at I-GENE
Risk I-GENE
of O
Ischaemic I-GENE
Events I-GENE
trial O
. O

The O
role O
of O
the O
Vp1 I-GENE
DBD I-GENE
during I-GENE
infection O
was O
investigated O
by O
taking O
advantage I-GENE
of O
NLS I-GENE
phenotypic I-GENE
complementation I-GENE
( O
N O
. O

The O
probability I-GENE
of O
treatment O
with O
lamotrigine I-GENE
being O
maintained O
for I-GENE
six I-GENE
months O
was O
86 I-GENE
%, O
for I-GENE
twelve I-GENE
months O
61 I-GENE
% O
and O
for I-GENE
three O
years O
31 I-GENE
%. O

Recent I-GENE
advances I-GENE
have O
shown O
that O
volatile I-GENE
sulfur I-GENE
is O
a O
result O
of O
ecological I-GENE
interactions O
and O
transformation I-GENE
processes O
through O
planktonic I-GENE
food O
webs I-GENE
. O

OsBBPI I-GENE
was O
found O
to O
be O
rapidly I-GENE
induced I-GENE
in O
rice I-GENE
seedling I-GENE
leaf I-GENE
in O
response O
to O
cut I-GENE
, O
exogenous I-GENE
jasmonic I-GENE
acid I-GENE
( O
JA I-GENE
), I-GENE
and O
two O
potent O
protein O
phosphatase I-GENE
2A I-GENE
( O
PP2A I-GENE
) O
inhibitors I-GENE
, O
cantharidin I-GENE
( O
CN I-GENE
) O
and O
endothall I-GENE
( O
EN I-GENE
), I-GENE
in O
a O
light O
/ O
dark O
-, I-GENE
time O
- I-GENE
and O
dose O
- I-GENE
dependent O
manner I-GENE
; O
this O
induction O
was O
completely I-GENE
inhibited O
by O
cycloheximide I-GENE
( O
CHX I-GENE
), I-GENE
indicating I-GENE
a O
requirement I-GENE
for I-GENE
de I-GENE
novo I-GENE
protein O
synthesis I-GENE
in O
its O
induction O
. O

Analysis I-GENE
of O
ace2Delta I-GENE
cells O
reveals I-GENE
that O
Ace2p I-GENE
is O
required O
for I-GENE
cell O
separation I-GENE
but O
not O
for I-GENE
polarized I-GENE
growth O
. O

The O
purpose I-GENE
of O
this O
investigation O
was O
to O
study O
the O
morphological O
characteristics O
of O
the O
fibrous I-GENE
tissue O
capsule I-GENE
resulting O
from O
the O
implantation O
of O
aluminum I-GENE
calcium I-GENE
phosphate I-GENE
( O
ALCAP I-GENE
) O
and O
hydroxyapetite I-GENE
( O
HA I-GENE
) O
bioceramics I-GENE
. O

The O
event I-GENE
rate O
in O
patients O
with O
chronic O
Irr I-GENE
- I-GENE
rMFP I-GENE
or O
Un I-GENE
- I-GENE
nrMFP I-GENE
was O
markedly O
higher I-GENE
than O
it O
was O
in O
those O
with O
Rev I-GENE
- I-GENE
rMFP I-GENE
or O
Sta I-GENE
- I-GENE
nrMFP I-GENE
. O

In I-GENE
summary I-GENE
, O
we O
conclude O
that O
the O
adenoviral I-GENE
oncoprotein I-GENE
E1A I-GENE
activates I-GENE
transcription O
from O
the O
endogenous O
AP I-GENE
- I-GENE
2alpha I-GENE
gene O
, O
an O
effect O
that O
involves I-GENE
transcriptional I-GENE
derepression I-GENE
of O
the O
AP I-GENE
- I-GENE
2alpha I-GENE
promoter I-GENE
by O
interaction O
of O
E1A I-GENE
with O
the O
AP I-GENE
- I-GENE
2rep I-GENE
corepressor I-GENE
CtBP1 I-GENE
. O

Unusual I-GENE
two O
- I-GENE
domain I-GENE
arginine I-GENE
kinases I-GENE
( O
AKs I-GENE
) O
arose I-GENE
independently I-GENE
at I-GENE
least O
two O
times O
during I-GENE
molecular I-GENE
evolution I-GENE
of O
phosphagen I-GENE
kinases I-GENE
: O
AKs I-GENE
from O
the O
primitive I-GENE
sea I-GENE
anemone I-GENE
Anthopleurura I-GENE
japonicus I-GENE
and O
from O
the O
clam I-GENE
Pseudocardium I-GENE
sachalinensis I-GENE
. O

Mutagenesis I-GENE
of O
SNT1 I-GENE
( O
IRS I-GENE
) O
CX I-GENE
identified O
three O
classes I-GENE
of O
effector I-GENE
motifs I-GENE
within O
SNT I-GENE
critical I-GENE
for I-GENE
both O
sustained I-GENE
ERK I-GENE
activation I-GENE
and O
neuronal I-GENE
differentiation I-GENE
: O
1 I-GENE
) O
four O
phosphotyrosine I-GENE
motifs I-GENE
that O
mediate O
recruitment I-GENE
of O
Grb2 I-GENE
, O
2 I-GENE
) O
two O
phosphotyrosine I-GENE
motifs I-GENE
that O
mediate O
recruitment I-GENE
of O
Shp2 I-GENE
, O
and O
3 O
) O
a O
C O
- I-GENE
terminal I-GENE
motif I-GENE
that O
functions O
by O
helping I-GENE
to O
recruit I-GENE
Sos I-GENE
. O

CONCLUSIONS I-GENE
: O
Our I-GENE
meta I-GENE
- I-GENE
analysis O
of O
randomized O
controlled I-GENE
trials I-GENE
of O
HRT I-GENE
noted O
a O
statistically O
significant O
reduction O
in O
nonvertebral I-GENE
fractures I-GENE
. O

However I-GENE
, O
C4B I-GENE
proteins O
encoded I-GENE
by O
monomodular I-GENE
short I-GENE
genes I-GENE
may O
have O
relatively O
higher I-GENE
concentrations O
than O
those O
from O
long O
C4A I-GENE
genes I-GENE
. O

CSR I-GENE
is O
directed I-GENE
to O
specific O
heavy O
chain I-GENE
isotypes I-GENE
by O
cytokines I-GENE
and O
B I-GENE
cell O
activators I-GENE
that O
induce I-GENE
transcription O
from O
the O
unrearranged I-GENE
, O
or O
germline I-GENE
( O
GL I-GENE
), I-GENE
C O
( O
H O
) O
region O
genes I-GENE
. O

The O
patterns O
of O
early O
mRNA I-GENE
and O
protein O
expression I-GENE
in O
these O
seven I-GENE
mutants I-GENE
were O
examined O
, O
and O
it O
was O
found O
that O
mutation I-GENE
of O
the O
T I-GENE
'( I-GENE
135 O
) O
acceptor I-GENE
site I-GENE
resulted O
in O
the O
utilization O
of O
cryptic I-GENE
splice I-GENE
sites O
and O
the O
generation O
of O
new O
T I-GENE
' O
species O
. O

Mutational I-GENE
analysis O
showed O
that O
the O
U I-GENE
- I-GENE
box I-GENE
, O
like O
the O
RING I-GENE
finger I-GENE
in O
other O
proteins O
, O
forms I-GENE
the O
physical O
basis O
for I-GENE
the O
interaction O
with O
E2 O
enzymes I-GENE
. O

GafChromic I-GENE
( O
MD I-GENE
- I-GENE
55 I-GENE
- I-GENE
2 I-GENE
) O
radiochromic I-GENE
film I-GENE
has O
become O
increasingly I-GENE
popular I-GENE
for I-GENE
medical O
applications I-GENE
and O
has O
proven I-GENE
to O
be O
useful O
for I-GENE
brachytherapy I-GENE
dosimetry I-GENE
. O

The O
438 I-GENE
bp I-GENE
EcoRI I-GENE
fragment O
, O
which O
was O
detected O
by O
Southern O
hybridization I-GENE
, O
reveals I-GENE
an O
open I-GENE
reading I-GENE
frame I-GENE
which O
encodes I-GENE
a O
protein O
of O
103 I-GENE
amino I-GENE
acids I-GENE
. O

Furthermore I-GENE
, O
hormonal I-GENE
regulation I-GENE
of O
G I-GENE
( O
1 I-GENE
) O
gene O
transcription O
can O
occur O
even O
without O
additional I-GENE
activation I-GENE
of O
the O
Mek I-GENE
- I-GENE
Erk1 I-GENE
/ O
2 I-GENE
pathway I-GENE
by O
estrogen I-GENE
receptors I-GENE
. O

In I-GENE
mammalian I-GENE
tissue O
culture O
cells O
, O
overexpression I-GENE
of O
any O
of O
the O
four O
mouse O
deltex I-GENE
homologs I-GENE
suppressed I-GENE
the O
transcriptional I-GENE
activity O
of O
E47 I-GENE
, O
a O
basic O
helix I-GENE
- I-GENE
loop O
- I-GENE
helix I-GENE
( O
bHLH I-GENE
) O
protein O
, O
in O
a O
manner I-GENE
similar O
to O
suppression O
by O
an O
activated I-GENE
form O
of O
human I-GENE
Notch1 I-GENE
or O
human I-GENE
DTX1 I-GENE
. O

The O
authors O
undertook I-GENE
a O
retrospective I-GENE
analysis O
of O
pathology I-GENE
with O
quantification I-GENE
of O
the O
percentage O
of O
papillary I-GENE
serous I-GENE
component I-GENE
(% I-GENE
PSC I-GENE
) O
and O
p53 I-GENE
expression I-GENE
. O

This I-GENE
function O
requires O
not O
only O
the O
kinase I-GENE
domain I-GENE
of O
Csk I-GENE
, O
but O
also O
its O
Src I-GENE
homology I-GENE
3 O
( O
SH3 I-GENE
) O
and O
SH2 I-GENE
regions O
. O

Nucleotide I-GENE
sequence O
, O
transcription O
map I-GENE
, O
and O
mutation I-GENE
analysis O
of O
the O
13q14 I-GENE
chromosomal I-GENE
region O
deleted I-GENE
in O
B I-GENE
- I-GENE
cell O
chronic O
lymphocytic I-GENE
leukemia O
. O

In I-GENE
conclusion I-GENE
, O
primary I-GENE
chemotherapy I-GENE
based O
on O
high O
dose O
MTX I-GENE
and O
ara I-GENE
- I-GENE
C O
is O
highly O
efficient O
in O
PCNSL I-GENE
. O

NGF I-GENE
, O
but O
not O
EGF I-GENE
, O
enhances I-GENE
the O
upper O
bands I-GENE
, O
corresponding O
to O
phosphorylated I-GENE
Fra I-GENE
- I-GENE
2 I-GENE
. O

METHODS I-GENE
AND I-GENE
RESULTS I-GENE
: O
Palmaz I-GENE
- I-GENE
Schatz I-GENE
stents I-GENE
were O
dip I-GENE
- I-GENE
coated I-GENE
with O
paclitaxel I-GENE
( O
0 I-GENE
, O
0 I-GENE
. O
2 I-GENE
, O
15 I-GENE
, O
or O
187 I-GENE
microgram O
/ O
stent I-GENE
) O
by O
immersion O
in O
ethanolic I-GENE
paclitaxel I-GENE
and O
evaporation I-GENE
of O
the O
solvent O
. O

Currently I-GENE
, O
the O
clinical O
use O
of O
5 I-GENE
- I-GENE
aminolaevulinic I-GENE
acid I-GENE
( O
ALA I-GENE
) O
induced I-GENE
protoporphyrin I-GENE
IX I-GENE
( O
PPIX I-GENE
) O
for I-GENE
photodynamic I-GENE
therapy O
( O
PDT I-GENE
) O
is O
limited O
by O
the O
maximum O
tolerated O
oral O
ALA I-GENE
dose O
( O
60 I-GENE
mg O
/ O
kg O
). O

A I-GENE
twelfth I-GENE
insertion I-GENE
disrupts I-GENE
two O
genes I-GENE
, O
Nrk I-GENE
, O
a O
" O
neurospecific I-GENE
" O
receptor I-GENE
tyrosine I-GENE
kinase I-GENE
, O
and O
Tpp I-GENE
, O
which O
encodes I-GENE
a O
neuropeptidase I-GENE
. O

These I-GENE
results O
indicate O
that O
ATF4 I-GENE
regulates I-GENE
basal O
and O
CdCl I-GENE
( O
2 I-GENE
)- O
induced I-GENE
expression I-GENE
of O
the O
ho I-GENE
- I-GENE
1 I-GENE
gene O
in O
a O
cell O
- I-GENE
specific O
manner I-GENE
and O
possibly I-GENE
in O
a O
complex O
with O
Nrf2 I-GENE
. O

Adjuvant I-GENE
and O
neoadjuvant I-GENE
treatment O
of O
breast O
cancer I-GENE
. O

The O
% O
SVend I-GENE
of O
HCM I-GENE
- I-GENE
I O
was O
significantly O
lower O
than O
the O
respective I-GENE
values O
of O
the O
HCM I-GENE
- I-GENE
II I-GENE
and O
Control O
groups O
. O

Inhibition I-GENE
of O
the O
Raf I-GENE
- I-GENE
1 I-GENE
target I-GENE
ERK I-GENE
kinase I-GENE
( O
MEK I-GENE
) O
either O
attenuated I-GENE
or O
abolished O
Rp I-GENE
- I-GENE
cAMPS I-GENE
- I-GENE
and O
PKI I-GENE
- I-GENE
induced I-GENE
ERK I-GENE
activation I-GENE
, O
caldesmon I-GENE
phosphorylation I-GENE
, O
and O
stress O
fiber O
formation O
. O

In I-GENE
the O
TVD I-GENE
- I-GENE
patients O
decreases O
in O
skin I-GENE
blood I-GENE
flow O
were O
similar O
compared O
with O
the O
healthy O
controls O
. O

Analysis I-GENE
of O
mCTR I-GENE
mRNAs I-GENE
has O
revealed I-GENE
that O
the O
three O
alternative I-GENE
promoters I-GENE
give O
rise O
to O
at I-GENE
least O
seven I-GENE
mCTR I-GENE
isoforms I-GENE
in O
the O
5 I-GENE
' O
region O
of O
the O
gene O
and O
generate I-GENE
5 I-GENE
'- O
untranslated I-GENE
regions O
of O
very O
different O
lengths I-GENE
. O

The O
regulation I-GENE
of O
PGHS I-GENE
- I-GENE
2 I-GENE
mRNA I-GENE
and O
protein O
was O
studied O
in O
primary I-GENE
cultures O
of O
bovine I-GENE
uterine I-GENE
stromal I-GENE
cells O
stimulated I-GENE
with O
phorbol I-GENE
12 O
- I-GENE
myristate I-GENE
13 I-GENE
- I-GENE
acetate I-GENE
( O
PMA I-GENE
; O
100 I-GENE
nM I-GENE
). O

There I-GENE
was O
no I-GENE
evidence O
of O
linkage I-GENE
disequilibrium I-GENE
between O
the O
polymorphic I-GENE
site I-GENE
in O
the O
B I-GENE
cell O
specific O
promoter I-GENE
and O
those O
in O
the O
3 O
' O
UTR I-GENE
. O

Several I-GENE
dozen I-GENE
HIF I-GENE
- I-GENE
1 I-GENE
targets I-GENE
are O
known O
, O
including O
the O
gene O
encoding I-GENE
vascular O
endothelial O
growth O
factor I-GENE
( O
VEGF I-GENE
). O

In I-GENE
Klinefelter I-GENE
' O
s O
syndrome I-GENE
( O
47XXY I-GENE
), I-GENE
serum I-GENE
testosterone O
levels O
are O
at I-GENE
the O
lower O
end O
of O
the O
normal O
range O
and O
dihydrotestosterone I-GENE
levels O
are O
low O
. O

The O
protein O
is O
composed I-GENE
of O
two O
major O
domains I-GENE
separated O
by O
a O
hydrophobic I-GENE
linker I-GENE
region O
of O
20 O
amino I-GENE
acid I-GENE
residues O
. O

When I-GENE
mixed I-GENE
with O
aqueous O
solutions O
of O
TMT I-GENE
- I-GENE
55 I-GENE
, O
aqueous O
solutions O
of O
either O
reagent I-GENE
- I-GENE
grade I-GENE
zinc O
, O
cadmium I-GENE
, O
or O
lead O
salts I-GENE
precipitate I-GENE
crystalline I-GENE
" O
Zn I-GENE
- I-GENE
TMT I-GENE
", I-GENE
amorphous I-GENE
or O
crystalline I-GENE
" O
Cd I-GENE
- I-GENE
TMT I-GENE
" O
or O
amorphous I-GENE
" O
Pb I-GENE
- I-GENE
TMT I-GENE
" O
( O
M3 I-GENE
[ I-GENE
S3C3N3 I-GENE
] O
2 I-GENE
. O
nH2O I-GENE
, O
where I-GENE
M O
= O
Cd2 I-GENE
+, I-GENE
Pb2 I-GENE
+, I-GENE
and O
Zn2 I-GENE
+ O
and O
n I-GENE
> I-GENE
or O
= O
0 I-GENE
) O
that O
may O
eventually I-GENE
crystallize I-GENE
if O
stored I-GENE
in O
air I-GENE
. O

Online I-GENE
teaching I-GENE
: O
design I-GENE
and O
techniques O
. O

This I-GENE
interaction O
is O
reciprocal I-GENE
, O
since I-GENE
C O
/ O
EBP I-GENE
dimer I-GENE
binding O
to O
a O
strong I-GENE
C O
/ O
EBP I-GENE
site I-GENE
leads I-GENE
to O
enhanced I-GENE
CREB I-GENE
- I-GENE
1 I-GENE
recruitment I-GENE
to O
ATF I-GENE
/ O
CREB I-GENE
sites O
that O
are O
weakly O
bound I-GENE
by O
CREB I-GENE
. O

The O
absorbed O
dose O
was O
measured O
by O
combination O
of O
two O
integrating I-GENE
detectors I-GENE
: O
thermo I-GENE
- I-GENE
luminescent I-GENE
dosemeter I-GENE
of O
Mg2SiO4 I-GENE
: O
Tb I-GENE
( O
TDMS I-GENE
) O
and O
plastic I-GENE
nuclear O
track I-GENE
detector I-GENE
( O
PNTD I-GENE
). O

To I-GENE
determine O
the O
genomic I-GENE
complexity I-GENE
of O
the O
deleted I-GENE
region O
shared I-GENE
among O
tumors O
, O
we O
assembled I-GENE
a O
physical O
map I-GENE
of O
the O
I O
Mbp I-GENE
SRO I-GENE
consisting I-GENE
predominantly I-GENE
of O
bacteriophage I-GENE
P1 I-GENE
- I-GENE
derived I-GENE
artificial O
chromosome I-GENE
( O
PAC I-GENE
) O
clones I-GENE
. O

Thus I-GENE
, O
Xlim I-GENE
- I-GENE
1 I-GENE
not O
only O
contains I-GENE
a O
unique I-GENE
tyrosine I-GENE
- I-GENE
rich I-GENE
activation I-GENE
domain I-GENE
but O
also O
contains I-GENE
a O
negative O
regulatory I-GENE
domain I-GENE
in O
CT239 I-GENE
- I-GENE
403 I-GENE
, O
suggesting O
a O
complex O
regulatory I-GENE
mechanism O
underlying I-GENE
the O
transcriptional I-GENE
activity O
of O
Xlim I-GENE
- I-GENE
1 I-GENE
in O
the O
organizer I-GENE
. O

Low O
- I-GENE
selenium I-GENE
diet O
has O
a O
human I-GENE
unfavourable I-GENE
impact O
. O

In I-GENE
the O
next I-GENE
week O
, O
the O
beta I-GENE
- I-GENE
adrenergic I-GENE
antagonist I-GENE
atenolol I-GENE
was O
added O
at I-GENE
an O
initial O
dose O
of O
25 I-GENE
mg O
/ O
day O
and O
titrated I-GENE
to O
50 O
mg O
/ O
day O
within O
1 I-GENE
week O
. O

To I-GENE
assess O
more O
specific O
PKA I-GENE
- I-GENE
dependent O
mediation I-GENE
of O
LH I-GENE
' O
s O
contribution O
to O
combined O
hormonal I-GENE
drive I-GENE
, O
the O
LDL I-GENE
receptor I-GENE
(- I-GENE
1076 I-GENE
to O
+ O
11 O
bp I-GENE
) O
reporter I-GENE
plasmid I-GENE
was O
cotransfected I-GENE
with O
a O
full I-GENE
- I-GENE
sequence O
rabbit I-GENE
muscle I-GENE
protein O
kinase I-GENE
inhibitor I-GENE
( O
PKI I-GENE
) O
minigene I-GENE
driven I-GENE
constitutively I-GENE
by O
a O
Rous I-GENE
sarcoma I-GENE
virus O
promoter I-GENE
. O

In I-GENE
SN I-GENE
- I-GENE
48 I-GENE
neuronal I-GENE
cells O
that O
express I-GENE
MR O
, O
GR I-GENE
, O
and O
5 I-GENE
- I-GENE
HT1A I-GENE
receptors I-GENE
, O
deletion I-GENE
or O
inactivation I-GENE
of O
the O
nGRE I-GENE
( O
negative O
GRE I-GENE
) O
eliminated I-GENE
negative O
regulation I-GENE
of O
the O
rat O
5 I-GENE
- I-GENE
HT1A I-GENE
or O
heterologous I-GENE
promoters I-GENE
by O
corticosteroids I-GENE
, O
whereas O
its O
inclusion I-GENE
conferred I-GENE
corticosteroid I-GENE
- I-GENE
induced I-GENE
inhibition O
to O
a O
heterologous I-GENE
promoter I-GENE
. O

Transition I-GENE
between O
P I-GENE
- I-GENE
and O
H O
- I-GENE
BPPV I-GENE
was O
found O
in O
6 I-GENE
cases O
. O

These I-GENE
included O
HNF I-GENE
- I-GENE
3 O
beta I-GENE
, O
HFH I-GENE
- I-GENE
1 I-GENE
, O
HFH I-GENE
- I-GENE
2 I-GENE
, O
HFH I-GENE
- I-GENE
3 O
, O
C O
/ O
EBP I-GENE
, O
and O
C O
/ O
EBP I-GENE
beta I-GENE
, O
all O
of O
which O
are O
consistent I-GENE
with O
the O
tissue O
- I-GENE
specific O
expression I-GENE
profiles I-GENE
of O
the O
gene O
. O

RESULTS I-GENE
: O
Of I-GENE
the O
24 I-GENE
patients O
, O
6 I-GENE
had O
Grade I-GENE
1 I-GENE
pneumonitis I-GENE
, O
and O
13 I-GENE
had O
Grade I-GENE
2 I-GENE
pneumonitis I-GENE
. O

METHODS I-GENE
: O
The O
passive O
and O
active I-GENE
transport I-GENE
of O
fluorescein I-GENE
through O
the O
BRB I-GENE
was O
quantitated I-GENE
by O
vitreous I-GENE
fluorometry I-GENE
. O

Sixteen I-GENE
out O
of O
52 I-GENE
seropositive I-GENE
MS O
patients O
( O
30 I-GENE
. O
8 I-GENE
%) O
showed O
intrathecal I-GENE
synthesis I-GENE
of O
C O
. O
pneumoniae I-GENE
- I-GENE
specific O
IgG I-GENE
but O
only O
one O
of O
43 I-GENE
seropositive I-GENE
controls O
( O
2 I-GENE
. O
3 O
%). O

Consistent I-GENE
with O
the O
specificity I-GENE
observed O
for I-GENE
the O
interaction O
of O
DmCKIIalpha I-GENE
with O
these O
bHLH I-GENE
proteins O
, O
sequence O
alignment I-GENE
suggests O
that O
only O
m5 I-GENE
, O
m7 I-GENE
, O
and O
m8 I-GENE
contain O
a O
consensus I-GENE
site I-GENE
for I-GENE
phosphorylation I-GENE
by O
CKII I-GENE
within O
a O
subdomain I-GENE
unique I-GENE
to O
these O
three O
proteins O
. O

Deletion I-GENE
of O
the O
potential I-GENE
initiator I-GENE
element I-GENE
does O
not O
affect O
repression I-GENE
of O
the O
p21 I-GENE
promoter I-GENE
by O
c O
- I-GENE
Myc I-GENE
. O

PATIENTS I-GENE
AND I-GENE
METHODS I-GENE
: O
Between I-GENE
June I-GENE
1991 I-GENE
and O
December I-GENE
1996 I-GENE
, O
we O
administered O
the O
nucleoside I-GENE
analog O
2 I-GENE
- I-GENE
chlorodeoxyadenosine I-GENE
( O
2 I-GENE
- I-GENE
CDA I-GENE
) O
to O
73 I-GENE
children O
with O
primary I-GENE
AML I-GENE
and O
20 O
children O
with O
secondary O
AML I-GENE
or O
myelodysplastic I-GENE
syndrome I-GENE
( O
MDS I-GENE
). O

Drosophila I-GENE
Menin1 I-GENE
gene O
transcripts O
use O
alternative I-GENE
polyadenylation I-GENE
sites O
resulting O
in O
4 O
. O
3 O
and O
5 I-GENE
- I-GENE
kb O
messages I-GENE
. O

Mice I-GENE
homozygous I-GENE
for I-GENE
the O
dlg I-GENE
mutation I-GENE
exhibit O
growth O
retardation I-GENE
in O
utero I-GENE
, O
have O
hypoplasia I-GENE
of O
the O
premaxilla I-GENE
and O
mandible I-GENE
, O
have O
a O
cleft I-GENE
secondary O
palate I-GENE
, O
and O
die I-GENE
perinatally I-GENE
. O

In I-GENE
contrast O
, O
we O
did O
not O
detect I-GENE
a O
significant O
correlation O
between O
plasma I-GENE
TNFalpha I-GENE
and O
radiation O
pneumonitis I-GENE
. O

Its I-GENE
transcription O
in O
vitro O
by O
pol I-GENE
III I-GENE
requires O
the O
same O
factors I-GENE
as I-GENE
the O
U6 I-GENE
gene O
with O
the O
major O
exception O
that O
the O
modified O
TATA I-GENE
- I-GENE
box I-GENE
of O
this O
construct I-GENE
only O
interacts I-GENE
with O
a O
TATA I-GENE
- I-GENE
binding O
protein O
( O
TBP I-GENE
) O
mutant I-GENE
( O
TBP I-GENE
- I-GENE
DR2 I-GENE
) O
but O
not O
with O
TBP I-GENE
wild I-GENE
- I-GENE
type I-GENE
( O
TBPwt I-GENE
). O

Expression I-GENE
of O
the O
src I-GENE
homology I-GENE
3 O
( O
SH3 I-GENE
)- O
encoding I-GENE
, O
expressed I-GENE
in O
tumorigenic I-GENE
astrocytes I-GENE
( O
SETA I-GENE
) O
gene O
is O
associated O
with O
astrocyte I-GENE
transformation I-GENE
in O
culture O
and O
tumors O
in O
the O
adult O
brain O
. O

In I-GENE
such O
conditions O
, O
the O
following O
kinetic I-GENE
reactions O
have O
been O
studied O
: O
N2 I-GENE
( O
A I-GENE
) O
+ O
N2 I-GENE
( O
A I-GENE
) O
--> I-GENE
N2 I-GENE
( O
C O
, O
B I-GENE
, O
V I-GENE
') I-GENE
+ O
N2 I-GENE
( O
X I-GENE
), I-GENE
N2 I-GENE
( O
A I-GENE
) O
+ O
N2 I-GENE
( O
X I-GENE
, O
V I-GENE
> I-GENE
5 I-GENE
) O
--> I-GENE
N2 I-GENE
( O
X I-GENE
) O
+ O
N2 I-GENE
( O
B I-GENE
, O
V I-GENE
') I-GENE
in O
pure O
N2 I-GENE
post O
- I-GENE
discharges I-GENE
and O
N2 I-GENE
( O
A I-GENE
) O
+ O
CH4 I-GENE
--> I-GENE
products I-GENE
, O
C O
+ O
N O
+ O
M2 I-GENE
--> I-GENE
CN I-GENE
( O
B I-GENE
, O
V I-GENE
') I-GENE
+ O
M2 I-GENE
, O
N2 I-GENE
( O
X I-GENE
, O
V I-GENE
> I-GENE
4 O
) O
+ O
CN I-GENE
--> I-GENE
N2 I-GENE
( O
X I-GENE
) O
+ O
CN I-GENE
( O
B I-GENE
, O
A I-GENE
, O
V I-GENE
'), I-GENE
in O
N2 I-GENE
- I-GENE
1 I-GENE
% O
CH4 I-GENE
post O
- I-GENE
discharges I-GENE
. O

BACKGROUND I-GENE
/ O
AIMS I-GENE
: O
Hepatitis I-GENE
C O
and O
nonalcoholic I-GENE
fatty I-GENE
liver O
disease I-GENE
( O
NAFL I-GENE
) O
are O
the O
two O
most O
common O
forms I-GENE
of O
liver O
disease I-GENE
in O
the O
United I-GENE
States I-GENE
. O

These I-GENE
results O
suggested O
a O
critical I-GENE
role O
for I-GENE
tyrosine I-GENE
residue I-GENE
1229 I-GENE
in O
the O
regulation I-GENE
of O
L1 O
endocytosis I-GENE
. O

The O
androgen I-GENE
receptor I-GENE
( O
AR I-GENE
) O
amino I-GENE
- I-GENE
terminus I-GENE
imposes I-GENE
androgen I-GENE
- I-GENE
specific O
regulation I-GENE
of O
AR I-GENE
gene O
expression I-GENE
via I-GENE
an O
exonic I-GENE
enhancer I-GENE
. O

Can I-GENE
survival I-GENE
be O
prolonged O
for I-GENE
patients O
with O
hormone I-GENE
- I-GENE
resistant O
prostate I-GENE
cancer I-GENE
? O

In I-GENE
conclusion I-GENE
, O
NF I-GENE
- I-GENE
Y O
and O
Sp1 I-GENE
binding O
sites O
play I-GENE
a O
decisive I-GENE
role O
in O
the O
basal O
expression I-GENE
of O
the O
rat O
mrp2 I-GENE
gene O
, O
while O
the O
human I-GENE
MRP2 I-GENE
gene O
is O
regulated I-GENE
differently O
. O

Intact I-GENE
Flag I-GENE
- I-GENE
tagged I-GENE
protein O
products I-GENE
from O
all O
six I-GENE
were O
produced O
from O
genomic I-GENE
expression I-GENE
vectors I-GENE
, O
although O
the O
ORF40 I-GENE
/ O
41 I-GENE
transcript I-GENE
encoding I-GENE
a O
primase I-GENE
- I-GENE
helicase I-GENE
component I-GENE
proved O
to O
be O
spliced I-GENE
with O
a O
127 I-GENE
- I-GENE
bp I-GENE
intron I-GENE
. O

Hypomorphic I-GENE
dSLBP I-GENE
alleles I-GENE
support O
zygotic I-GENE
development O
but O
cause O
female O
sterility I-GENE
. O

In I-GENE
hypertensive O
nephrosclerosis I-GENE
, O
therapy O
containing O
an O
ACEI I-GENE
alone O
or O
in O
combination O
significantly O
reduces O
the O
incidence O
of O
renal I-GENE
events I-GENE
. O

We I-GENE
confirmed I-GENE
the O
interaction O
between O
TLS I-GENE
and O
p65 I-GENE
by O
the O
pull I-GENE
- I-GENE
down I-GENE
assay O
in O
vitro O
and O
by O
a O
coimmunoprecipitation I-GENE
experiment O
followed O
by O
Western I-GENE
blot I-GENE
of O
the O
cultured I-GENE
cell O
in O
vivo O
. O

In I-GENE
addition O
, O
we O
did O
not O
detect I-GENE
significant O
differences O
in O
CDR3 I-GENE
sequences O
of O
endogenous O
Ig I-GENE
lambdaL I-GENE
and O
kappaL I-GENE
chain I-GENE
gene O
loci O
cloned I-GENE
from O
peripheral O
blood I-GENE
lymphocytes O
of O
an O
NBS I-GENE
patient O
and O
of O
healthy O
individuals I-GENE
. O

The O
diet O
of O
migrants I-GENE
showed O
both O
positive O
( O
macronutrients I-GENE
) O
and O
negative O
( O
micronutrients I-GENE
) O
differences O
with O
the O
general I-GENE
Dutch I-GENE
diet O
. O

Copyright I-GENE
2001 I-GENE
Academic I-GENE
Press I-GENE
. O

Experimental I-GENE
study O
of O
ta I-GENE
chengchi I-GENE
tang I-GENE
decoction I-GENE
for I-GENE
relieving I-GENE
lung I-GENE
injury I-GENE
during I-GENE
acute O
necrotizing I-GENE
pancreatitis O
] O
The O
objectives I-GENE
of O
the O
study O
were O
to O
investigate O
the O
changes O
of O
leukocyte I-GENE
adhesiveness I-GENE
and O
tumor O
necrosis I-GENE
factor I-GENE
( O
TNF I-GENE
) O
in O
the O
early O
stage I-GENE
of O
acute O
necrotizing I-GENE
pancreatitis O
( O
ANP I-GENE
), I-GENE
to O
go I-GENE
further O
into O
the O
relation I-GENE
of O
those O
changes O
to O
lung I-GENE
injury I-GENE
of O
ANP I-GENE
, O
and O
to O
evaluate I-GENE
the O
prohibitive I-GENE
effect O
of O
ta I-GENE
chengchi I-GENE
tang I-GENE
Decoction I-GENE
on O
leukocyte I-GENE
adhesion I-GENE
and O
TNF I-GENE
secretion I-GENE
. O

We I-GENE
suggest O
that O
ventriculopleural I-GENE
shunting I-GENE
should O
be O
considered O
as I-GENE
the O
preferred I-GENE
alternative I-GENE
to O
peritoneal O
drainage I-GENE
in O
children O
with O
intra I-GENE
- I-GENE
abdominal O
adhesions I-GENE
or O
with O
a O
history O
of O
recent O
peritoneal O
infection O
. O

Positive I-GENE
and O
significant O
correlations O
were O
found O
between O
the O
weeks O
of O
pregnancy I-GENE
and O
Se I-GENE
levels O
in O
kidney I-GENE
( O
r I-GENE
= O
0 I-GENE
. O
433 I-GENE
, O
P I-GENE
= O
0 I-GENE
. O
023 I-GENE
) O
and O
heart I-GENE
( O
r I-GENE
= O
0 I-GENE
. O
313 I-GENE
, O
P I-GENE
= O
0 I-GENE
. O
030 I-GENE
). O

Doxorubicin I-GENE
( O
DOX I-GENE
) O
is O
commonly O
used O
for I-GENE
the O
treatment O
of O
hematological I-GENE
and O
solid O
tumors O
. O

There I-GENE
was O
no I-GENE
significant O
difference O
in O
developmental I-GENE
scores O
at I-GENE
9 O
or O
18 O
months O
, O
although O
PDF I-GENE
infants O
had O
a O
2 I-GENE
. O
8 I-GENE
(- I-GENE
1 I-GENE
. O
3 O
- I-GENE
6 I-GENE
. O
8 I-GENE
) O
point I-GENE
advantage I-GENE
in O
Bayley I-GENE
motor O
score O
scales I-GENE
. O

Immunofixation I-GENE
experiments I-GENE
of O
C4A I-GENE
and O
C4B I-GENE
demonstrate O
> I-GENE
41 I-GENE
allotypes I-GENE
in O
the O
two O
classes I-GENE
of O
proteins O
. O

These I-GENE
effects O
were O
not O
seen O
with O
SHIP2 I-GENE
possessing I-GENE
a O
mutation I-GENE
in O
the O
SH2 I-GENE
domain I-GENE
( O
R47G I-GENE
). O

Myasthenia I-GENE
gravis I-GENE
is O
an O
autoimmune I-GENE
disease I-GENE
resulting O
from O
the O
production O
of O
antibodies I-GENE
against O
the O
ACh I-GENE
receptors I-GENE
of O
the O
neuromuscular I-GENE
synapse I-GENE
. O

Human I-GENE
homologue I-GENE
of O
yeast I-GENE
Rad23 I-GENE
protein O
A I-GENE
interacts I-GENE
with O
p300 I-GENE
/ O
cyclic O
AMP O
- I-GENE
responsive O
element I-GENE
binding O
( O
CREB I-GENE
)- O
binding O
protein O
to O
down I-GENE
- I-GENE
regulate I-GENE
transcriptional I-GENE
activity O
of O
p53 I-GENE
. O

METHODS I-GENE
: O
Sixteen I-GENE
pigs O
were O
assigned O
randomly I-GENE
to O
control O
and O
shock I-GENE
groups O
. O

RESULTS I-GENE
: O
There I-GENE
is O
a O
considerable I-GENE
amount O
of O
variation O
between O
the O
results O
of O
TRA1 I-GENE
and O
TRA2 I-GENE
and O
between O
the O
results O
of O
both O
TRA I-GENE
' O
s O
and O
the O
door I-GENE
- I-GENE
to O
- I-GENE
door I-GENE
survey O
. O

Thus I-GENE
, O
our O
studies O
define I-GENE
Rac I-GENE
/ O
Cdc42 I-GENE
/ O
Pak I-GENE
as I-GENE
a O
module I-GENE
upstream O
of O
Raf I-GENE
- I-GENE
1 I-GENE
during I-GENE
its O
activation I-GENE
by O
microtubule I-GENE
disruption I-GENE
. O

Zhu I-GENE
, O
V I-GENE
. O

However I-GENE
, O
plasmids I-GENE
carrying I-GENE
the O
yeast I-GENE
TyrRS I-GENE
gene O
could O
not O
be O
stably I-GENE
maintained O
in O
E I-GENE
. O
coli I-GENE
. O

This I-GENE
supports I-GENE
previous O
arguments I-GENE
for I-GENE
the O
improbability I-GENE
of O
biological O
effects O
at I-GENE
UHF I-GENE
frequencies I-GENE
unless I-GENE
a O
mechanism O
can O
be O
found O
for I-GENE
accumulating I-GENE
energy I-GENE
over O
time O
and O
space I-GENE
and O
focussing I-GENE
it O
. O

The O
students O
who O
had O
abnormal O
urine I-GENE
screening I-GENE
results O
at I-GENE
the O
first I-GENE
time O
received O
a O
second O
urine I-GENE
analysis O
10 O
to O
15 I-GENE
days O
later O
to O
confirm O
the O
abnormal O
urine I-GENE
analysis O
. O

Cells I-GENE
containing O
alpha I-GENE
subunits I-GENE
that O
lacked I-GENE
a O
distal I-GENE
domain I-GENE
( O
term O
- I-GENE
3 O
) O
or O
had O
the O
alternatively I-GENE
spliced I-GENE
alpha I-GENE
- I-GENE
2 I-GENE
distal I-GENE
domain I-GENE
showed O
markedly O
decreased O
ability O
to O
support O
tyrosine I-GENE
phosphorylation I-GENE
of O
Jak I-GENE
- I-GENE
2 I-GENE
and O
its O
substrates I-GENE
or O
to O
up I-GENE
- I-GENE
regulate I-GENE
CD86 I-GENE
. O

Despite I-GENE
abundant I-GENE
expression I-GENE
of O
NtmybAS I-GENE
transcripts O
in O
mature I-GENE
pollen I-GENE
, O
gPAL1 I-GENE
transcripts O
were O
not O
detectable I-GENE
in O
pollen I-GENE
. O

Finally I-GENE
, O
profiling I-GENE
of O
a O
gcn4Delta I-GENE
mutant I-GENE
uncovered I-GENE
an O
alternative I-GENE
induction O
pathway I-GENE
operating O
at I-GENE
many O
Gcn4p I-GENE
target I-GENE
genes I-GENE
in O
histidine I-GENE
- I-GENE
starved I-GENE
cells O
. O

The O
R2 I-GENE
between O
MFI I-GENE
of O
fresh O
and O
frozen I-GENE
muscle I-GENE
was O
0 I-GENE
. O
94 I-GENE
and O
0 I-GENE
. O
92 I-GENE
for I-GENE
lamb I-GENE
and O
pork I-GENE
longissimus I-GENE
, O
respectively O
. O

To I-GENE
this O
end O
, O
an O
expression I-GENE
cassette I-GENE
consisting I-GENE
of O
the O
gene O
for I-GENE
a O
green I-GENE
fluorescent I-GENE
protein O
( O
GFP I-GENE
) O
flanked I-GENE
at I-GENE
its O
3 O
' O
end O
by O
EAV I-GENE
- I-GENE
specific O
transcription O
- I-GENE
regulating I-GENE
sequences O
was O
constructed I-GENE
. O

Significantly I-GENE
higher I-GENE
lung I-GENE
function O
parameters O
were O
obtained O
in O
extubated I-GENE
recipients O
of O
LPD I-GENE
preserved I-GENE
grafts I-GENE
2 I-GENE
weeks O
after O
TX I-GENE
. O

Lack I-GENE
of O
association O
between O
Kawasaki I-GENE
syndrome I-GENE
and O
infection O
with O
Rickettsia I-GENE
conorii I-GENE
, O
Rickettsia I-GENE
typhi I-GENE
, O
Coxiella I-GENE
burnetii I-GENE
or O
Ehrlichia I-GENE
phagocytophila I-GENE
group O
. O

These I-GENE
utilisation I-GENE
data O
imply I-GENE
annual I-GENE
drug O
costs I-GENE
in O
the O
range O
of O
$ I-GENE
US I-GENE
480 I-GENE
, O
000 I-GENE
to O
$ I-GENE
US I-GENE
3 O
, O
600 O
, O
000 I-GENE
for I-GENE
TNF I-GENE
antagonists I-GENE
for I-GENE
RA I-GENE
per O
1 I-GENE
million O
population O
. O

Alignment I-GENE
of O
different O
cDNAs I-GENE
of O
the O
NR5A2 I-GENE
( O
hB1F I-GENE
) O
gene O
with O
the O
genomic I-GENE
sequence O
facilitated I-GENE
the O
delineation I-GENE
of O
its O
structural I-GENE
organization I-GENE
, O
which O
spans I-GENE
over O
150 I-GENE
kb O
and O
consists I-GENE
of O
eight I-GENE
exons I-GENE
interrupted I-GENE
by O
seven I-GENE
introns I-GENE
. O

CONCLUSIONS I-GENE
: O
Ketamine I-GENE
- I-GENE
induced I-GENE
dissociative I-GENE
anesthesia O
produces I-GENE
persistently I-GENE
elevated O
BIS I-GENE
index O
which O
is O
different O
from O
thiamylal I-GENE
and O
those O
reported O
with O
other O
conventional O
anesthetic I-GENE
agents O
. O

In I-GENE
the O
remaining O
case O
, O
the O
aneurysm I-GENE
originated I-GENE
from O
the O
proximal I-GENE
end O
of O
the O
associated O
A1 I-GENE
fenestration I-GENE
. O

This I-GENE
domain I-GENE
without O
the O
canonical I-GENE
anticodon I-GENE
loop O
or O
the O
tyrosine I-GENE
anticodon I-GENE
acts I-GENE
as I-GENE
an O
anchor I-GENE
for I-GENE
TyrRS I-GENE
interaction O
leading O
to O
a O
better O
efficiency I-GENE
of O
tyrosylation I-GENE
. O

Temperature I-GENE
measurement O
in O
microfluidic I-GENE
systems I-GENE
using O
a O
temperature I-GENE
- I-GENE
dependent O
fluorescent I-GENE
dye I-GENE
. O

The O
first I-GENE
exon I-GENE
( O
exon I-GENE
1A I-GENE
) O
that O
corresponded I-GENE
to O
the O
5 I-GENE
'- O
untranslated I-GENE
region O
of O
the O
GHR I-GENE
1A I-GENE
mRNA I-GENE
was O
15 I-GENE
, O
250 I-GENE
bp I-GENE
upstream O
from O
exon I-GENE
2 I-GENE
in O
the O
GHR I-GENE
gene O
. O

The O
NAUSICAA I-GENE
system I-GENE
gives O
a O
good O
knowledge I-GENE
of O
LET I-GENE
spectra I-GENE
for I-GENE
the O
first I-GENE
time O
in O
space I-GENE
dosimetry I-GENE
. O

The O
MABP I-GENE
and O
MCBFV I-GENE
signals I-GENE
were O
bandpass I-GENE
filtered I-GENE
in O
the O
very O
low O
- I-GENE
frequency O
range O
( O
VLF I-GENE
, O
0 I-GENE
. O
015 I-GENE
- I-GENE
0 I-GENE
. O
07 I-GENE
Hz I-GENE
), I-GENE
low O
- I-GENE
frequency O
range O
( O
LF I-GENE
, O
0 I-GENE
. O
07 I-GENE
- I-GENE
0 I-GENE
. O
15 I-GENE
Hz I-GENE
) O
and O
high O
- I-GENE
frequency O
range O
( O
HF I-GENE
, O
0 I-GENE
. O
15 I-GENE
- I-GENE
0 I-GENE
. O
40 O
Hz I-GENE
) O
before O
applying I-GENE
CCF I-GENE
for I-GENE
the O
purpose I-GENE
of O
studying O
the O
effect O
of O
different O
bandwidths I-GENE
on O
the O
resulting O
mean O
CCFs I-GENE
. O

At I-GENE
cross O
purposes I-GENE
. O

For I-GENE
these O
patients O
the O
introduction I-GENE
of O
a O
separate O
category I-GENE
" O
extended I-GENE
oligoarthritis I-GENE
at I-GENE
onset O
" O
should O
be O
considered O
to O
establish I-GENE
comparable O
patient O
groups O
. O

The O
susceptibility I-GENE
of O
Aspergillus I-GENE
fumigatus I-GENE
to O
mulundocandin I-GENE
, O
an O
echinocandin I-GENE
- I-GENE
like O
compound O
, O
and O
other O
antifungal I-GENE
agents O
was O
assessed O
by O
the O
National O
Committee O
for I-GENE
Clinical I-GENE
Laboratory I-GENE
Standards I-GENE
( O
NCCLS I-GENE
) O
M38 I-GENE
- I-GENE
P I-GENE
method O
, O
a O
2 I-GENE
, O
3 O
- I-GENE
bis I-GENE
( O
2 I-GENE
- I-GENE
methoxy I-GENE
- I-GENE
4 O
- I-GENE
nitro I-GENE
- I-GENE
5 I-GENE
- I-GENE
sulfophenyl I-GENE
)- O
5 I-GENE
-[( I-GENE
phenyl I-GENE
- I-GENE
amino I-GENE
) O
carbonyl I-GENE
]- I-GENE
2H I-GENE
- I-GENE
tetrazolium I-GENE
hydroxide I-GENE
( O
XTT I-GENE
)- O
based O
colorimetric I-GENE
assay O
, O
and O
determination O
of O
morphologic I-GENE
alterations O
by O
microscopy O
. O

The O
most O
important O
risk O
factors I-GENE
are O
: O
1 I-GENE
) O
genetic I-GENE
; O
2 I-GENE
) O
Epstein O
- I-GENE
Barr O
virus O
( O
infectious O
mononucleosis I-GENE
); O
3 O
) O
congenital I-GENE
and O
acquired I-GENE
immunodeficiency I-GENE
; O
4 O
) O
occupational I-GENE
exposure O
( O
the O
wood I-GENE
industry I-GENE
). O

Members I-GENE
of O
the O
AP I-GENE
- I-GENE
1 I-GENE
superfamily I-GENE
of O
basic O
- I-GENE
leucine I-GENE
zipper I-GENE
factors I-GENE
bind I-GENE
to O
the O
StRE I-GENE
. O

DNA I-GENE
recognition O
by O
F O
factor I-GENE
TraI36 I-GENE
: O
highly O
sequence O
- I-GENE
specific O
binding O
of O
single O
- I-GENE
stranded I-GENE
DNA I-GENE
. O

Overexpression I-GENE
of O
RORgamma I-GENE
has O
been O
shown O
to O
inhibit I-GENE
T I-GENE
cell O
receptor I-GENE
- I-GENE
mediated I-GENE
apoptosis I-GENE
in O
T I-GENE
cell O
hybridomas I-GENE
and O
to O
repress I-GENE
the O
induction O
of O
Fas I-GENE
- I-GENE
ligand I-GENE
and O
interleukin I-GENE
2 I-GENE
. O

Although I-GENE
metabolized I-GENE
by O
the O
cytochrome I-GENE
P I-GENE
- I-GENE
450 I-GENE
( O
CYP I-GENE
) O
system I-GENE
, O
venlafaxine I-GENE
inhibits O
CYP I-GENE
2D6 I-GENE
and O
3A4 I-GENE
to O
a O
far O
lesser I-GENE
extent I-GENE
than O
do O
the O
SSRIs I-GENE
. O

SAPK I-GENE
/ O
JNK I-GENE
activation I-GENE
was O
completely I-GENE
abolished O
in O
the O
absence O
of O
MKK7 I-GENE
, O
even O
though I-GENE
expression I-GENE
of O
MKK4 I-GENE
was O
strongly O
upregulated I-GENE
in O
mkk7 I-GENE
(-/-) I-GENE
mast I-GENE
cell O
lines I-GENE
, O
and O
phosphorylation I-GENE
of O
MKK4 I-GENE
occurred O
normally O
in O
response O
to O
multiple O
stress O
stimuli O
. O

However I-GENE
these O
search I-GENE
engines I-GENE
respond O
with O
such O
cumbersome I-GENE
results O
that O
domain I-GENE
specific O
experts I-GENE
can O
not O
tolerate I-GENE
. O

The O
titer I-GENE
of O
TSH I-GENE
binding O
inhibitor I-GENE
immunoglobulin I-GENE
( O
TBII I-GENE
), I-GENE
which O
had O
been O
8 I-GENE
. O
6 I-GENE
% O
at I-GENE
initial O
presentation O
, O
rose I-GENE
to O
14 O
. O
9 O
% O
in O
2 I-GENE
weeks O
. O

The O
extraordinary I-GENE
stability O
of O
peptide I-GENE
-- I-GENE
gp96 I-GENE
complexes I-GENE
and O
the O
plasticity I-GENE
of O
the O
peptide I-GENE
- I-GENE
binding O
pocket I-GENE
support O
the O
proposed I-GENE
relay I-GENE
of O
diverse I-GENE
peptides I-GENE
to O
MHC I-GENE
and O
/ O
or O
other O
molecules O
via I-GENE
molecular I-GENE
recognition O
. O

Elevated I-GENE
expression I-GENE
of O
full I-GENE
- I-GENE
length O
UhpB I-GENE
or O
of O
a O
soluble I-GENE
hybrid I-GENE
protein O
, O
GST I-GENE
- I-GENE
Bc I-GENE
, O
which O
is O
glutathione I-GENE
S O
- I-GENE
transferase I-GENE
( O
GST I-GENE
) O
fused I-GENE
to O
the O
cytoplasmic I-GENE
C O
- I-GENE
terminal I-GENE
portion O
of O
UhpB I-GENE
, O
results O
in O
complete I-GENE
blockage I-GENE
of O
uhpT I-GENE
expression I-GENE
in O
a O
uhp I-GENE
(+) I-GENE
strain I-GENE
. O

Physical I-GENE
principles I-GENE
in O
therapeutic O
apheresis I-GENE
. O

Evidence I-GENE
from O
a O
Northern O
hybridization I-GENE
indicated O
that O
jadM I-GENE
expression I-GENE
is O
correlated O
with O
jadomycin I-GENE
B I-GENE
synthesis I-GENE
. O

Multiple I-GENE
copies I-GENE
of O
rsmB I-GENE
+ O
DNA I-GENE
, O
on O
the O
other O
hand I-GENE
, O
stimulate I-GENE
exoenzyme I-GENE
production O
by O
relieving I-GENE
the O
negative O
effects O
of O
a O
chromosomal I-GENE
copy I-GENE
of O
hexA I-GENE
+. I-GENE

Systematic I-GENE
review O
of O
diagnostic O
tests O
for I-GENE
vaginal O
trichomoniasis I-GENE
. O

Anecdotal I-GENE
observations O
scattered I-GENE
throughout O
the O
literature O
have O
often I-GENE
provided O
clues I-GENE
to O
underlying I-GENE
variations O
in O
humans O
' O
ability O
to O
handle I-GENE
dietary I-GENE
chemicals I-GENE
. O

Here I-GENE
we O
show O
that O
phosphorylation I-GENE
- I-GENE
induced I-GENE
loss I-GENE
of O
the O
protein O
kinase I-GENE
activity O
of O
DNA I-GENE
- I-GENE
PK I-GENE
is O
restored I-GENE
by O
the O
addition O
of O
the O
purified I-GENE
catalytic I-GENE
subunit I-GENE
of O
either O
protein O
phosphatase I-GENE
1 I-GENE
or O
protein O
phosphatase I-GENE
2A I-GENE
( O
PP2A I-GENE
) O
and O
that O
this O
reactivation I-GENE
is O
blocked I-GENE
by O
the O
potent O
protein O
phosphatase I-GENE
inhibitor I-GENE
, O
microcystin I-GENE
. O

Herein I-GENE
PPARgamma I-GENE
, O
liganded I-GENE
by O
either O
natural I-GENE
( O
15d I-GENE
- I-GENE
PGJ I-GENE
( O
2 I-GENE
) O
and O
PGD I-GENE
( O
2 I-GENE
)) I-GENE
or O
synthetic I-GENE
ligands I-GENE
( O
BRL49653 I-GENE
and O
troglitazone I-GENE
), I-GENE
selectively I-GENE
inhibited O
expression I-GENE
of O
the O
cyclin I-GENE
D1 I-GENE
gene O
. O

An I-GENE
integrated I-GENE
RTC I-GENE
algorithm I-GENE
for I-GENE
the O
urban I-GENE
wastewater I-GENE
system I-GENE
is O
formulated I-GENE
, O
the O
parameters O
of O
which O
are O
optimized I-GENE
using O
various O
global O
optimization I-GENE
routines I-GENE
. O

Recently I-GENE
, O
we O
discovered I-GENE
that O
alanine O
substitutions I-GENE
of O
the O
active I-GENE
center I-GENE
cleft I-GENE
residues O
significantly O
impair I-GENE
the O
depurinating I-GENE
and O
ribosome I-GENE
inhibitory I-GENE
activity O
of O
PAP I-GENE
. O

This I-GENE
partial O
transection I-GENE
could O
permit I-GENE
vasopressin I-GENE
to O
be O
secreted I-GENE
in O
response O
to O
a O
larger O
rise O
in O
plasma I-GENE
sodium I-GENE
concentration O
. O

Reciprocally I-GENE
, O
HMGI I-GENE
- I-GENE
C O
expression I-GENE
also O
coordinately I-GENE
enhances I-GENE
PIAS3 I-GENE
- I-GENE
mediated I-GENE
repression I-GENE
of O
STAT3 I-GENE
- I-GENE
dependent O
transactivation I-GENE
. O

The O
genomic I-GENE
structure I-GENE
of O
the O
human I-GENE
SPEC1 I-GENE
gene O
reveals I-GENE
complex O
splicing I-GENE
and O
close I-GENE
promoter I-GENE
proximity I-GENE
to O
the O
AF1q I-GENE
translocation I-GENE
gene O
. O

Here I-GENE
, O
the O
PEX5 I-GENE
- I-GENE
TPR I-GENE
domains I-GENE
from O
human I-GENE
, O
tobacco I-GENE
, O
and O
nematode I-GENE
were O
inserted I-GENE
into O
a O
TPR I-GENE
- I-GENE
less O
yeast I-GENE
Pex5p I-GENE
construct I-GENE
to O
generate I-GENE
Pex5p I-GENE
chimaeras I-GENE
. O

This I-GENE
study O
demonstrates I-GENE
that O
inducible I-GENE
expression I-GENE
in O
response O
to O
either O
PMA I-GENE
or O
TPO I-GENE
is O
mediated I-GENE
through O
the O
Ets I-GENE
site I-GENE
in O
the O
proximal I-GENE
promoter I-GENE
of O
GPIX I-GENE
and O
is O
dependent O
upon O
the O
upstream O
activation I-GENE
of O
MAPK I-GENE
/ O
extracellular O
signal I-GENE
- I-GENE
regulated I-GENE
kinase I-GENE
. O

Molecular I-GENE
identification I-GENE
of O
smg I-GENE
- I-GENE
4 O
, O
required O
for I-GENE
mRNA I-GENE
surveillance I-GENE
in O
C O
. O
elegans I-GENE
. O

Cytosolic I-GENE
acetyl I-GENE
- I-GENE
CoA I-GENE
synthetase I-GENE
( O
AceCS1 I-GENE
) O
activates I-GENE
acetate I-GENE
to O
supply O
the O
cells O
with O
acetyl I-GENE
- I-GENE
CoA I-GENE
for I-GENE
lipid I-GENE
synthesis I-GENE
. O

There I-GENE
was O
an O
increase O
in O
protein O
binding O
onto I-GENE
this O
element I-GENE
only O
after O
peptide I-GENE
treatment O
. O

While I-GENE
these O
results O
are O
consistent I-GENE
with O
previously O
reported O
effects O
of O
the O
C O
- I-GENE
terminal I-GENE
domain I-GENE
on O
nucleotide I-GENE
binding O
, O
they O
also O
demonstrate O
that O
interactions O
with O
the O
N O
- I-GENE
terminal I-GENE
domains I-GENE
are O
necessary O
to O
inhibit I-GENE
proton I-GENE
transport I-GENE
. O

These I-GENE
findings O
suggest O
that O
an O
intracellular I-GENE
WT I-GENE
- I-GENE
1 I-GENE
/ O
HSAL2 I-GENE
pathway I-GENE
may O
play I-GENE
a O
role O
in O
development O
and O
hematopoiesis I-GENE
. O

The O
radial I-GENE
forearm I-GENE
flap I-GENE
is O
used O
most O
commonly O
, O
however O
the O
lateral I-GENE
arm I-GENE
flap I-GENE
may O
be O
the O
flap I-GENE
of O
choice I-GENE
in O
certain O
situations I-GENE
. O

The O
procedure O
is O
less O
aggressive I-GENE
and O
painful I-GENE
than O
sternotomy I-GENE
. O

In I-GENE
addition O
, O
we O
have O
isolated O
a O
genomic I-GENE
fragment O
containing O
the O
most O
distal I-GENE
5 I-GENE
' O
sequences O
of O
the O
major O
GGT I-GENE
mRNA I-GENE
in O
HepG2 I-GENE
cells O
. O

Further I-GENE
, O
the O
osteo I-GENE
- I-GENE
retentive I-GENE
ability O
of O
the O
hydroxyapatite I-GENE
in O
the O
sockets I-GENE
was O
seen O
to O
be O
close I-GENE
to O
significance O
( O
after O
six I-GENE
months O
width I-GENE
differences O
, O
in O
the O
canine I-GENE
region O
: O
P I-GENE
= O
0 I-GENE
. O
059 I-GENE
, O
LHS I-GENE
, O
and O
P I-GENE
= O
0 I-GENE
. O
065 I-GENE
, O
RHS I-GENE
). O

These I-GENE
findings O
suggest O
a O
novel I-GENE
ankyrin I-GENE
- I-GENE
independent O
role O
for I-GENE
LAD I-GENE
- I-GENE
1 I-GENE
related O
to O
FGFR I-GENE
signaling I-GENE
. O

Managing I-GENE
vertigo I-GENE
and O
vertigo I-GENE
syndromes I-GENE
in O
the O
elderly I-GENE

A I-GENE
single O
base I-GENE
change O
( O
A8G I-GENE
) O
in O
either O
sequence O
reduces O
hnRNP I-GENE
A2 I-GENE
binding O
and O
, O
in O
the O
case O
of O
A2RE I-GENE
- I-GENE
2 I-GENE
, O
inhibits O
RNA O
transport I-GENE
. O

A I-GENE
method O
of O
three O
- I-GENE
station I-GENE
three O
- I-GENE
dimensional I-GENE
magnetic I-GENE
resonance I-GENE
( O
MR O
) O
angiography O
of O
the O
lower O
extremities I-GENE
with O
segmented I-GENE
volume O
acquisition O
is O
presented O
. O

Treatment O
of O
N18TG I-GENE
- I-GENE
2 I-GENE
cells O
with O
a O
demethylating I-GENE
agent O
, O
5 I-GENE
- I-GENE
aza I-GENE
- I-GENE
deoxycytidine I-GENE
, O
resulted O
in O
an O
expression I-GENE
of O
mlt I-GENE
1 I-GENE
, O
indicating I-GENE
that O
the O
repression I-GENE
of O
mlt I-GENE
1 I-GENE
is O
attributable I-GENE
to O
methylation I-GENE
Thus I-GENE
, O
mlt I-GENE
1 I-GENE
is O
a O
novel I-GENE
target I-GENE
gene O
that O
is O
silenced I-GENE
by O
methylation I-GENE
during I-GENE
liver O
tumorigenesis I-GENE
initiated I-GENE
by O
SV40 O
T I-GENE
antigen I-GENE
. O

We I-GENE
found O
in O
the O
control O
subjects O
rCBF I-GENE
increases O
in O
regions O
associated O
with O
the O
meso I-GENE
- I-GENE
striatal I-GENE
and O
meso I-GENE
- I-GENE
corticolimbic I-GENE
circuits I-GENE
in O
response O
to O
both O
monetary I-GENE
reward I-GENE
and O
nonmonetary I-GENE
reinforcement I-GENE
. O

Reverse I-GENE
transcriptase I-GENE
- I-GENE
polymerase I-GENE
chain I-GENE
reaction O
assays O
showed O
that O
PKRDeltaE7 I-GENE
is O
expressed I-GENE
in O
a O
broad I-GENE
range O
of O
human I-GENE
tissues O
at I-GENE
variable I-GENE
levels O
. O

For I-GENE
this O
purpose I-GENE
, O
the O
immediate I-GENE
and O
the O
final O
( O
after O
swelling I-GENE
) O
fixation I-GENE
strengths I-GENE
of O
two O
variations O
of O
the O
swellable I-GENE
bone O
anchor I-GENE
designs I-GENE
( O
a O
smooth I-GENE
anchor I-GENE
and O
a O
screw I-GENE
anchor I-GENE
) O
were O
measured O
in O
two O
different O
foams I-GENE
( O
used O
to O
simulate I-GENE
bone O
) O
with O
different O
densities I-GENE
. O

CYP2C19 I-GENE
genotype I-GENE
was O
determined O
by O
the O
polymerase I-GENE
chain I-GENE
reaction O
- I-GENE
restriction I-GENE
fragment O
length O
polymorphism I-GENE
method O
. O

It O
is O
useful O
as I-GENE
an O
adjunct I-GENE
to O
mammography I-GENE
in O
those O
patients O
with O
radiographically I-GENE
dense I-GENE
breasts I-GENE
for I-GENE
the O
characterization I-GENE
of O
palpable I-GENE
masses I-GENE
. O

Activation I-GENE
of O
transcription O
through O
the O
AP I-GENE
- I-GENE
1 I-GENE
site I-GENE
in O
Jurkat I-GENE
cells O
by O
JunD I-GENE
and O
/ O
or O
Fra I-GENE
- I-GENE
2 I-GENE
was O
weak O
. O
c O
- I-GENE
Jun I-GENE
, O
JunB I-GENE
, O
and O
c O
- I-GENE
Fos I-GENE
activation I-GENE
was O
greater O
, O
although O
the O
level O
was O
still O
less O
than O
that O
with O
Tax I-GENE
. O

Thus I-GENE
, O
the O
screen I-GENE
for I-GENE
toxic O
p53 I-GENE
mutants I-GENE
in O
yeast I-GENE
can O
identify I-GENE
novel I-GENE
p53 I-GENE
variants I-GENE
that O
may O
be O
useful O
in O
dissecting I-GENE
p53 I-GENE
regulated I-GENE
cellular O
responses O
and O
in O
developing I-GENE
p53 I-GENE
- I-GENE
based O
cancer I-GENE
therapies I-GENE
. O

Local I-GENE
control O
rates O
were O
91 O
% O
for I-GENE
metastatic I-GENE
lung I-GENE
cancer I-GENE
, O
89 I-GENE
% O
for I-GENE
primary I-GENE
lung I-GENE
cancer I-GENE
and O
85 I-GENE
% O
for I-GENE
T1 I-GENE
, O
2N0M0 I-GENE
cases O
. O

The O
results O
show O
that O
cognitive I-GENE
stimulation I-GENE
enhanced I-GENE
performance O
on O
the O
Boston I-GENE
Naming I-GENE
Test O
and O
a O
Word I-GENE
List I-GENE
Recognition I-GENE
Task I-GENE
; O
physical O
intervention I-GENE
, O
however O
, O
did O
not O
reach I-GENE
statistical I-GENE
significance O
. O

Gimpl I-GENE
, O
F O
. O

The O
actA I-GENE
gene O
is O
present O
as I-GENE
a O
single O
copy I-GENE
in O
the O
genome I-GENE
of O
A I-GENE
. O
chrysogenum I-GENE
; O
and O
its O
expression I-GENE
level O
, O
opposite I-GENE
to O
pcbC I-GENE
and O
cefEF I-GENE
cephalosporin I-GENE
biosynthetic I-GENE
genes I-GENE
, O
was O
steady I-GENE
during I-GENE
cephalosporin I-GENE
fermentation I-GENE
, O
showing O
a O
single O
1 I-GENE
. O
4 O
- I-GENE
kb O
transcript I-GENE
. O

Maternal I-GENE
p O
, O
p O
' O
DDE I-GENE
and O
beta I-GENE
- I-GENE
HCH I-GENE
levels O
were O
also O
associated O
with O
newborn O
levels O
, O
but O
levels O
of O
PCBs I-GENE
were O
not O
. O

The O
patients O
and O
their O
families I-GENE
were O
closely I-GENE
questioned I-GENE
, O
and O
full I-GENE
clinical O
examination I-GENE
included O
a O
test O
for I-GENE
orthostasia I-GENE
. O

The O
expression I-GENE
of O
alpha I-GENE
- I-GENE
amylase I-GENE
can O
be O
transactivated I-GENE
by O
the O
transcription O
factor I-GENE
GAMyb I-GENE
, O
which O
is O
itself O
induced I-GENE
by O
GA I-GENE
. O

Cardiac I-GENE
output O
at I-GENE
anaerobic I-GENE
threshold O
( O
COAT I-GENE
) O
< I-GENE
or O
= O
7 O
. O
3 O
L O
/ O
min O
was O
the O
best O
cutoff I-GENE
value O
for I-GENE
identifying I-GENE
multivessel I-GENE
coronary O
artery O
disease I-GENE
( O
relative O
risk O
, O
3 O
. O
1 I-GENE
). O

Tolerance I-GENE
to O
ADAL I-GENE
- I-GENE
2 I-GENE
was O
similar O
to O
that O
of O
Vicryl I-GENE
suture I-GENE
and O
tolerance O
to O
ADAL I-GENE
- I-GENE
2 I-GENE
was O
superior O
to O
that O
to O
Tisuacryl I-GENE
. O

In I-GENE
the O
base I-GENE
- I-GENE
case O
analysis O
, O
total I-GENE
direct O
costs I-GENE
per O
patient O
were O
$ I-GENE
728 I-GENE
for I-GENE
zoledronic I-GENE
acid I-GENE
and O
$ I-GENE
776 I-GENE
for I-GENE
pamidronate I-GENE
. O

METHODS I-GENE
: O
We I-GENE
retrospectively I-GENE
selected I-GENE
13 I-GENE
TFCD I-GENE
patients O
who O
underwent O
surgery O
for I-GENE
intractable I-GENE
epilepsy I-GENE
with O
the O
aim I-GENE
of O
removing I-GENE
the O
magnetic I-GENE
resonance I-GENE
( O
MR O
)- O
detectable I-GENE
lesion O
and O
/ O
or O
the O
epileptogenic I-GENE
zone I-GENE
defined O
by O
stereoelectroencephalographic I-GENE
recordings O
. O

To I-GENE
gain O
an O
understanding I-GENE
of O
the O
mGSTM2 I-GENE
regulation I-GENE
, O
we O
have O
also O
cloned I-GENE
and O
analyzed O
its O
promoter I-GENE
region O
. O

Cyclins I-GENE
are O
one O
of O
the O
pivotal I-GENE
determinants I-GENE
regulating I-GENE
cell O
cycle I-GENE
progression I-GENE
. O

Architecture I-GENE
and O
anatomy I-GENE
of O
the O
genomic I-GENE
locus I-GENE
encoding I-GENE
the O
human I-GENE
leukemia O
- I-GENE
associated O
transcription O
factor I-GENE
RUNX1 I-GENE
/ O
AML1 I-GENE
. O

Three I-GENE
of O
the O
proteins O
involved I-GENE
in O
checkpoint I-GENE
signaling I-GENE
, O
Rad1 I-GENE
, O
Hus1 I-GENE
, O
and O
Rad9 I-GENE
, O
have O
been O
shown O
to O
interact I-GENE
by O
immunoprecipitation I-GENE
and O
yeast I-GENE
two O
- I-GENE
hybrid I-GENE
studies O
. O

Together I-GENE
these O
data O
imply I-GENE
that O
the O
HFV I-GENE
R O
region O
acts I-GENE
in O
the O
nucleus O
to O
modify O
the O
cytoplasmic I-GENE
fate I-GENE
of O
target I-GENE
HFV I-GENE
mRNA I-GENE
. O

However I-GENE
, O
patients O
with O
isolated O
office I-GENE
hypertension O
had O
fewer I-GENE
previous O
cardiovascular O
complications O
. O

Through I-GENE
deletion I-GENE
mutagenesis I-GENE
, O
we O
identify I-GENE
amino I-GENE
acids I-GENE
2003 I-GENE
to O
2212 I-GENE
of O
CBP I-GENE
, O
which O
we O
call I-GENE
carboxy I-GENE
- I-GENE
terminal I-GENE
region O
2 I-GENE
( O
CR2 I-GENE
), I-GENE
as I-GENE
the O
minimal I-GENE
region O
for I-GENE
Tax I-GENE
interaction O
. O

Fetal I-GENE
lung I-GENE
volume O
: O
estimation I-GENE
at I-GENE
MR O
imaging O
- I-GENE
initial O
results O
. O

Plane I-GENE
wave I-GENE
geometry I-GENE
is O
impractical I-GENE
for I-GENE
clinical O
use O
but O
the O
results O
of O
this O
work O
encouraged I-GENE
us O
to O
further O
develop O
the O
P3 I-GENE
approximation I-GENE
for I-GENE
a O
spherical I-GENE
geometry I-GENE
, O
described O
in O
this O
paper O
. O

For I-GENE
the O
sample O
of O
systematic O
reviews I-GENE
drawn I-GENE
from O
ACP I-GENE
Journal I-GENE
Club I-GENE
( O
n I-GENE
= O
103 I-GENE
), I-GENE
the O
PubMed I-GENE
strategy I-GENE
achieved I-GENE
a O
sensitivity O
of O
97 I-GENE
% O
( O
CI I-GENE
, O
91 O
% O
to O
99 I-GENE
%). O

In I-GENE
addition O
to O
that O
, O
she I-GENE
received O
hepatic I-GENE
intra I-GENE
- I-GENE
arterial O
infusion O
of O
levoforinate I-GENE
( O
l I-GENE
- I-GENE
LV O
) O
250 I-GENE
mg O
and O
5 I-GENE
- I-GENE
fluorouracil I-GENE
( O
5 I-GENE
- I-GENE
FU I-GENE
) O
500 I-GENE
mg O
for I-GENE
combined O
multiple O
hepatic I-GENE
metastases O
starting I-GENE
on O
postoperative I-GENE
day O
14 O
, O
and O
these O
medications I-GENE
were O
administered O
over O
48 I-GENE
hours O
once O
weekly O
by O
infuser I-GENE
pump I-GENE
. O

Because I-GENE
of O
differences O
in O
patient O
characteristics O
, O
control O
measurements O
were O
obtained O
from O
normal O
muscle I-GENE
in O
all O
patients O
. O

Two I-GENE
families I-GENE
with O
concordant I-GENE
inheritance I-GENE
of O
DNAH9 I-GENE
alleles I-GENE
in O
affected O
individuals I-GENE
were O
observed O
. O

NIRS I-GENE
was O
used O
for I-GENE
the O
quantitative O
measurement O
of O
muscle I-GENE
O I-GENE
( O
2 I-GENE
) O
consumption I-GENE
( O
mV I-GENE
. O
O I-GENE
( O
2 I-GENE
)) I-GENE
and O
forearm I-GENE
blood I-GENE
flow O
( O
FBF I-GENE
) O
in O
78 I-GENE
healthy O
subjects O
. O

Many I-GENE
factors I-GENE
do O
influence O
the O
educational I-GENE
outcome I-GENE
in O
students O
and O
large O
statistical I-GENE
power O
( O
such O
as I-GENE
meta I-GENE
analysis O
) O
should O
be O
helpful O
to O
eliminate I-GENE
many O
sources O
of O
error O
. O

B I-GENE
- I-GENE
myb I-GENE
is O
essential O
for I-GENE
G1 I-GENE
/ O
S O
transition I-GENE
and O
has O
been O
shown O
to O
be O
phosphorylated I-GENE
by O
the O
cyclin I-GENE
A2 I-GENE
/ O
cdk2 I-GENE
complex O
. O

Like I-GENE
the O
consensus I-GENE
mammalian I-GENE
LHbeta I-GENE
gene O
, O
the O
5 I-GENE
'- O
flanking I-GENE
region O
of O
the O
gpLH I-GENE
/ O
CGbeta I-GENE
gene O
contains I-GENE
a O
single O
TATA I-GENE
sequence O
37 O
bp I-GENE
upstream O
of O
the O
translation I-GENE
start I-GENE
codon I-GENE
. O

HTLV I-GENE
- I-GENE
1 I-GENE
decreases O
Th2 I-GENE
type I-GENE
of O
immune I-GENE
response O
in O
patients O
with O
strongyloidiasis I-GENE
. O

Indeed I-GENE
, O
mutation I-GENE
of O
two O
of O
these O
motifs I-GENE
, O
known O
to O
be O
important O
to O
regulation I-GENE
of O
sid1 I-GENE
, O
altered O
the O
differential O
regulation I-GENE
of O
sid2 I-GENE
by O
iron O
. O

Nutritional I-GENE
status O
in O
adults O
on O
an O
alternative I-GENE
or O
traditional I-GENE
diet O
] O
BACKGROUND I-GENE
: O
Plant I-GENE
food O
lacks I-GENE
vitamin O
B12 I-GENE
, O
vitamin O
D O
and O
higher I-GENE
n I-GENE
- I-GENE
3 O
polyunsaturated I-GENE
fatty I-GENE
acids I-GENE
. O

On I-GENE
the O
other O
hand I-GENE
, O
forced I-GENE
overexpression I-GENE
of O
the O
wild I-GENE
type I-GENE
, O
but O
not O
the O
kinase I-GENE
- I-GENE
inactivated I-GENE
mutant I-GENE
of O
nm23H1 I-GENE
, O
converted I-GENE
the O
GDP I-GENE
- I-GENE
bound I-GENE
forms I-GENE
of O
Rac1 I-GENE
, O
Cdc42 I-GENE
, O
and O
RhoA I-GENE
to O
their O
GTP I-GENE
- I-GENE
bound I-GENE
forms I-GENE
in O
vitro O
by O
its O
nucleoside I-GENE
diphosphate I-GENE
kinase I-GENE
activity O
, O
but O
nm23H1 I-GENE
alone O
apparently I-GENE
did O
not O
produce O
the O
GTP I-GENE
- I-GENE
bound I-GENE
form O
of O
these O
GTPases I-GENE
in O
vivo O
. O

Novel I-GENE
intronic I-GENE
promoter I-GENE
in O
the O
rat O
ER I-GENE
alpha I-GENE
gene O
responsible O
for I-GENE
the O
transient O
transcription O
of O
a O
variant O
receptor I-GENE
. O

RESULTS I-GENE
: O
Coronary I-GENE
mortality O
during I-GENE
the O
median O
follow O
- I-GENE
up I-GENE
time O
of O
17 I-GENE
months O
was O
6 I-GENE
- I-GENE
fold I-GENE
higher I-GENE
in O
the O
highest O
tertile I-GENE
for I-GENE
CRP I-GENE
and O
IL I-GENE
- I-GENE
6 I-GENE
and O
3 O
. O
5 I-GENE
- I-GENE
fold I-GENE
higher I-GENE
in O
the O
highest O
tertile I-GENE
for I-GENE
fibrinogen I-GENE
and O
TNF I-GENE
- I-GENE
alpha I-GENE
than O
in O
the O
respective I-GENE
combined O
lower O
tertiles I-GENE
. O

HIV I-GENE
- I-GENE
1 I-GENE
and O
hepatitis I-GENE
B I-GENE
virus O
infections O
in O
adolescents I-GENE
lodged I-GENE
in O
security I-GENE
institutes I-GENE
of O
Buenos I-GENE
Aires I-GENE
. O

However I-GENE
, O
the O
promoter I-GENE
region O
contains I-GENE
several I-GENE
potential I-GENE
cis I-GENE
- I-GENE
regulatory I-GENE
elements I-GENE
such O
as I-GENE
Sp1 I-GENE
, O
early O
growth O
response O
- I-GENE
1 I-GENE
, O
activator I-GENE
protein O
- I-GENE
2 I-GENE
, O
MyoD I-GENE
, O
p300 I-GENE
, O
nuclear O
factor I-GENE
- I-GENE
kappaB I-GENE
, O
myeloid I-GENE
zinc O
finger I-GENE
protein O
- I-GENE
1 I-GENE
, O
caudal I-GENE
- I-GENE
related O
homeobox I-GENE
( O
Cdx I-GENE
) O
gene O
A I-GENE
, O
and O
Cdx I-GENE
protein O
- I-GENE
2 I-GENE
binding O
sites O
. O

RPM I-GENE
/ O
RGL3 I-GENE
resembled I-GENE
AF I-GENE
- I-GENE
6 I-GENE
and O
Nore1 I-GENE
in O
interacting I-GENE
strongly O
with O
constitutively I-GENE
active I-GENE
M O
- I-GENE
Ras I-GENE
and O
p21 I-GENE
Ras I-GENE
. O

METHODS I-GENE
: O
93 I-GENE
female O
and O
43 I-GENE
male O
patients O
undergoing O
thyroid O
surgery O
were O
stratified I-GENE
according I-GENE
to O
gender I-GENE
and O
then O
randomised I-GENE
to O
receive I-GENE
double O
- I-GENE
blind O
one O
of O
four O
antiemetic I-GENE
regimes I-GENE
: O
50 O
mg O
dolasetron I-GENE
given O
orally O
45 I-GENE
minutes O
prior I-GENE
to O
induction O
of O
anaesthesia I-GENE
( O
group O
I O
), I-GENE
12 O
. O
5 I-GENE
mg O
dolasetron I-GENE
given O
intravenously O
during I-GENE
induction O
of O
anaesthesia I-GENE
( O
group O
II I-GENE
), I-GENE
1 I-GENE
. O
25 I-GENE
mg O
DHB I-GENE
given O
intravenously O
during I-GENE
induction O
of O
anaesthesia I-GENE
( O
group O
III I-GENE
) O
or O
placebo O
( O
group O
IV O
). O

Transcriptional I-GENE
regulation I-GENE
of O
the O
estrogen I-GENE
- I-GENE
inducible I-GENE
pS2 I-GENE
breast O
cancer I-GENE
marker I-GENE
gene O
by O
the O
ERR I-GENE
family I-GENE
of O
orphan I-GENE
nuclear O
receptors I-GENE
. O

